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Abstract 
Despite high responses to initial chemotherapy most patients with ovarian cancer (OC) 
relapse and inevitably die from their disease.  Aberrant DNA methylation is frequently 
seen in ovarian tumours and may provide biomarkers of clinical outcome or insight into 
mechanisms of chemoresistance.   
 
We firstly performed Differential Methylation Hybridisation (DMH) to identify loci that 
gained methylation between 34 matched cisplatin sensitive and resistant OC tumour cell 
lines.  Differentially methylated loci identified were further validated by Methylation 
Specific PCR (MSP) and bisulphite pyrosequencing.  Selected loci were further 
investigated for association with clinical outcome in primary OC tumour samples and 
matched tumour samples from patients‟ pre- and post- chemotherapy.  Frequent increased 
methylation of a CpG island at the NR2E1 gene was identified in this experiment. 
Increased methylation correlated with decreased gene expression and could be reversed 
following treatment with a demethylating agent. Increased methylation at NR2E1 was 
observed between matched pre- and post- treatment tumour pairs.   
 
A novel biostatistical method, methylation linear discrimination analysis (MLDA), was 
next used to identify differentially methylated loci in sensitive and resistant A2780 human 
ovarian cell lines.  Eight of nine loci identified were validated by MSP.  A locus at the SP5 
gene was further investigated by pyrosequencing and found to show a very high level 
methylation in most cell lines and ovarian tumours. Increased methylation correlated with 
decreased gene expression and this could be reversed using decitabine treatment.  
Knockdown of SP5 expression caused increased apoptosis.   
 
DMH was next used to identify loci that gained methylation between 3 in vivo derived 
matched sensitive and resistant cell lines.  KIAA1383, a gene of unknown function, was 
identified and methylation shown to correlate with response to chemotherapy and 
progression-free survival (PFS) in patients with OC.  Over-expression was found to 
attenuate the response to cisplatin, in the PEA2 cell line, as measured by cell cycle 
analysis. 
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 Abbreviations 
Abbreviation In full 
A Adenine 
BLAT Blast-like alignment tool 
BLAST Basic local alignment search tool 
BP Base pair 
C Cytosine 
CGH Comparative genomic hybridisation 
CGI CpG Island 
CIMP CpG Island methylator phenotype 
CMV Cytomegalovirus  
COBRA Combined bisulphite restriction analysis 
CR Complete response 
CSC Cancer stem cells 
DAC Decitabine 
DMH Differential methylation hybridisation 
DMSO Dimethyl sulfoxide 
DNA Deoxyribose nucleic acid 
dNTP Deoxyribonucleotide triphosphate 
EOC Epithelial ovarian cancer 
FDR False discovery rate 
FIGO International Federation of Gynaecology and Obstetrics 
FISH Fluorescent in situ hybridisation 
G Guanine 
GST Glutathione S transferase 
HGS High grade serous 
HRT Hormone replacement therapy 
HSP Heat shock protein 
IP Intraperitoneal 
IV Intravenous 
IVM In vitro methylated 
K Thousand 
LGS Low grade serous 
LINE Long interspersed nucleotide element 
LRP Lung resistance related protein 
M Methylated 
mi RNA MicroRNA 
MLDA Methylation linear discrimination analysis 
MMR Mismatch repair 
MSP Methylation specific PCR 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
  
n(OSE) (Normal) ovarian surface epithelium 
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N/ PBMC Normal/ Peripheral blood mononucelocite/whole male genomic DNA  
NER Nucelotide excision repair 
OCP Oral contraceptive pill 
 
 
 
OGT Oxford gene technology 
OS Overall survival 
PAM Prediction analysis microarrays 
PCR Polymerase chain reaction 
PD Pharmacodynamic 
PD Progressive disease 
PFI Platinum free interval 
PGP P glycoprotein 
PK Pharmacokinetic 
PR Partial response 
PS Performance status 
(q)RTPCR (quantitative/ real time) Reverse Transcription PCR  
RNA Ribose nucleic acid 
RNAi RNA interferance 
SAM Significance analysis microarrays 
SD Stable disease 
SDS Sodium citrate 
SDS Sequence detection analysis 
si RNA Small interfering RNA 
SNP Single nucelotide polymorphism 
SSC Sodium dodecyl sulfate 
SWOG Southwest Oncology Group 
T Thymine 
t RNA Transfer RNA 
TAH BSO Total abdominal hysterectomy and bilateral salpingoophorectomy 
TBE Tris borate EDTA 
TCGA The cancer genome atlas 
TSG Tumour suppressor gene 
U Uracil 
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Introduction 
1.1 Overview of the management of 
epithelial ovarian cancer 
Around 130 women are diagnosed with ovarian cancer, in the UK, every week.  It is 
the most lethal of the gynaecological tract malignancies and the fourth most common 
cause of cancer death in women.  Despite advances in research and treatment the 
incidence continues to increase while mortality has remained stable (except for 
younger patients where a small improvement has been observed) 
(http://info.cancerresearch.org/cancerstats). 
Approximately 80% of patients are diagnosed at over 50 years of age and most known 
risk factors appear to be hormonally driven.  These include nuliparity, infertility, use 
of postmenopausal Hormone Replacement Therapy (HRT), obesity and endometriosis 
(Modugno, Ness et al. 2004) (Calle, Rodriguez et al. 2003).  Breastfeeding, tubal 
ligation and the use of the oral contraceptive pill (OCP) are protective and 
interestingly the protective effects of the OCP are sustained for up to 25 years after 
stopping (Whittemore, Balise et al. 2004) (Modugno, Ness et al. 2004).  In addition 
10-15% of patients have a germline mutation in BRCA1 or 2 and these younger 
patients have an increased risk of ovarian cancer in addition to other cancers (most 
commonly breast cancer but also cervical, uterine, pancreatic and colon cancers for 
females with BRCA1 mutations, and breast, pancreas, stomach, gallbladder, bile duct 
and melanoma for females with BRCA2) (Thompson and Easton 2002; Kadouri, 
Hubert et al. 2007). 
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Ovarian cancer is a heterogeneous disease with the different histological subtypes 
behaving differently biologically and showing differential responses to standard and 
more experimental treatments.  The serous subtype is the most common of the 
epithelial ovarian cancers (EOC), accounting for approximately sixty percent of 
epithelial cancers, but others include clear cell (approximately ten percent), mucinous 
(less than five percent) and endometrioid tumours (fifteen percent) (Lalwani, Prasad 
et al. 2011).  In addition, tumours of germ cell origin account for approximately 
twenty percent of ovarian masses and five percent of cancers. (Kaku, Ogawa et al. 
2003).    
EOC tumours are graded I-III with grade I being the most differentiated/ least 
aggressive and grade III being the least differentiated/most aggressive.  Recently there 
has been a move to classify tumours only as high or low grade and eliminating the 
intermediate Grade II, and serous cancer is increasingly considered as two distinct 
types depending on Grade: „High Grade Serous (HGS)‟ and „Low Grade Serous 
(LGS)‟ (Mishra and Crasta 2010).  HGS make up approximately fifty five percent of 
tumours and are characterised by very frequent mutations in the TP53 gene (Singer, 
Stohr et al. 2005; Kobel, Reuss et al. 2010; Mishra and Crasta 2010), while LGS, 
which account for five percent of tumours, lack TP53 mutations, but have more 
frequent mutations in KRAS and BRAF (Singer, Oldt et al. 2003).  This is summarised 
in table 1 below (Lalwani, Prasad et al. 2011).   
In addition, the various subtypes are now collectively divided into type I and type II.  
Type I tumours include LGS, mucinous and low grade endometriod tumours and type 
II tumours describe HGS, high grade endometriod and undifferentiated variants.  Type 
I tumours present as large ovarian masses, are often early stage at diagnosis and 
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generally follow an adenoma to carcinoma step wise progression with a relatively 
good prognosis.  In contrast type II tumours are more aggressive, originate outwith the 
ovary e.g. the fallopian tube, and along with a nearly 100% rate of p53 mutations have 
a high rate of BRCA dysfunction and chromosomal instability.  They present late and 
are associated with poor prognosis.  These findings were recently reviewed by 
Lalwani et al and are integrated into table 1 below (Lalwani, Prasad et al. 2011):    
Table 1: Summary of the key observations related to the different histological subtypes 
(Lalwani, Prasad et al. 2011). 
Subtype Suspected precursor  Dysregulated 
genes 
Salient features 
LGS cancer 
5% 
Borderline ovarian 
tumours 
Serous cyst adenomas 
KRAS 
BRAF 
Median age 60 
Bilateral 
Peritoneal 
metastases 
commonly 
Platinum „resistant‟  
HGS cancer 
55% 
Fallopian tube BRCA 
p53 (approaching 
100%) 
PTEN 
Median age 55 
Bilateral 
Early peritoneal 
metastases 
Platinum sensitive 
Mucinous 
<5% 
Borderline ovarian 
tumours 
Mucinous cyst adenomas 
 
Display an adenoma to 
carcinoma progression 
KRAS 
HER2 
p53 
Median age 45 
>90% unilateral 
Often large 
 
 
Endometriod 
15% 
Borderline ovarian 
tumours 
Endometriosis (40%) 
 
Display an adenoma to 
carcinoma progression 
CTNNB1* 
PTEN* 
PIK3CA* 
 
p53** 
BRCA1** 
PIK3C1** 
 
Median age 50 
80% unilateral 
30% stage I 
Platinum 
„sensitive‟  
Clear cell 
10% 
Borderline ovarian 
tumours 
Endometriosis (50%) 
Display an adenoma to 
carcinoma progression 
HNFIβ 
PTEN 
Median age 60 
60% unilateral 
40% stage I 
Platinum „resistant‟ 
LGS Low grade serous, HGS high grade serous * dysregulated in LG subtype, ** dysregulated in HG subtype 
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Controversy surrounds the origin of ovarian cancer; historically all subtypes were 
thought to arise from ovarian surface epithelium (OSE) but more recently it has been 
argued that at least some of the subtypes, particularly HGS, may arise in the fallopian 
tube or sites of endometriosis or from the peritoneal lining itself (Auersperg, Wong et 
al. 2001; Bell 2005; Jarboe, Folkins et al. 2008; Kurman and Shih Ie 2008). 
Staging is performed at the time of definitive surgical resection (usually total 
abdominal hysterectomy and bilateral salpingoophorectomy (TAH BSO), 
omentectomy and pelvic washings).  Stage I tumours describe ovarian cancer limited 
to one or both ovaries with Stage IC used if ascites is present or the capsule ruptures 
at the time of surgery.  Stage II disease is confined to gynaecological organs, Stage 3 
disease to other abdominal organs and lymph nodes and Stage IV describes 
metastases to lungs or other viscera, for example, liver, spleen or brain.  Although 
local spread onto the outer surface of the liver is common, parencymal/intrahepatic 
liver metastases (and other visceral metastases) are rare.  Ovarian cancer is unique in 
its pattern of spread, which tends to be localized to the peritoneum rather than more 
distant metastases, and patients most often die of this local infiltration, causing for 
example bowel obstruction, as opposed to more distant metastases (Janczar S, Graham 
JS et al. 2009).   
The biology underpinning these distinct epithelial phenotypes (i.e. serous, clear cell, 
endometriod) is less well defined than in other cancers, for example breast cancer, 
where the gene expression profile is beginning to be used predictively and 
prognostically to drive research and treatment choices, and it is generally accepted 
that no gene expression profile, as yet, has surpassed using the known historical risk 
factors; age at diagnosis, stage and grade of the tumour, amount of residual disease 
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and histological subtype (Cannistra 2004), (Bristow, Tomacruz et al. 2002).  Many 
groups are working on this though and in the last couple of years much larger, more 
adequately powered studies, have begun to emerge, including the work of Tothill and 
colleagues who identified six subtypes; two of which clearly highlighted groups of 
patients with significantly worse survival - and they were able to validate this in an 
independent array (Tothill, Tinker et al. 2008).  
Ninety percent of early stage patients (FIGO stage I/II) (International Federation of 
Gynaecology and Obstetrics) can be treated with surgery alone although patients with 
grade 3 or stage 1C or II are often considered for systemic chemotherapy.  However 
due to the nature of the presenting symptoms which can be vague (for example 
constipation, abdominal bloating, dyspepsia, back ache, urinary frequency, early siety 
or nausea) approximately 80% present with advanced disease and these patients 
require chemotherapy in addition to surgery (FIGO Stage III/IV) (Agarwal and Kaye 
2003; Cannistra 2004).  
Survival is improved for patients who undergo surgery by a specialist surgeon and 
optimal debulking (no residual disease following surgery) also impacts on survival.  
Patients with residual tumour mass of greater than 2cm have a median survival of 12-
16 months compared to 40-45 months if residual disease is less than 2cm (Mutch 
2002).  However more recently it has been suggested that it is patients with less 
advanced disease who derive maximal benefit from this approach (Crawford, Vasey et 
al. 2005). For most patients TAH, BSO, omentectomy and pelvic washings is standard 
but for those with very early disease and or young age a fertility sparing approach is 
sometimes undertaken.  
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Adjuvant chemotherapy is offered to most patients with advanced (Stage III and IV 
cancer) and also to patients with early-stage tumours with an increased risk of relapse, 
i.e. those with Stage Ia/b high grade, Stage Ic and Stage II disease (Winter-Roach, 
Kitchener et al. 2009).  For these patients the use of platinum-based chemotherapy can 
result in a 5 year disease-free survival of approximately 80% compared to 
approximately 65% in those patients who do not receive platinum adjuvant therapy 
(Young 2003; Young, Brady et al. 2003). There is significant variation in clinical 
practice but generally most patients are offered carboplatin and paclitaxel for 6 cycles.  
ICON3 concluded that single agent carboplatin can be regarded as reasonable first-
line treatment in ovarian cancer (ICON Group, 2002) and as a result some centres use 
single agent carboplatin leaving the taxane for use in relapse.  Less fit or earlier stage 
patients are also often offered carboplatin alone.  This has the advantage of avoiding 
the peripheral neuropathy, increased emesis and hair loss of combined treatment but 
has the disadvantage of additional thrombocytopenia).   
It has long been established that taxanes offer a platelet sparing effect when 
administered along with carboplatin although the mechanism is not understood 
(Sharma R, Graham JS, manuscript in press).  Paclitaxel is generally the taxane of 
choice although “The Scottish Randomised Trial in Ovarian Cancer” (SCOTROC1) 
study compared docetaxel-carboplatin with paclitaxel-carboplatin in first-line 
treatment and found equivalent efficacy (Vasey, Jayson et al. 2004).  Patients with 
advanced disease who respond to chemotherapy but have not had a complete response 
by 6 cycles are sometimes offered up to 3 additional cycles of chemotherapy.  More 
recent studies, such as CHORUS (ISRCTN 74802813), have investigated the use of 
neoadjuvant chemotherapy – the rationale being that if maximal debulking has 
prognostic implications that for some patients – especially those with upper 
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abdominal disease – the use of up front chemotherapy could improve later surgical 
results.  Interim analysis has shown no disadvantage to proceeding first with 
chemotherapy and in some centres this has already become established practice for 
certain patients.  
Mucinous tumours show a lower response to chemotherapy than serous tumours and 
hence confer a poorer prognosis (Pignata, Ferrandina et al. 2008), and are usually only 
diagnosed when a colorectal cancer has been definitively excluded.   A clinical trial 
randomizing patients with mucinous ovarian cancer to carboplatin and paclitaxel vs. 
capecitabine and oxaliplatin (an established colorectal regimen) is due to open in the 
UK (http://www.controlled-trials.com/ISRCTN83438782).  Patients with clear cell 
pathology also show a much lower response to carboplatin and paclitaxel and a Phase 
III collaborative study, sponsored by CRUK, called CCC1 is currently investigating 
carboplatin and paclitaxel vs. cisplatin and irinotecan (www.cancerresearchuk.org) in 
patients with clear cell ovarian cancer.    In addition patients with LGS tumours have a 
higher rate of expression of BRAF and KRAS and a trial is currently planned to 
investigate a MEK inhibitor in these patients. 
As patients with ovarian cancer tend to die from local spread of their disease as 
opposed to distinct metastases the role of intraperitoneal (IP) chemotherapy has been 
examined more recently.  Although some controversy surrounds these trials it is 
generally accepted that although a combination of intravenous (IV) and IP 
chemotherapy is less well tolerated than a purely IV approach that patients do gain a 
statistically significant survival benefit.  However, although this practice has become 
standard of care in some countries this is not the case in most of the UK.  There are 
multiple reasons for hesitancy to take up this approach including increased toxicity, 
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the resource implications (both in terms of insertion of the IP catheters and their 
subsequent maintenance and complication management) and the belief that in most of 
the studies like was not compared with like – the patients in the IP arm often received 
a more dose intense regimen.  A number of comprehensive reviews reflecting both 
sides of the ongoing debate have been published (Armstrong and Brady 2006; Gore, 
du Bois et al. 2006; Jaaback and Johnson 2006; Petignat, du Bois et al. 2006; Elit, 
Oliver et al. 2007; Fujiwara, Armstrong et al. 2007; Fung-Kee-Fung, Provencher et al. 
2007; Marth, Walker et al. 2007) and current studies aim to reduce toxicity and 
compare regimens of the same dose intensity. 
Patients with germline mutations in BRCA 1 and 2 have disease which is clinically 
distinct from the other subtypes - recently a significantly higher incidence of visceral 
metastases was reported in these patient‟s (74% of patients compared to 16%) 
(Gourley, Michie et al. 2009). For patients carrying a BRCA1 or 2 germline mutation 
very encouraging results have been seen using PARP inhibitors.   
BRCA1 is required for double strand repair, using homologous recombination (HR). 
PARP inhibitors inhibit Poly ADP ribose polymerase, leading to generation of single 
strand breaks and replication fork collapse during DNA replication, leading to DNA 
double strand breaks.  Such double strand breaks can be repaired by HR if functional 
BRAC1 or 2 is present, but in the absence of HR cells are sensitive to PARP inhibition 
and die.  Thus, although the cell can survive with one or other of these mechanisms 
intact if both are knocked out simultaneously this has dramatic effects and this is 
termed synthetic lethality.  Additionally, in BRCA1 or 2 carriers their normal cells are 
heterozygous (i.e. one mutant and one wild type copy), and have normal HR activity 
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and therefore normal cells avoid this effect and hence toxicity.  In contrast, tumours 
have lost the wild type allele and have defective HR (Dedes, Wilkerson et al. 2011).  
Fong et al recently reported an overall clinical benefit rate of PARP inhibitors in 
ovarian cancer of 46% (95% CI, 32%
 
to 61%) and median response duration was 28 
weeks. There was a
 
significant association between the clinical benefit rate and
 
platinum-free interval across the platinum-sensitive, resistant,
 
and refractory 
subgroups (69%, 45%, and 23%, respectively).
 
In addition a retrospective analysis of 
the data indicated an association between platinum sensitivity
 
and extent of olaparib 
response (radiologic change, p =0.001;
 
CA125 change, p = 0.002) (Fong, Yap et al. 
2010).  Teodoridis and colleagues have shown that BRCA 1 and 2 are frequently 
silenced by methylation in ovarian cancer (Teodoridis, Hall et al. 2005).  
There is hope that this therapeutic exploitation could be expanded to patients who 
have other dysfunctions of their HR/ BRCA pathway – so called „BRCAness‟ patients.  
Potential reasons for dysfunction of homologous recombination are thought to include 
epigenetic hypermethylation of the BRCA1 promoter (Teodoridis, Hall et al. 2005), 
somatic mutations of BRCA1/2  (Foster, Harrington et al. 1996; Geisler, Hatterman-
Zogg et al. 2002) or loss of function mutations of other genes important in the 
pathway (Taniguchi, Tischkowitz et al. 2003).  Recently Konstantinopoulos et al 
reported a gene expression profile capable of identifying such patients 
(Konstantinopoulos, Spentzos et al. 2010).   
A multitude of targeted agents are in clinical trials although their role is not as 
established as in other cancers - the exception being the use of PARP inhibitors in 
patients with germline mutations in BRCA 1 or 2 (Fong, Yap et al. 2010), and perhaps 
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a further role out to include „BRCAness patients‟ (Konstantinopoulos, Spentzos et al. 
2010) (J. A. Ledermann 2011) .  
Currently an adequate screening test for ovarian cancer has not been identified.  
Although Ca125 is useful in diagnosis and disease monitoring approximately 20% of 
patients with the disease do not express this marker (Lalwani, Prasad et al. 2011) and 
in addition because ovarian cancer remains relatively rare within the general 
population, optimising a test with high enough sensitivity and specificity is difficult.  
This means that the majority of patients still present with advanced disease and the 
mainstay of treatment remains surgery and adjuvant chemotherapy. 
1.1 Biomarkers in ovarian cancer. 
No prospective biomarkers, independent for known clinical/pathological markers, 
have been validated, in epithelial ovarian cancer, to a high enough level as to be 
clinically useful when attempting to differentiate these heterogeneous responses to 
treatment in patients (with the exception of identifying patients with germline 
mutations in BRCA).  The implication of this is that many patients are given 
chemotherapy who do not benefit from it – either because they don‟t need it or 
because they will not respond to it and this represents a large group of patients 
receiving toxicity without gain.   
Currently the only useful clinical surrogate marker in relapsed disease is the platinum 
free interval (PFI).  This is defined as the time in months from the end of treatment 
(with a platinum containing regimen) to relapse.    Patients who relapse within 6 
months are termed platinum resistant, those who never respond platinum refractory 
and those who relapse after more than one year platinum sensitive.  The term partially 
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sensitive has more recently been used to describe the patients with a PFI of 6 to 12 
months.  Which of these groups a patient fits into has a significant impact on their 
projected response to future treatment and their overall survival.  Patients who relapse 
within 6 months have a response to second line platinum based chemotherapy of 
around 10% whereas those who relapse 24 months following chemotherapy can 
expect a response of >60% to platinum rechallenge (Gordon, Tonda et al. 2004; 
Mutch, Orlando et al. 2007; Ferrandina, Ludovisi et al. 2008).   
The standard treatment of platinum sensitive patients is rechallenge with platinum +/- 
a taxane whereas for platinum resistant patients other agents such as liposomal 
doxorubicin or topotecan are offered – or more recently „dose dense‟ platinum based 
regimens (were treatment is given weekly rather than three weekly).  Although dose 
dense treatment has shown encouraging responses of up to 50% in early phase trials, 
the impact on overall survival (OS) remains to be tested in a larger randomised setting 
(Sharma, Graham et al. 2009).   
The problem with using the PFI as a surrogate marker is that it tells you the patient 
will do well or badly according to how quickly they relapse and so it does not help to 
guide a patient‟s initial treatment.  Most clinicians and researchers would agree that 
what is really needed is to be able to prospectively predict a patients prognosis and 
guide the use of adjuvant treatment accordingly (prognostic biomarker) and to be able 
to stratify particular groups to targeted treatments as a result of the molecular 
phenotype of their tumour (predictive biomarker).  In advanced disease predictive 
markers are much more needed than prognostic markers - all patients should receive 
platinum unless it could be predicted that they were resistant to this and should 
receive an alternative drug.  In early stage disease there is a role for prognostic 
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markers as if the prognosis was exceptionally good this would be an argument for not 
needing chemotherapy.   
In the next subchapter the role of epigenetics, and more especially DNA methylation 
will be discussed followed by the various mechanisms of drug resistance in ovarian 
cancer – many of which are epigenetically regulated. 
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1.2 Epigenetic gene regulation 
Epigenetics describe a heritable change in gene expression without a change in the 
DNA sequence.  Abnormal gene regulation, which can be as a result of genetic or 
epigenetic changes, is central to the initiation and maintenance of cancer and it has 
been hypothesised that epigenetic mechanisms are the most prevalent driver of 
tumourogenesis (Sjoblom, Jones et al. 2006).  Three main epigenetic modifications 
exist; DNA methylation, histone modifications (methylation, acetylation, 
phosphorylation and others) and epigenetic regulation of microRNA‟s.  These will 
next be discussed in more detail. 
1.2.1 DNA methylation  
1.2.1.1 Physiological methylation 
DNA methylation is the most widely studied epigenetic modification, which occurs in 
mammalian DNA at CpG dinucleotides, where the hydrogen bond at the fifth position 
of cytosine becomes methylated (Bird 2002).  This is illustrated in Figure 1 below.  
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Three to five percent of all cytosines in the human genome are methylated.  
Approximately 70% of genes have CpG rich regions, called CpG islands (CGI‟s), 
often located in the promoter or first exon regions – which under normal conditions 
are unmethylated but if methylation occurs this can have a profound effect on gene 
transcription, resulting in gene silencing (Saxonov, Berg et al. 2006).  There are 
estimated to be about 30 000 of such CGIs in the human genome.  Various definitions 
for a CGI exist – in this thesis the Gardener Garden definition is used – this defines a 
CGI as a region with at least 200 base pairs and with a GC percentage that is greater 
than 50% and with an observed/expected CpG ratio that is greater than 60% 
(Gardiner-Garden and Frommer 1987).  More recently epigenetic mapping of lung 
fibroblasts and human embryonic stem cells has uncovered that stem cells show a 
unique ability to methylate non CG residues and DNMT3A and DNMT3L have been 
implicated in this process (Costello, Krzywinski et al. 2009).  
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Figure 1.  Chemical modification of cytosine methylation. (A) The chemical structure of the 
base cytosine. (B) the chemical structure of 5-methylcytosine following enzymatic transfer of a 
methyl (CH3) group (Graham, Kaye et al. 2009).  
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In contrast to CpG islands, repetitive genomic sequences are heavily methylated and 
this is thought to have a role in the protection of chromosome integrity, by preventing 
chromosome instability, translocations and gene disruption through the reactivation of 
endoparasitic sequences (Esteller 2007).  This area has recently provoked increased 
interest and it is thought that global demethylation is likely to contribute to a large 
number of genetic changes that are a feature of carcinogenesis (Esteller 2007).  As yet 
it is not clear whether global demethylation influences promoter hypermethylation or 
vice versa.   
Cytosine methylation represents a stable heritable yet reversible mark.  Evidence that 
the well known long term effects of early environmental exposures have an epigenetic 
component that can be maintained across generations has sparked great interest in the 
epigenetic field (Costello, Krzywinski et al. 2009).  DNA methylation is usually 
associated with transcriptional repression – either due to inhibition of the binding of 
factors to their cognate DNA recognition sequences or because it recruits methyl CpG 
binding proteins (MeCPs and MBDs) together with co-repressor molecules (Guil and 
Esteller 2009). 
DNA methylation patterns are established via DNA methyltransferases (DNMT‟s).  
Four mammalian subtypes are known – DNMT1, 2, 3a and 3b (Bird 2002).  DNMT1 
is classically described as the maintenance DNMT whereas the others are thought to 
induce de novo methylation (Bestor and Ingram 1983; Li, Bestor et al. 1992). DNMT1 
mediates the reinstatement of fully methylated sites from initially hemi-methylated 
substrates in daughter cells and consistent with this it has been shown to bind to 
proliferating cell nuclear antigen during S phase (Leonhardt, Page et al. 1992).  In fact 
it seems DNMT1 is not just a maintenance enzyme but also has the ability to induce 
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de novo methylation in cancer by interacting with proteins such as transcription 
factors (p53, STAT3, HP1), histone modifiers (HDAC1, HDAC2) and ligands 
(DAXX) to specifically repress targeted genes (Cheung, Lee et al. 2009) . 
DNMT3a and b are thought to show a preference for unmethylated DNA and are 
involved in initiating methylation patterns during embryogenesis including embryonic 
stem cells, in mice (Cheung, Lee et al. 2009).  A further DNMT known as DNMT3L 
is essential for the establishment of germ line DNA methylation and stimulates de 
novo methylation by DNMT3a and b.  These two enzymes are clearly of fundamental 
importance as knock outs for DNMT1 cause mice to die at 4 weeks and homozygous 
knockout of DNMT1 and 3b is embryonically lethal  (Li, Bestor et al. 1992).   
There have been several reports associating increased levels of DNMT1 with solid 
tumours including pancreatic, gastric, cholangiocarcinomas and colon cancers (Etoh, 
Kanai et al. 2004; Peng, Kanai et al. 2005; Zuo, Luo et al. 2008).  Zuo found that co-
transfection with antisense eukaryotic expression plasmids of DNMT1 and DNMT3b 
gene and single transfection with antisense eukaryotic expression plasmid of DNMT1 
gene could suppress the growth and proliferation of QBC-939 (cholangiocarcinoma 
cell line), block the cell cycle at G1 phase and increase apoptosis, resulting in a 
smaller tumour in the subcutaneous tissue of nude mouse. The suppressing biological 
effect of co-transfection was stronger than single transfection with antisense DNMT1 
and single transfection with antisense eukaryotic expression plasmid of DNMT3b 
gene had no effects on the biological characteristics of QBC-939 (Zuo, Luo et al. 
2008).   
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DNMTs interact with EZH2 (a Polycomb Group protein) (Vire, Brenner et al. 2006) 
to tri-methylate histone H3 at the lysine at position 27 from the carboxy tail 
(H3K27me3).  EZH2 is required for H3K27 trimethylation, which is associated with a 
repressive chromatin state and transcriptional silencing, and so DNMTs modulate 
gene repression at both the DNA and histone level (Shen, Liu et al. 2008).   
DNA methylation is required for the maintenance of a variety of cell types and is 
involved, along with transcription factors, in programming cells to adopt different 
phenotypes.  It regulates the genome by influencing gene expression and chromosome 
structure and by suppressing transposons (Costello, Krzywinski et al. 2009) , and 
other potentially harmful viral and parasitic sequences (Liu, Wylie et al. 2003).   
In humans two waves of global demethylation are observed.  Soon after fertilization 
the highly methylated gametes are actively demethylated (termed reprogramming).  
Then in the gamete further demethylation occurs at different times in male and female 
genomes.  In males this is believed to be an active process whereas in the female it 
has been proposed to be a passive process, involving the dilution of methylation 
secondary to a lack of DNMT1 as the DNA replicates (Cheung, Lee et al. 2009).  
Both sexes then regain methylation during implantation and DNMT3 has been 
implicated here.  DNA methylation is also responsible for silencing of the second X 
chromosome in females (Santos, Hendrich et al. 2002) (so they do not have twice as 
much expression of genes).  
In addition, DNA methylation is important in genomic imprinting where promoter 
methylation of either the paternal or maternal allele is associated with transcriptional 
repression (Bartolomei and Tilghman 1997).  Imprinted genes are protected from the 
first wave of global demethylation and this ensures proper monoallelic expression of 
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imprinted genes which are necessary in early embryogenesis (Cheung, Lee et al. 
2009).  Methylation has also been implicated in cell type-specific gene expression.  
MCJ (Strathdee, Davies et al. 2004), HOXA5 (Strathdee, Sim et al. 2007) and 
MASPIN (Futscher, Oshiro et al. 2002) have all been shown to be regulated in this 
way. 
 
1.2.1.2 Pathological methylation 
Several congenital malignancies have been linked to abnormal DNA methylation.  
Immunodeficiency Centromeric Region Instability Facial anomalies (ICF) syndrome 
is associated with mutations in DNMT3B (Xu, Bestor et al. 1999) and Beckwith-
Wiedemann and Prader-Willi syndromes are both associated with abnormal 
imprinting as a result of aberrant DNA methylation (Robertson 2005).   
In ageing and cancer the usual patterns of methylation tend to reverse, with the coding 
CpG sites becoming hypomethylated (Issa 1999; Ahuja and Issa 2000; Issa 2000; Liu, 
Wylie et al. 2003; Richardson 2003), while promoter CGI‟s become hypermethylated.  
The genome wide hypomethylation is thought to cause genomic instability and re-
expression of harmful viral genomic sequences and oncogenes, whereas the promoter 
hypermethylation can result in silencing of genes.   
 
This is illustrated in Figure 2 below: 
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It has been proposed that distinct subsets of tumours have a marked propensity for 
promoter CpG island DNA methylation and associated gene silencing.  This has been 
shown most convincingly for colorectal cancer, where it is termed CIMP (CpG island 
methylator phenotype), but is also proposed for other solid tumours.  Issa and 
colleagues initially observed a group of promoters whose methylation was associated 
with proximal colon cancers showing mucinous differentiation and a high frequency 
of micro satellite instability (MSI) (Toyota, Ahuja et al. 1999).  Yasmashita contested 
the existence of such a phenotype and that gradually acquired epigenetic changes 
could supersede genetic mutations (Yamashita, Dai et al. 2003).    Following this a 
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Figure 2.  DNA methylation and cancer. A representation of a region of DNA in non-cancerous 
(top; green) and cancerous (bottom; red) tissues showing the differences in DNA methylation in 
the two phenotypes. In non-cancerous tissue, genome wide hypermethylation of CpG's (closed 
green circles) and an actively transcribed tumour suppressor gene (TSG) is associated with a 
hypomethylated CGI (green lines). In cancerous tissue, the opposite is seen with genome wide 
hypomethylation (red lines) leading to genomic instability, and CGI hypermethylation (closed red 
circles) contributing to transcriptional silencing of a TSG (Graham, Kaye et al. 2009).   
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study by Laird and colleagues strongly suggests that CIMP does exist and that it is 
closely associated with colon cancers exhibiting BRAF mutations and MSI 
(Weisenberger, Siegmund et al. 2006).   
A similar phenotype, consisting of genes associated with DNA damage response, has 
been proposed for ovarian cancer (Strathdee, Appleton et al. 2001) (Teodoridis 2005), 
although the genes concordantly methylated are different from that seen on the 
methylator phenotype associated with colon cancer.   This study determined the 
methylation frequencies of 24 CGI‟s of genes associated with DNA damage responses 
or with ovarian cancer in 106 advanced stage EOCs.  Frequent methylation was 
observed for 6 genes including BRCA1.  Unsupervised gene shaving identified a non-
random pattern of methylation for 5 of these genes.  Methylation of at least one of the 
three genes associated with DNA repair/ detoxification was associated with an 
improved response to chemotherapy and the study supported the hypothesis of a 
methylator phenotype in EOC.   Examples of individual genes or pathways that have 
been shown to be regulated by DNA methylation are discussed in Chapter 1.3.   
In addition to promoter DNA hypermethylation and global hypomethylation various 
corresponding histone modifications are key to organising nuclear architecture and 
subsequent gene transcription and DNA methylation and histone modification have 
been shown to closely influence each other in order to regulate gene expression.  It is 
thought that chromatin alterations can determine gene expression and that subsequent 
methylation changes „lock‟ the pattern of expression; rather like a gate and a lock.   
Adult cancers may derive from stem or early progenitor cells. Ohm et al found that in 
embryonic stem cells, certain genes are held in a 'transcription-ready' state mediated 
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by a 'bivalent' promoter chromatin pattern consisting of the repressive mark, histone 
H3 methylated at Lys27 (H3K27) by polycomb group proteins, plus the active mark, 
methylated H3K4. The authors hypothesized that cell chromatin patterns and transient 
silencing of these important regulatory genes in stem or progenitor cells may leave 
these genes vulnerable to aberrant DNA hypermethylation and heritable gene 
silencing during tumour initiation and progression (Ohm, McGarvey et al. 2007).   
Embryonic stem cells rely on Polycomb group proteins to reversibly repress genes 
required for differentiation. Widschwendter et al demonstrated that stem cell 
Polycomb group targets are up to 12-fold more likely to have cancer-specific 
promoter DNA hypermethylation than non-targets, supporting a stem cell origin of 
cancer in which reversible gene repression is replaced by permanent silencing, 
locking the cell into a perpetual state of self-renewal and thereby predisposing to 
subsequent malignant transformation (Widschwendter, Fiegl et al. 2007). 
1.2.2 Histone modifications 
Histones are the protein moiety around which DNA is packaged within chromatin and 
DNA methylation at CGIs is associated with chromatin being in a repressive state for 
gene transcription.  Nucleosomes form the basic repeating subunit of chromatin and 
consist of around 147 base pairs of DNA wrapped around a histone octamer that is 
formed by four histone partners – H3, H4, H2A and H2B (Kouzarides 2007).  In 
general condensed chromatin (heterochromatin) mediates transcriptional repression, 
whereas transcriptionally active genes are in areas of open chromatin (euchromatin) 
(Kouzarides 2007).   
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Extending out of the nucleosome are charged amino-terminal histone tails which are 
subjected to a huge number of potential post-translational modifications (Kouzarides 
2007).  At least eight modifications have been observed of which the most common 
are methylation, acetylation and phosphorylation.  Modifications have previously 
been detected in more than sixty different residues and in addition the situation is 
more complex because lysines can be mono-, di- or trimethylated and arginines can be 
mono- or dimethylated (Kouzarides 2007).  Acetylation of lysine residues is catalyzed 
by histone acetyltransferases (HATS) resulting in a more open chromatin whereas 
deacetylation is performed by HDACs and associated with transcriptional repression. 
Some of the most common activating and repressive marks are shown in table 2 
below.   
Table 2  Examples of histone marks caused by methylation and acetylation. 
Histone  
Residue 
Histone  
Modification 
Histone  
Residue 
Histone  
Modification 
Activating Repressive 
H3 K4 
H3 K9 
M 
A 
H3 K9 M 
H4 K5 A H3 K27 M 
H4 K8 A   
H4 K12 A H4 K20 M 
H4 K16 A   
H histone, K lysine, M methylation, A acetylation 
 
Methylated DNA can recruit methyl binding domain proteins (MBD proteins) and 
these are able to associate with protein complexes involving histone deacetylases 
(HDAC‟s) and chromatin remodelling proteins (sin3a and mi-2).  As illustrated in 
Figure 3, transcriptionally active genes have an open structure with acetylated lysine 
residues.  In order for transcriptional repression histone deacetylation occurs which 
leads to a closed tighter binding between the positively charged lysines and the 
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negatively charged DNA backbone.  This tighter binding makes it more difficult for 
transcription factors to bind. 
 
 
 
 
 
 
 
 
 
Figure 3.  Epigenetic mechanism of transcriptional repression and chromatin 
remodelling. Active transcription is associated with an open chromatin structure, acetylated 
histones and unmethylated CpG‟s (white). RNA polymerase (RNA Pol II) (peach) and 
transcription factors can access and transcribe the gene. DNMTs methylate CpG‟s (black) 
and bind methyl binding domain, MBD, proteins (orange). Subsequent recruitment of histone 
deacetylases, HDAC, (blue) and chromatin remodelling proteins, sin3a/mi-2, (green) leads to 
remodelling of chromatin and deacetylation of histone tails. Histone methyltransferases, 
HMTs, methylate lysine residues, allowing binding of heterochromatin protein 1, HP1, (grey) 
to chromatin (Graham, Kaye et al. 2009). 
As stated, the methylation of DNA is usually connected to certain histone 
modifications and this sets a mark for the binding of methyl-binding domain proteins, 
which act in a chromatin-repressive mode (Chapman-Rothe Nadine 2009).  As an 
example of the interaction between the various histone modifications, the histone 
position H3K9 is a site of both acetylation and methylation.  Deacetylation of H3K9 is 
required for methylation to occur, which is then a repressive epigenetic mark.  
Trimethylation of H3K9 results in the recruitment and binding of the transcriptional 
repressor, heterochromatin protein HP1.  HP1 binding to the methylated H3 forms a 
positive feedback loop, mediating the propagation of heterochromatin over wide 
chromosomal ranges.  Thus, covalent modification of the histone tails directly affects 
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higher order chromatin structure and thereby offers a mechanism of epigenetic gene 
activation or silencing (Graham, Kaye et al. 2009). 
1.2.3 MicroRNA 
The most recent area of interest has been of the role of microRNAs (miRNAs) in 
epigenetic regulation.  MiRNA‟s are short pieces of non-coding, single stranded 
RNA, 21-25 nucleotides long, which can also control genes expression (He and 
Hannon 2004; Chapman-Rothe Nadine 2009).  They were first identified in C 
elegans, where Lin-4 was shown to have a key role in development, and have since 
been shown to be highly conserved amongst species (Pasquinelli, Reinhart et al. 2000)  
Most miRNAs bind to the target 3‟ untranslated region (UTR) and act as translational 
repressors (Bartel 2004).  An additional role has been characterised whereby they 
have shown to be components of the RNA interference pathway (RNAi).  Here they 
behave in a similar manner to siRNAs although there are some differences; miRNAs, 
especially those in animals, usually exhibit imperfect base pairing to a target and 
inhibit the translation of many different mRNAs (messenger RNA) with similar 
sequences. In contrast, siRNAs typically base-pair perfectly and induce mRNA 
cleavage only in a single, specific target (Pillai, Bhattacharyya et al. 2007).  
MiRNA profiling has been performed in ovarian cancer and has been shown to 
successfully differentiate ovarian tumours from normal ovary.  It has also been able to 
define sub groups with significantly different survival times.  MiRNAs could 
potentially be a rich source of epigenetic markers, like DNA methylation.  Exosomes, 
generated from tumour cells and circulating in the blood, have been shown to contain 
miRNA reflecting that expressed in the original tumour, representing a potential 
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surrogate marker (Taylor and Gercel-Taylor 2008).  In addition, miRNAs may play a 
role in regulating cisplatin response as miR-214 has been shown to negatively 
regulate PTEN at the 3‟ UTR and this particular miRNA is upregulated in many 
ovarian tumours.  Interestingly this effect could be reversed using AKT inhibitors 
confirming the link between miR-214, the AKT pathway and platinum resistance 
(Yang, Kong et al. 2008).   
As discussed, there is thought to be a complex interaction between DNA methylation, 
histone modifications and more recently microRNA, which is not fully understood - 
and in the case of DNA methylation it is likely that small changes in lots of genes 
rather than substantial methylation of an individual candidate is clinically relevant.  
This means that the ability to detect small real changes as opposed to false positives 
remains a big challenge if we are to be able to translate from the bench to the bedside, 
using high throughput studies such as methylation and expression arrays.  For the 
purpose of this thesis I will concentrate solely on the role of DNA methylation at the 
gene promoter in cancer and more specifically its role in acquired drug resistance.  
  
1.3 Drug resistance in ovarian cancer 
For the majority of patients the standard of care remains extensive surgery +/- 
carboplatin and paclitaxel. Although approximately 80% respond to initial treatment, 
5 year survival remains poor at approximately 40% and drug resistance is thought to 
cause treatment failure and death in more than 90% of patients with metastatic disease 
(Greenlee, Hill-Harmon et al. 2001; Agarwal and Kaye 2003).   
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The 20% of patients who essentially never respond to chemotherapy are defined as 
having intrinsic drug resistance and for the rest who initially respond and then relapse 
the term acquired drug resistance is used.  For this group less frequent and shorter 
duration of responses are consistently seen following re-treatment (Vasey 2005). The 
mechanisms underlying intrinsic and acquired drug resistance are thought to be 
different.   
 
There are two main hypotheses for how acquired drug resistance occurs and this is 
one of the most controversial parts of ovarian research in current times.  One theory is 
that ovarian cancer is derived from different clones and that over time a selective 
pressure is applied, via chemotherapy, whereby the chemosensitive clones disappear 
and the chemoresistant clones are left – survival of the fittest.   
 
The alternative hypothesis is that „cancer stem cells‟ (CSC) exist and that 
chemotherapy kills off the standard cancer cells but the cancer stem cells are not 
targeted effectively (Agarwal and Kaye 2003).  Cancer stem cells must be capable of 
self renewal and able to form cells which differentiate into multiple different cell 
types.  In addition they must be highly tumorogenic and often the test of whether a 
subpopulation is tumour initiating is their ability to cause tumours from a very low 
cell number.  The two hypotheses are shown in Figure 4 below: 
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Figure 4.  Models of drug resistance in ovarian cancer. (a) Regrowth of a persistent stem 
cell population (peach) which can be initially chemosensitive. (b) Initial response to 
chemotherapy (CTX) seen due to drug sensitive cells (peach) followed by clonal expansion of 
a subpopulation of chemoresistant cells/regrowth of a chemoresistant progenitor cell 
population (red).  (c) Most likely scenario is a combination of (A) and (B) where 
chemoresistance develops after initial chemosensitive relapse. Illustration modified from 
Agarwal and Kaye, 2003 (Agarwal and Kaye 2003). 
 
The underlying cause of acquired drug resistance was recently investigated by Cooke 
et al.  In order to investigate this in high-grade serous (HGS) ovarian cancers, the 
authors first analysed cell line series derived from three cases of HGS carcinoma 
before and after platinum resistance had developed (PEO1, PEO4 and PEO6; PEA1 
and PEA2; and PEO14 and PEO23) (see chapter 2.17.4). They then performed 
analysis using 24-colour fluorescence in situ hybridisation (FISH) and SNP array 
comparative genomic hybridisation (CGH) and showed mutually exclusive 
endoreduplication and loss of heterozygosity events in clones present at different time 
points in the same individual. This implies that platinum-sensitive and -resistant 
disease was not linearly related, but shared a common ancestor at an early stage of 
tumour development. Array CGH analysis of six paired pre- and post-neoadjuvant 
treatment HGS samples from the CTCR-OV01 clinical study did not show extensive 
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copy number differences and this suggested that one clone was strongly dominant at 
presentation. Their data demonstrated that cisplatin resistance in HGS carcinoma 
develops from pre-existing minor clones but that enrichment for these clones is not 
apparent during short-term chemotherapy treatment (Cooke, Ng et al. 2010). 
 
Tumour sustaining cells were first identified in leukaemia cells (CD34+/CD38-) by 
Bonnet and colleagues (Bonnet and Dick 1997).  In solid tumours sub populations 
with stem cell properties were first demonstrated in breast cancer (CD 44+/24-) (Al-
Hajj, Wicha et al. 2003) and more recently in ovarian cancer among others (glioma, 
melanoma, prostate, colon, lung, head and neck and pancreatic cancer)(Collins, Berry 
et al. 2005; Fang, Nguyen et al. 2005; Kim, Jackson et al. 2005; Dalerba, Dylla et al. 
2007; Li, Heidt et al. 2007; Prince, Sivanandan et al. 2007).   
 
Cancer initiating cells in ovarian cancer were first proposed in 2005 by Bapat and 
colleagues (Bapat, Mali et al. 2005).  They identified a subgroup of cells that could 
grow in spheroid culture, in a similar manner to that found in ascites (Burleson, Casey 
et al. 2004), and when injected into mice could form tumours similar to the original 
tumour.  These cells expressed CD117 (Natali, Nicotra et al. 1992).  Szotek et al one 
year later demonstrated a subpopulation, using their dye efflux ability, which were 
highly tumorogenic compared to the cells that had retained the dye (Szotek, Pieretti-
Vanmarcke et al. 2006).  These cells also expressed CD117.   
 
More recently Zhang et al demonstrated a distinct sub population in ovarian cancer 
that fulfilled all the criteria of a tumour sustaining cells – they were highly 
tumorogenic, showed increased chemoresistance and up regulation of stem cell and 
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chemoresistance associated genes as demonstrated by RTPCR.  OCT4, NESTIN, 
NANOG, SCF, NOTCH-1, BMI-1 and ABCG2 were examined in two tumour samples.  
All genes showed a clear increase in expression in the ovarian cancer initiating cells 
(OCIC‟s) grown under stem cell selective conditions as compared to the parental bulk 
of cancer cells or OCIC‟s grown in differentiated conditions (withdrawal of growth 
factors and addition of 10% FBS). OCT4, NESTIN and NANOG are established stem 
cell markers necessary for embryogenesis, neurigenesis and haemopoiesis (Loh, Wu 
et al. 2006) (Mohle and Kanz 2007) (Wiese, Rolletschek et al. 2004).  The Notch 
pathway was shown to be important by Hopfer et al (Hopfer, Zwahlen et al. 2005).   
 
Tumour sustaining cells possess several of the characteristics that promote 
chemoresistance such as expression of membrane efflux transporters, enhanced DNA 
repair and low mitotic index hence the addition of ABCG2 to the RTPCR profile 
(Sharom 2008).  Zhang used CD117 and additional CD44+ selection to define the 
stem cell population (Zhang and Rosen 2006).  The main controversy surrounds the 
origin of these cells – i.e. do cancer stem cells originate from normal stem cells or do 
they arise within the tumour itself somehow acquiring this phenotype.   
 
In addition to the debate as to whether drug resistance is selected for during 
chemotherapy as a result of the emergence/ persistence of drug resistant clones or 
CSC‟s a wide variety of mechanisms for acquired drug resistance have been 
investigated in vitro.  These can broadly be divided into pharmacokinetic (PK) and 
pharmacogenomic (PD) variation relating to the individual patient and changes in the 
tumour itself and its microenvironment.   
 
  47 
 
1.3.1 Intrapatient variation 
Patients have varying first pass metabolism, ability to convert prodrugs to their active 
metabolite and varying rates of hepatic metabolism and renal clearance.  It is thought 
that some patients are more able to efficiently efflux active drug from their cells.  In 
addition silencing of drug sensitivity genes, TSGs and genes involved in for example 
DNA damage response (as cisplatin induces DNA damage) are likely to affect 
chemosensitivity and hence resistance.   Currently most chemotherapies are dosed 
using the patient‟s surface area (a measure proportional to their height and weight) but 
it is clear from the huge variation in toxicity that patients get from chemotherapy that 
this is over simplistic.  If a biomarker could be optimized that predicted the dose 
necessary for a patient to obtain the maximal biological effect with minimal toxicity 
this would be of huge utility. 
 
1.3.2 Key processes and pathways implicated in drug 
resistance  
1.3.2.1 Drug efflux 
Cancers often develop resistance to multiple drugs and this is termed multi drug 
resistance.  The ABC transporter proteins consist of several members - P-glycoprotein 
(PGP) (Baekelandt, Holm et al. 2000), multidrug resistance protein (MRP1 or 
ABCB1) (Marsh, King et al. 2006; Green, Soderkvist et al. 2008; Johnatty, Beesley et 
al. 2008; Grimm, Polterauer et al. 2010), lung resistance-related protein (LRP) and 
breast cancer resistance protein (BCRP or ABCG2) (Dou, Jiang et al. 2010).  LRP 
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expression has been shown to confer a poorer prognosis in squamous lung cancer and 
acute myeloid leukaemia (AML) (Zhou, Zittoun et al. 1995) and to predict a poorer 
response to treatment in AML and ovarian cancer (Izquierdo, van der Zee et al. 1995).  
These proteins are all involved in drug efflux – i.e. they result in more of the cancer 
drug being excluded from the cancer cell and interestingly, more recently, this 
property has been utilized to identify „side populations‟ thought to represent cancer 
stem cells; as this is thought to be one of their key attributes.   
Various single nucleotide polymorphisms (SNPs) have been investigated in drug 
efflux proteins in ovarian cancer although results have been conflicting.  Bosch et al 
demonstrated that ovarian cancer patients homozygous for the C1236T SNP in 
ABCB1 showed a 25% decrease in the clearance of docetaxel compared to wild-type 
or heterozygous however Nakajima and colleagues could not reproduce this in their 
population.  And in contrast Nakajima found the C3435T SNP in ABCB1 to be 
associated with paclitaxel clearance whereas Bosch had not found this (Bosch, 
Huitema et al. 2006), (Nakajima, Fujiki et al. 2005).  Equally inconsistent results have 
been seen when predicting response to chemotherapy (Johnatty, Beesley et al. 2008). 
PGP is normally expressed at detectable levels in organs including the colon, adrenal 
gland, kidney and liver.  The MDR1 gene encodes PGP and is thought to be over-
expressed in about 50% of cancers (Hochhauser and Harris 1991).  In solid tumours 
the most research relating to this protein has been in breast cancer.  High PGP levels 
in post-treatment samples correlate with poor outcome but it was unclear what the 
mechanism for this was (Trock, Leonessa et al. 1997).  In osteosarcoma and colon 
cancer uncertainty also exists about the correlation between PGP over expression and 
drug efflux and there is some suggestion that PGP may also confer increased 
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aggressiveness (Linn and Giaccone 1995; Eid, Bodrogi et al. 1996; Oka, Fukuda et al. 
1997). 
1.3.2.2 Drug inactivation 
In addition to the pumps themselves, others have also investigated the level of 
activating and detoxifying enzymes present within cells.  The Glutathione S-
transferases (GSTs) are a group of detoxifying enzymes that are involved in cisplatin 
and doxorubicin metabolism, among others.  Multiple isoenzymes exist of which GST 
π is the predominant one in ovarian cancer (Ikeda, Sakai et al. 2003; Cao, Shen et al. 
2007).   
GSTP1 is frequently methylated in prostate and ovarian cancer and epigenetic 
silencing may increase chemosensitivity by preventing detoxification of 
chemotherapy  (Hayes and Strange 2000).  Conflicting studies have been published in 
ovarian cancer with some laboratories demonstrating a correlation between the 
isoenzyme expression and poorer response to chemotherapy, overall survival, and 
increased residual tumour at the end of chemotherapy (Green, Robertson et al. 1993) - 
whilst others have not been able to reproduce this (Tanner, Hengstler et al. 1997).   
1.3.2.3 DNA repair, damage signaling and apoptosis 
As outlined in Chapter 1.1 the platinum family of drugs are the cornerstone 
chemotherapies in ovarian cancer.  Originally cisplatin was utilized but more recently 
carboplatin was shown to be at least as efficacious and less toxic (Darcy, Tian et al. 
2007).  These drugs exert their effects by forming DNA-platinum adducts, resulting in 
apoptosis (Kartalou and Essigmann 2001).  DNA is repaired when these DNA adducts 
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are recognized and removed via the nucleotide excision repair (NER) pathway.  As 
most patients initially respond to treatment but subsequently relapse aberration of the 
DNA repair pathways is thought to be a critical mechanism of acquired drug 
resistance.     
ERCC1 is a nucleotide excision repair gene, which is hypothesized to have a role in 
ovarian cancer although conflicting studies exist.  It encodes a DNA repair protein 
that forms part of the NER pathway.  GOG 158 was a large randomized Phase III 
which reported in 2000.  It compared cisplatin and a long infusion of paclitaxel with 
carboplatin and a short infusion of paclitaxel.  One of the secondary endpoints of this 
study was the correlation between mRNA expression of ERCC1 and PFS and OS in 
peripheral blood leukocytes and no link was seen (Darcy, Tian et al. 2007).    
Most of the other clinical studies have investigated the role of SNPs in ERCC1 and 
response to treatment or prognosis.  GOG-172, a randomized Phase III study of IP and 
IV cisplatin and paclitaxel vs. IV administration only, for the treatment of newly 
diagnosed, stage III ovarian cancer included a secondary endpoints which investigated 
whether the codon 118 polymorphism in ERCC1 was associated with prognosis.  This 
particular SNP was not significantly associated with disease progression or death 
although other studies have suggested that there is a correlation between ERCC1 
SNPs and both PFS and OS in ovarian cancer (Krivak, Darcy et al. 2008).  Steffenson 
et al though found that in ovarian cancer, ERCC1 codon 118 SNPs predicted response 
to chemotherapy but did not impact on survival.  The main criticism leveled at the 
SNP studies to date is that most have been too small and therefore not adequately 
powered to answer these questions definitively.   
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Mismatch repair (MMR) is another key DNA repair pathway; it is required for 
engagement of apoptosis (Anthoney, McIlwrath et al. 1996; Drummond, Anthoney et 
al. 1996) and loss of MMR results in microsatellite instability which can be detected 
in plasma DNA.  MLH1 is part of this pathway and its gene expression can be 
silenced by methylation.  Such methylation has been demonstrated in 40% of ovarian 
tumours and is more frequent in samples from recurrence (compared with the primary 
tumour).  Gifford et al have shown that a high proportion of EOC patients in the 
SCOTROC1 trial acquire methylation of MLH1, as detected in plasma DNA, 
following chemotherapy and that this correlates with poorer survival in ovarian cancer 
(Gifford, Paul et al. 2004).    
MLH1 methylation can be reversed using decitabine (dac) and this results in reversal 
of drug resistance in human tumour xenografts (Plumb, Strathdee et al. 2000) hence 
showing the potential of methylation as both a biomarker and a potentially drugable 
target in ovarian cancer.  Although these pre-clinical results suggest that 
demethylating agents could enhance tumour sensitivity to platinum based 
chemotherapy via re-expression of MLH1 especially in patients with ovarian cancer 
who have relapsed following chemotherapy this has not been proven prospectively in 
a clinical trial, as yet.  
FANCF is another protein, belonging to the same family as BRCA2, which is known 
to have a role in modulating DNA repair.  Gene expression can be affected by 
mutation or methylation and this results in increased susceptibility to DNA cross 
linking agents such as cisplatin (D'Andrea 2003).  Taniguchi showed that FANCF was 
methylated in EOC cell lines and that this correlated with lack of mono-ubiquitinated 
FANCD2 and hypersensitivity to cisplatin and mitomycin C (Taniguchi, Tischkowitz 
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et al. 2003).  This is an example of the double-edged sword of demethylating agents, 
as in this case there is a risk that demethylating drugs could actually result in 
decreased response to chemotherapy. 
Numerous components of the apoptosis pathway have been implicated in cisplatin 
resistance, including BCL2, BAD, BAX and XIAP although a direct link to acquired 
drug resistance in ovarian cancer remains to be established for most.  RASSF1A is 
frequently methylated in ovarian cancer (Yoon, Dammann et al. 2001) and has been 
associated with disease progression in breast cancer (Yan, Shi et al. 2003).  RASSF1A 
binds to tubulin resulting in microtubule stabilization and as the taxanes are the 
second key group of drug in ovarian cancer this is likely to be of clinical relevance.  
Heat shock protein (HSP) 90 inhibitors, which target this pathway, are currently being 
tested in clinical trials in solid tumours  (Powers and Workman 2006) .   
1.3.2.4 Growth factor signaling 
The growth factor signaling pathways are the focus of many research groups and 
much of the interest in developing novel therapies has been channeled towards 
designing molecules that target these pathways.  EGFR (ERBB1) and ERBB2, both 
cell surface receptor tyrosine kinases, are overexpressed in ovarian cancer (Nielsen, 
Jakobsen et al. 2004; Zhou, Qiu et al. 2006; Sheng and Liu 2011).  They signal via 
both the MAPK and P13K pathways and activation of these pathways can lead to 
phosphorylation of BAD and BCL2 inhibiting apoptosis.  Overexpression of EGFR 
and ERBB2 has been associated with cisplatin resistance in vitro and poor prognosis 
in ovarian cancer, in vivo (Benedetti, Perego et al. 2008).  In addition amplifications 
of PI3K and activation of AKT have been predicted in approximately one third of 
patients with ovarian cancer and drugs targeting both these pathways are in 
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development (Zhang, Zhang et al. 2009).  PTEN, the frequently dysregulated tumour 
suppressor gene, is known to regulate AKT signaling (Li, Gao et al.).  In addition to 
inactivation by deletions and mutations it has been shown to be epigenetically 
regulated, with gene silencing secondary to methylation in lung amongst other cancers 
(Soria, Lee et al. 2002). 
1.4 Summary of key points from the 
introduction relevant to this project 
Epigenetic silencing of genes via DNA promoter methylation is seen in multiple 
critical genes and pathways associated with ovarian cancer.  Epimutations occur more 
frequently than genetic mutations and they can be detected readily in surrogate tissues 
such as plasma and ascites (Gifford, Paul et al. 2004).  This means that methylation 
profiling can be utilised to identify key pathways which can then be investigated in 
more depth, by functional analysis of key genes.   
 
Aberrant DNA methylation can potentially be used to diagnose cancer earlier or to 
identify groups of patients who may benefit from epigenetic and other targeted 
therapies(Gifford, Paul et al. 2004).  In addition, for genes that acquire methylation 
during the course of chemotherapy it can highlight pathways and key genes that are 
important in ovarian cancer pathogenesis (Dai, Teodoridis et al. 2010).  Epigenetics is 
being increasingly implicated in both embryonic and cancer stem cell initiation and 
maintenance and therefore study of DNA methylation may help to further unravel the 
answers to cancer initiation and maintenance (Rizzo, Hersey et al. 2011).    
 
  54 
It appears that small changes in multiple genes may be of more functional 
consequence than large changes in one gene and this presents a real challenge when 
interpreting results from high throughput analyses.  In addition, differentiating 
mutations that are fundamental – so called „driver (epi) mutations‟ from ones that are 
observed but not critical – so called „passenger mutations‟ will be the key to using 
these techniques to increase our knowledge.  The field of epigenetics is becoming 
increasingly complex and the interplay between DNA promoter methylation, histone 
modifications and micro- and non-coding RNAs is not fully understood. 
 
1.4.1 Thesis hypotheses to be tested 
The aim of the experiments outlined in this thesis was to investigate whether 
increased methylation of genes in drug resistant ovarian tumour cell lines could 
identify novel biomarkers of acquired drug resistance in EOC.  If this was the case 
one would predict that these candidates would show increased methylation in matched 
tumour pairs following chemotherapy if in vitro resistance correlates with in vivo 
resistance.  In addition it could be hypothesised that changes in methylation would 
cluster to particular key pathways which are required for ovarian cancer initiation and 
progression.  In order for methylation to have a phenotypic effect it would be 
predicted that an increase in methylation would correlate with a decrease in 
expression and that this could be reversed using demethylating agents.  In order to 
address these questions bioinformatic approaches were combined with microarray 
analysis of methylation by differential methylation hybridistion (DMH) in order to 
identify differentially methylated genes in human ovarian cell line models of acquired 
drug resistance.  Any genes identified in this manner were independently validated in 
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the laboratory using MSP or pyrosequencing of bisulphite modified DNA – in 
matched sensitive and resistant cell lines, primary ovarian cancer tumour pairs and 
matched samples from patients with ovarian cancer, pre- and post- relapse.  The 
correlation between promoter methylation and gene expression was investigated using 
qRTPCR in cell lines that had been treated with or without decitabine, and in order to 
assess the phenotypic effect of knockdown or over-expression of key genes short 
interfering RNA (siRNA) and over-expression following gene reintroduction were 
performed respectively.   
1.4.2 Outline of the aims of the experiments outlined in each 
individual chapter 
The aim of the experiments outlined in chapter 3 was to identify and validate novel 
DNA methylation markers for acquired drug resistance in ovarian cell lines and 
evaluate their relevance to acquired resistance in patient samples using prediction 
analysis for microarrays (PAM).  We also aimed to validate pyrosequencing of 
bisulphite-modified DNA as a better technique for examining candidate loci in the 
laboratory, than MSP.   
 
In Chapter 4, following a comparison of the A2780 sensitive and resistant cell lines, 
the loci identified using methylation linear discrimination analysis (MLDA) vs. PAM 
were characterised in order to assess whether this novel statistical method was useful 
as a means of detecting differentially methylated loci.  Again loci identified 
biostatistically were characterised in the laboratory by both MSP and pyrosequencing.   
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In Chapter 5 the main aim of the experiments outlined was to assess whether loci 
identified by comparing in vivo derived cell lines (as opposed to the previous 
experiments which had all compared in vitro derived cell lines) could guide us to 
more clinically important genes or pathways.   
 
The primary aim of Chapter 6 was to use functional assays to further assess the effect 
of over- and under-expression of two genes which had been identified in previous 
chapters.  qRTPCR, siRNA knockdown and over expression using whole gene 
cloning were all utilised.   
 
In work that was performed in parallel to these experiments, in Chapter 7 OGT 
customised arrays were used to hybridise both cell lines and primary tumour samples, 
using DMH.  The preliminary results of loci identified from these experiments are 
discussed and in particular the loci which had been identified from the original 12k 
array, and characterised in earlier chapters of the thesis, were re-examined in this 
independent data set.    
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2 Materials and Methods 
2.1 Addresses for companies used. 
Abgene Abgene House, Blenheim House, Epsom, Surrey, 
KT19 9AP 
Ambion Now Applied Biosystems 
Amersham Biosciences  Now GE Healthcare Life Sciences; Amersham 
Place, Little Chalfont, Buckinghamshire, HP7 9NA 
Anachem, Lambda Anachem House, 1&2 Titan Court, Laport Way, 
Luton, Bedforshire, LU4 8EF 
Applied Biosystems Lingley House, 120 Birchwood Boulevard, 
Warrington, Cheshire, WA3 7QH 
Autogen Bioclear 1 Orchard Place, Nottingham Business Park, 
Nottingham, NG8 6PX 
B Braun Thorncliffe Park, Sheffield, S35 2PW 
Beckman Coulter Oakley Court, Kingsmead Business Park, London 
Road, High Wycombe, HP11 1JU 
Becton Dickinson (BD) The Danby Building, Edmund Halley Road, Oxford, 
OX4 4DQ 
Bibby-Sterilin Limited Parkway Building, Pen - Y - Fan Industrial State, 
Newport, Gwent, NP11 3EF 
Biorad Bio-Rad House, Maxted Road, Hemel Hempstead, 
Hertfordshire, HP2 7DX 
Biotage GB limited Distribution Way, Dyffryn Business Park, Ystrad 
Mynach, Hengoed CF82 7TS  
Biotek UK 6 Bull Street, Potton, Bedfordshire SG19 2NR 
Chemicon Now Millipore 
Corning Elwy House, Lakeside Business Village, St. David's 
Park, Ewloe, Flintshire, CH5 3XD 
Dharmacon  Now Thermo Scientific 
Drummond Scientific Distributed in UK by Alpha laboratories; Alpha 
Laboratories, 40 Parham Drive, Eastleigh, 
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Hampshire, SO50 4NU 
Eppendorf AG Endurance House, Vision Park, Histon, Cambridge, 
CB24 9ZR 
Falcon Now BD 
Finnzymes Now Thermo Scientific 
Fisher Bishop Meadow Road, Loughbororugh, 
Leicestershire, LE11 5RG 
FlowJo Tree star Inc 340 A Street Suite # 206 - Ashland, OR 
97520 USA 
Genisphere LLC 2801 Sterling Drive, Hatfield, PA 19440 
Genlab Tanhouse Lane, Riverview Industrial Estate, 
Widnes, Cheshire, WA8 0SR. 
Gibco Supplied by Invitrogen 
Grant  Shepreth, Cambridgeshire, SG8 6GB 
Greiner bio-one Greiner Bio-One Ltd. Brunel Way, Stroudwater 
Business Park, Stonehouse, GL10 3SX 
Hayman supplied by Fisher 
Heraeus Now Thermo Scientific 
Hettich Zentrifugen Föhrenstr.12, D-78532 Tuttlingen, Germany 
Imperial College London Imperial College London central stores, 
Hammersmith Hospital Campus, Du Cane Road, 
London, W12 0NN 
Invitrogen 3 Fountain Drive, Inchinnan Business Park, Paisley, 
PA4 9RF 
Iwaki  Now Corning 
Labcaire 175 Kenn Road, Clevedon, Somerset, BS21 6LH 
Labsystems Now Thermo Scientific 
LabTech 1 Acorn House, The Broyle, Ringmer, East Sussex, 
BN8 5NW 
MMM Medical Equipment 
UK 
Unit 2-3, Gateway Drive Business Park, Gate Way 
Drive, Yeadon, Leeds (West Yorkshire), LS19 7XY 
Lomita Distributed in UK by VWR 
Melford Bildeston Road, Chelsworth, Ipswich, Suffolk, IP7 
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7LE 
Mettler 64 Boston Road, Beaumont Leys, Leicester, LE4 
1AW 
Millipore Units 3&5 The Courtyards, Hatters Lane, Watford, 
Hertfordshire, WD18 8YH 
MJ Research 1815 Edgewood Street , St. Bruno (Quebec), 
Canada, J3V 4P1  
Molecular devices 660-665 Eskadale Road, Winnersh Triangle, 
Wokingham, RG41 5TS 
Nanodrop Now Thermo Scientific 
NBS Biologicals 14 Tower Square, Huntingdon, Cambridgeshire, 
PE29 7DT 
New Brunswick Scientific 17 Alban Park, Hatfield Road, St Albans, 
Hertfordshire, AL4 0JJ 
New England Biolabs 67 Knowl Piece, Wilbury Way, Hitchin, 
Hertfordshire, SG4 0TY 
Nunc Now Thermo Scientific 
Ohaus Ohaus Europe GmbH, Heuwinkelstrasse 3, CH-8606 
Nänikon, Switzerland (European Headquaters) 
Origene UK distributor Cambridge Biosciences; Munro 
House, Trafalgar Way, Bar Hill, Cambridge CB23  
PAA Termare Close, Hounstone Business Park, Yeovil, 
Somerset, BA22 8YG 
Perkin Elmer Chalfont Road, Seer Green, Beaconsfield, 
Buckinghamshire, HP9 2FX 
Pharmacia Davy Avenue, Knowlhill, Milton Keynes, MK5 8PH 
Pharmacia Biotech Now GE Healthcare Life Sciences; Amersham 
Place, Little Chalfont, Buckinghamshire, HP7 9NA 
Promega Delta House, Chilworth Science Park, Southampton, 
Hampshire, SO16 7NS 
Qiagen Qiagen House, Fleming Way, Crawley, West 
Sussex, RH10 9NQ 
Roche  Charles Avenue, Burgess Hill, East Sussex, RH15 
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9RY 
Sanyo 9 The Office Village, North Road, Loughborough, 
Leicestershire, LE11 1QJ 
Scientific Industries Distributed in UK by VWR 
Sigma Fancy Road, Poole, Dorset, BH12 4QH 
Sterilin Parkway Building, Pen - Y - Fan Industrial State, 
Newport, Gwent, NP11 3EF 
Syngene Beacon House, Nuffield Road, Cambridge, CB4 1TF 
Thermo Electron 
Corporation 
Unit 5 The Ringway Centre, Edison Road, 
Basingstoke, RG21 6YH 
Thermo Scientific Stafford House, Boundary Way, Hemel Hempstead, 
Hertfordshire, HP2 7GE 
Trigene Supplied by Medichem International; PO Box 237, 
Sevenoaks, Kent, TN15 0ZJ 
VWR  Hunter Boulevard, Magna Park, Lutterworth, 
Leicestershire, LE17 4XN 
 
2.2 General equipment 
Accuspin micro 17 centrifuge  Fisher 
Gilson Pipettes     Anachem, Lambda 
Heating block Dri-Block DB 2A  Techne 
Incubator (37
o
C)    Genlab 
Innova 4000 incubator shaker   New Brunswick Scientific 
Microcentaur microcentrifuge  Hettich Zentrifugen 
Microwave      Sanyo 
Nanodrop ND-1000 spectrophotometer LabTech  
PCR workstation    Labcaire  
Luckham Rocking Table    MMM Medical Equipment UK 
Set of scales PM 300     Mettler 
Tetrad 2 peltier thermal cycler  Biorad 
Genie 2 Vortex      Scientific Industries 
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Water bath SUB36    Grant  
Electrophoresis power supply EPS600   Pharmacia Biotech 
Electrophoresis tank     Fisher 
Magnetic stirrer     Fisher 
Pyromark MD pyrosequencer   Biotage 
 
  
 
2.3 General chemicals 
All chemicals were of the highest quality available and supplied by Sigma unless 
stated.  
2.4 General glass and plasticware 
Bijous (5ml)      Bibby-Sterilin Limited 
Eppendorf tubes (1.5ml)    Eppendorf AG 
Falcon tubes (15ml and 50ml)   Becton Dickinson Labware 
Glass pipettes (5, 10, 25ml)    Becton Dickinson Labware 
Sterile Pipette filter tips (10, 20, 200, 1000µl) Greiner bio-one  
Universal containers (20ml)    Bibby-Steriline Limited 
Universal containers (30ml and 100ml)  Sterilin 
 
2.5 Patient samples and characteristics 
2.5.1 Primary ovarian cancer and residual disease matched 
pairs 
12 pairs of ovarian surface epithelial tumours were obtained from the University 
Medical Center Groningen (Groningen, The Netherlands), with appropriate ethical 
approval. Of these, one sample was taken before chemotherapy; the second sample 
was taken at second look surgery after chemotherapy. All samples were stored frozen 
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at -70°C.  All paired tumour samples were sent to the Paediatric Malignancy Core 
Facility at Great Ormond Street Hospital for genotyping.  They used the Promega 
Powerplex 16 system (www.promega.com/products/genetic.../str.../powerplex-16-
system/) which identifies matching probabilities that fall between 1 in 1.83x10
17
 and 1 
in 1.41x10
18
.  Unfortunately two of the relapse pairs were found to not be matched.  
Samples 55 and 57 had 10 matched and 33 unmatched alleles.  Samples 125 and 98 
had 11 matched and 32 unmatched alleles.  These samples therefore had to be 
removed from the analysis, limiting the number of samples to a maximum of 10 pairs. 
 
2.5.2 Primary ovarian cancer and relapsed disease matched 
pairs 
14 pairs of ovarian surface epithelial tumours were obtained from the Department of 
women and children at Leuven University Belgium, again with appropriate ethical 
approval.  One sample was taken at diagnosis and one at relapse.  All samples were 
stored frozen at -70°C.  All paired tumour samples were sent to the Paediatric 
Malignancy Core Facility at Great Ormond Street Hospital for genotyping and found 
to be true matches.   
2.5.3 Ovarian cancer “retrospective” primary tumour samples 
Tumour samples and matching adjacent normal tissue were collected from 
chemonaive patients who had surgery for suspected ovarian cancer.  Only those 
patients with pathologically confirmed EOC were included in the analysis. Ethical 
approval for all samples collected was obtained from relevant authorities and samples 
were collected according to Medical Research Council operational and ethical 
guidelines on “Human tissue and biological samples for use in research”.  The 
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following data were recorded: age at diagnosis, stage and grade of tumour at 
diagnosis, details of any chemotherapy given and the subsequent response to this in 
months (chemotherapy at diagnosis or relapse),  (responses categorised as complete 
response (CR), partial response (PR), stable disease (SD), progressive disease (PD)).  
PFS and OS were also documented for most patients.  DNA was extracted from the 
primary tumours and also from matching adjacent normal where available, and stored 
anonymously at -70
o
C.  Stage was categorised I-IV using FIGO and age was 
categorised on the median value. 
2.5.4 Ovarian cancer “prospective” primary tumour samples 
Tumour samples were collected from chemonaive patients undergoing cytoreductive 
surgery for suspected ovarian cancer. Matched blood samples were collected from a 
number of patients in the prospective “DNA Methylation Study” at the time of 
admission to hospital for surgery. Again, only those patients with pathologically 
confirmed EOC were included in the analysis. Ethical approval for all samples 
collected was obtained from relevant authorities and samples were collected 
according to Medical Research Council operational and ethical guidelines on “Human 
tissue and biological samples for use in research”.  
All tumour and separated blood samples were stored at -70
o
C until required for 
analysis. Pathology reports, including histological subtype and grade, were obtained 
where possible.  Reasonably complete clinical data sets were available for the 
following clinical factors: FIGO stage at diagnosis, age, performance status (PS) and 
size of residual disease at primary surgical procedure. These data were collected 
prospectively through the Glasgow West of Scotland Cancer Centre Clinical Trials 
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Unit. Stage was categorised using FIGO criteria into early (Stage I/II) versus late 
(Stage III/IV), age was categorised on the median value, PS was classified as 0, 1 or 
2/3 and residual disease as ≤2cm or >2cm. 
Response to chemotherapy was measured in all patients that had evaluable disease i.e. 
had measurable disease following cytoreductive surgery prior to chemotherapy. This 
was done anonymously, blinded to the methylation status of each patient and response 
was defined by modified Southwest Oncology Group (SWOG) criteria (Vasey, Jayson 
et al. 2004). Patients who were evaluable for response to chemotherapy were 
classified into two groups: responders were those with complete response or partial 
response and non-responders were those with stable disease or progressive disease.  
For all sample collections PFS was defined as the time from first chemotherapy or 
entry into a clinical trial (if applicable) until date of second line chemotherapy or 
progression or cancer related death. Progression was defined as either a ≥25% 
increase in size of at least one measureable lesion, worsening previously evaluable 
disease, recurrence of a previously successfully treated lesion or appearance of a new 
lesion as measured on CT scan. Overall survival was calculated from the date of first 
chemotherapy or date of entry onto a trial (if applicable) until the date of cancer 
related death. 
2.5.5 Patient characteristics 
The primary tumour characteristics are outlined below; mean age was 60 and the 
majority of tumours were of advanced stage.  Known clear cell and mucinous 
histology was excluded. Table 3a shows the cohort of tumours that were used for 
analysis of methylation of candidate loci. Table 3b shows the sub-cohort that were 
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used for DMH using customised arrays (OGT II).  Table 3c is the updated table that 
appeared in the Dai et al publication following reviewers comments re correct 
pathology for “unknown” samples (Dai, Teodoridis et al. 2010). 
Table 3a Characteristics of primary tumour samples (combined cohort). 
Clinical Parameters (n=210) (includes test and validation samples) 
Age 
Range (19, 83) 
mean (95% CI), Years 60 (59, 62) 
FIGO Stage 
Ic 16 
II 7 
III 142 
 IV 43 
 Missing 2 
Grade 
G1 61 
G2 29 
G3 76  
Gx 44 
Histology 
Serous 148 
Endometrioid 20 
Unknown 42 
Chemotherapy 
Platinum alone 50 
Platinum + Taxane 118 
Other Platinum-based 12 
 Taxane 2 
 No treatment 6  
 Unknown 22  
Response 
CR (Complete response) 54  
PR (Partial response) 42 
SD (Stable disease) 23  
PD (Progressive disease) 19  
NE (not evaluable) 19  
Missing 53 
Overall survival (OS) 
Alive/censored 75  
Dead 127  
Missing 8  
Median (95% CI), Years 2.66 (2.13, 3.19) 
Progression free 
survival (PFS) 
Not progressed 26  
Progressed 173  
Missing 11  
Median (95% CI), Years 1.25 (1.07, 1.43) 
Table from Wei Dai 
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Table 3b Characteristics of primary tumour samples (OGT II cohort). 
Clinical Parameters (n=111)  
Age 
Range (32,83) 
mean (95% CI), Years 61 (59,63) 
FIGO Stage 
Ic 2 (1.8) 
III 85 (76.6) 
IV 24 (21.6) 
Grade 
G1 4 (3.6) 
G2 16 (14.4) 
G3 71 (64.0) 
Unknown 20 (18.0) 
Histology 
Serous 42 (37.8) 
Endometriod 8 (7.2) 
Other 35 (31.5) 
Unknown 26 (23.4) 
Chemotherapy 
Platinum 26 (23.4) 
Platinum + Taxane 67 (60.4) 
Other 18 (16.2) 
 Missing 0 
Response 
CR (Complete response) 27 (24.3) 
PR (Partial response) 20 (18.0) 
SD (Stable disease) 13 (11.7) 
PD (Progressive disease) 8 (7.2) 
NE (not evaluable) 14 (12.6) 
Missing 29 (26.1) 
Overall survival (OS) 
Alive/censored 37 (33.3) 
Dead 74 (66.7) 
Missing 0 
Median (95% CI), Years 2.52 (1.67,3.37) 
Progression free 
survival (PFS) 
Not progressed 9 (8.1) 
Progressed 102 (91.9) 
Missing 0 
Median (95% CI), Years 0.92 (0.76,1.08) 
Table from Wei Dai prior to publication (Dai, Teodoridis et al. 2010). 
The above is the original table which was submitted for the Dai et al manuscript but 
following reviewers‟ comments further work was done to establish the histological 
diagnosis for unknown cases and this is shown below, in order to provide further 
information, as it was available at the time of doing the corrections to this thesis.  The 
table below is therefore the one that appeared in the final publication.  It includes 159 
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patients in total (OGT II&III).  The results of the OGT III study were not available 
when this thesis was written up and are therefore not presented. 
Table 3c: OGT II: Updated patient characteristics (N=159) (OGT II and III). 
Clinical Parameters 
OGT II 
N=111 (%) 
OGT III 
N=48 (%) 
Age 
Range (32,83) (44,86) 
mean (95% CI), Years 61 (59,63) 64 (61,67) 
FIGO Stage 
Ic 2 (1.8) 7 (14.6) 
III 85 (76.6) 35 (72.9) 
IV 24 (21.6) 6 (12.5) 
Grade 
G1 4 (3.6) 4 (8.3) 
G2 16 (14.4) 10 (20.8) 
G3 71 (64.0) 28 (58.3) 
Unknown 20 (18.0) 6 (12.5) 
Histology Serous 102 (91.9) 44 (91.7) 
 Endometrioid 8 (7.2) 4 (8.3) 
 Unknown 1 (0.9) 0 
Chemotherapy 
Platinum 26 (23.4) 19 (39.6) 
Platinum + Taxane 67 (60.4) 24 (50.0) 
Other 14 (12.6) 2(4.2) 
 Missing 4 (3.6) 3 (6.3) 
Response 
CR (Complete response) 27 (24.3) 2 (4.2) 
PR (Partial response) 20 (18.0) 5 (10.4) 
SD (Stable disease) 13 (11.7) 3 (6.3) 
PD (Progressive disease) 8 (7.2) 5 (10.4) 
NE (not evaluable) 14 (12.6) 20 (41.6) 
Missing 29 (26.1) 13 (27.1) 
Overall 
survival (OS) 
Alive/censored 37 (33.3) 27 (56.3) 
Dead 74 (66.7) 18 (37.5) 
Missing 0 3 (6.2) 
Median (95% CI), Years 2.52 (1.67,3.37) 2.79 (2.18, 3.41) 
Progression 
free survival 
(PFS) 
Not progressed 9 (8.1) 14 (29.2) 
Progressed 102 (91.9) 31 (64.6) 
Missing 0 3 (6.2) 
Median (95% CI), Years 0.92 (0.76,1.08) 1.15 (0.81, 1.49) 
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The standard parameters which are known to affect PFS and OS were examined in the data 
set and the results are shown in the tables on the following pages:  Table 4a shows the 
results for PFS in the combined data set (test and validation sets).  Table 4b the results for 
OS in the combined data set (N=210) and table 4c shows the results for PFS and OS in the 
OGT II examination (Chapter 7) (Dai, Teodoridis et al. 2010).   
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Table 4a: Progression-free survival analysis 
Variable   
No. of 
cases 
Disease progression 
Median PFS (95% CI), 
years 
HR
1
 95% CI
2
 p value 
Stage       <0.001
3
 
Stage Ic 16 4 NE 1.00   
Stage II 7 2 NE 0.81 (0.15, 4.42) 0.805
4
 
Stage III 142 125 1.08 (0.9, 1.26) 5.32 (1.96, 14.42) 0.001
4
 
Stage IV 43 41 1.25 (1.07, 1.43) 5.79 (2.07, 16.24) 0.001
4
 
Grade       <0.001
3
 
G1 61 47 2.42 (1.93, 2.91) 1.00   
G2 29 21 1.72 (1.02, 2.42) 1.25 (0.74, 2.11) 0.396
4
 
G3 76 68 1.00 (0.77, 1.23) 2.14 (1.45, 3.14) <0.001
4
 
Gx 44 37 0.96 (1.07, 1.43) 2.15 (1.39, 3.33) 0.001
4
 
Age  210 173 1.25 (1.07, 1.43) 1.02 (1.01, 1.04) 0.004
3
 
Chemotherapy       0.045
3
 
Platinum 50 44 0.92 (0.47, 1.37) 1.00   
Platinum+Taxane 118 105 1.33 (0.84, 1.83) 0.68 (0.47, 0.96) 0.03
4
 
Other 12 12 1.58 (1.55, 1.61) 0.51 (0.26, 1.00) 0.05
4
 
Response
4
      0.018
3
 
Responders (CR+PR) 96 89 1.42 (1.02, 1.82) 1.00   
Non-responders (PD+SD) 42 39 0.90 (0.63, 1.17) 1.57 (1.08, 2.30)  
1: Hazard ratio; -2: 95% confidence interval of HR; -3: p value of score test; -4: p value of Wald test.  Table from Wei Dai. 
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Table 4b: Overall survival analysis 
Variable   No. of cases Death 
Median OS (95% CI), 
years 
HR
1
 95% CI
2
 p value 
Stage       0.021
3
 
Stage Ic 16 4 NE 1.00   
Stage II 7 1 NE 0.39 (0.04, 3.50) 0.401
4
 
Stage III 142 89 2.58 (2.00, 3.16) 2.62 (0.96, 7.14) 0.060
4
 
Stage IV 43 32 2.66 (2.13, 3.19) 3.09 (1.08, 8.78) 0.035
4
 
Grade       0.103
3
 
G1 61 33 2.66 (1.85, 3.47) 1.00   
G2 29 18 2.50 (0.75, 4.26) 1.36 (0.77, 2.43) 0.293
4
 
G3 76 49 3.05 (2.39, 3.71) 1.10 (0.71, 1.71) 0.680
4
 
Gx 44 27 1.74 (2.13, 3.19) 1.80 (1.08, 3.01) 0.024
4
 
Age  210 127 2.66 (2.13, 3.19) 1.03 (1.01, 1.05) 0.001
3
 
Chemotherapy       <0.001
3
 
Platinum 50 35 1.25 (1.08, 1.42) 1.00   
Platinum+Taxane 118 70 3.00 (2.59, 3.41) 0.468 (0.31, 0.71) <0.001
4
 
Other 12 10 3.58 (1.46, 5.70) 0.335 (0.15, 0.74) 0.007
4
 
Response
4
      0.005
3
 
Responders (CR+PR) 96 58 3.05 (2.61, 3.49) 1.00   
Non-responders (PD+SD) 42 31 1.83 (0.53, 3.13) 1.87 (1.20, 2.93)  
1: Hazard ratio; -2: 95% confidence interval of HR; -3: p value of score test; -4: p value of Wald test.  Table from Wei Dai 
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Table 4c Univariate analysis of effect of established clinical parameters on survival  
Variable   
No. of 
cases 
Disease progression 
 (%) 
Median PFS (95% CI), 
years 
1-Year PFS Rate  
(95% CI), % 
B HR1 95% CI2 p value 
Stage         0.1823 
Stage Ic 2 0 NE 100 NE NE NE NE 
Stage III 85 78 (92) 0.96 (0.76, 1.16) 45 (34, 56) 0 1.00   
Stage IV 24 24 (100) 0.76 (0.52, 1.00) 38 (19, 57) 0.31 1.37 (0.86,2.18) 0.184 
Histological type        0.1393 
Serous 102 95 (93) 0.92 (0.72, 1.12) 44 (34, 54) 0 1.00   
Endometrioid 8 6 (75) 1.50 (0.70, 2.30) 63 (29, 97) -0.61 0.54 (0.24, 1.24) 0.145 
Unknown 1 1 (100) NE NE NE NE NE  
Grade         0.3713 
G1 4 4 (100) 0.92 (0.03, 1.81) 50 (0, 100) 0 1.00   
G2 16 13 (81) 0.88 (0.26, 1.50) 47 (22, 72) 0.04 1.04 (0.34, 3.20) 0.946 
G3 71 65 (92) 0.92 (0.67, 1.17) 47 (35, 59) 0.03 1.03 (0.37, 2.84) 0.953 
Unknown 20 20 (100) 0.67 (0, 1.53) 35 (14, 56) 0.47 1.60 (0.55, 4.70) 0.391 
Age  111 102 (92) 0.92 (0.76, 1.08) 41 (31, 51) 0.01 1.01 (0.99, 1.03) 0.1813 
Chemotherapy         0.0873 
Platinum 26 25 (96) 0.60 (0.48, 0.72) 31 (13, 49) 0 1.00   
Platinum+Taxane 67 59 (88) 1.07 (0.89, 1.25) 52 (40, 64) -0.52 0.60 (0.37, 0.96) 0.031* 
Other 14 14 (100) 0.92 (0.11, 1.73) 50 (24, 76) -0.22 0.81 (0.42, 1.56) 0.523 
Response4        <0.0015*** 
Responders (CR+PR) 47 45 (96) 1.14 (1.03, 1.25) 60 (46, 74) 0.00 1.00   
Non-responders (PD+SD) 21 21 (100) 0.58 (0.79, 1.05) 14 (0, 0.29) 1.25 3.49 (1.97, 6.17) <0.0015*** 
For legend see footnote at bottom of next 
  72 
Table 4c cont. Univariate analysis of effect of established clinical parameters on survival N=111, PFS event=102, death=73) 
Variable   
No. of 
cases 
Death, % 
Median OS (95% CI), 
years 
1-Year OS Rate (95% CI), % B HR 95% CI p value 
Stage         0.216
3
 
Stage Ic 2 0 NE  NE NE NE  
Stage III 85 39 (46) 3.00 (2.46, 3.54) 89 (81, 97) 0 1.00   
Stage IV 24 7 (29) 0.67 (0, 1.59) 50 (15, 85) 0.33 1.39 (0.82, 2.36) 0.218 
Histological type        0.175
3
 
Serous 102 71 (70) 2.25 (1.47, 3.03) 77 (69, 85) 0 1.00   
Endometrioid 8 2 (25) NE 83 (53, 100) -0.95 0.39 (0.10, 1.60) 0.191 
Unknown 1 1 (100) NE NE NE NE NE  
Grade         0.157
3
 
G1 4 3 (75) 2.17 (0.47, 3.88) 75 (32, 100) 0 1.00   
G2 16 11 (69) 1.51 (0.45, 2.57) 58 (32,84) 0.56 1.76 (0.48, 6.44) 0.395 
G3 71 46 (65) 3.00 (2.29, 3.72) 82 (73, 91) 0.01 1.01 (0.31, 3.30) 0.992 
Unknown 20 14 (70) 1.62 (0.94, 2.30) 70 (48, 90) 0.58 1.78 (0.50, 6.34) 0.374 
Age  111 73 (66)  2.58 (1.77, 3.39) 71 (63, 79) 0.02 1.02 (1.00,1.04) 0.0625
3
 
Chemotherapy         0.002**
3
 
Platinum 26 25 (96) 1.25 (0.79, 1.71) 59 (39, 79) 0 1.00   
Platinum+Taxane 67 59 (88) 3.00 (2.67, 3.33) 86 (78, 94) -0.82 0.44 (0.26, 0.76) 0.003** 
Other 14 14 (100) 3.58 (0.05, 7.11) 84 (64, 1.04) -1.21 0.30 (0.12, 0.72) 0.007** 
Response
4
        0.007**
3
 
Responders (CR+PR) 47 30 (64) 3.08 (2.51, 3.65) 91 (82, 99) 0 1.00   
Non-responders (PD+SD) 21 16 (76) 1.25 (0.63, 1.87) 71 (51, 91) 0.84 2.32 (1.24, 4.35) 0.009** 
 
B, coefficient of Cox proportional hazard regression model; HR, hazard ratio; CI, confidence interval; NR, not reached; 1Hazard ratio estimated from Cox proportional hazard regression 
model.2Confidence interval of the estimated hazard ratio. 3p value of Score test. 4 Response was measured by RECIST 1.0; the patients with complete/partial response are the responders to chemotherapy, while 
the patients with progressive or stable disease are those who did not response to chemotherapy +p<0.1;*p<0.05;**p<0.01.  Table taken from Wei Dai (Dai, Teodoridis et al. 2010).
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2.6 Sodium bisulphite modification of 
extracted DNA 
2.6.1 Materials 
Epitect bisulphite conversion kit  Qiagen 
Ethanol     Sigma 
RNA-ase free water    Qiagen 
 
2.6.2 Method 
Sodium bisulphite modification is based on the selective deamination of unmethylated 
cytosines to uracils whereas methylated cytosines remain unchanged (Clark, Statham et al. 
2006). This chemical reaction converts a difference in methylation into a difference in 
sequence. The Qiagen epitect bisulphite modification kit was used, as per the 
manufacturer‟s instructions using 1000 ng DNA.  The final reaction was eluted in 20 µl of 
elution buffer.  This step was repeated once.  40 µl of bisulphite modified DNA was 
therefore obtained and this could be stored at minus 20°C for at least 12 weeks. 
2.6.3 Calponin PCR control to check adequate bisulphite 
modification 
Incomplete bisulphite modification can lead to false positive results using MSP (Rand, Qu 
et al. 2002). Therefore it is important to avoid using incompletely modified DNA samples 
as these could result in an overestimation of CpG methylation. In order to address this 
problem, successful bisulphite modification of the DNA was verified, before proceeding to 
MSP, using calponin primers.  These do not contain CpG sites and will only give an 
amplified product if the cytosines in the original sequence have been successfully 
converted to uracils, irrelevant of methylation status.  Samples that did not give a band of 
similar intensity were considered unmodified or incompletely modified and the 
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modification reaction was repeated for those samples. The materials and methods are the 
same as that for MSP (described in the next section, Chapter 2.6) except, that following 
PCR amplification, 5 µl of product was ran on an agarose gel as opposed to 20 µl.  This 
was to aid detection of partially modified samples as this could be missed using 20 µl of 
PCR product as this produced a very bright signal. 
2.7 Methylation Specific PCR (MSP) 
2.7.1 Brief outline of the technique 
Methylation Specific PCR (MSP) is used to detect either the presence or absence of 
methylation in bisulphite modified genomic DNA. Bisulphite treatment results in all 
unmethylated cytosines (Cs) being converted to uracils (U‟s) but methylated cytosines (Cs) 
are protected from this.  Following a subsequent PCR the final sequence of methylated and 
unmethylated DNA is therefore different and this can be utilised by designing primers 
which are specific to each.  This is illustrated in figure 5 below.  The methylated primer 
should only bind to the methylated sequence and therefore a product only seen on the gel if 
methylation is present.  It is unusual for DNA to be entirely methylated and therefore a 
sample can show amplification with the unmethylated primer even if there is a high degree 
of methylation present. 
 
 
 
 
 
 
 
Figure 5.  A change in methylation status becomes a change in sequence following sodium 
bisulphite PCR.  CGm, methylated CpG illustrated in red, unmethylated CpG is Green.   
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MSP is a highly sensitive PCR technique (Herman, Graff et al. 1996) however it is limited 
by the fact it is only a semi-quantitative assay.  The degree of methylation is estimated 
using serial dilutions of the positive and negative control as illustrated in figure 6 below.  
This does allow for an estimate of the degree of differential methylation between samples 
in one experiment but it limits the ability to compare results across experiments or between 
different clinical centres.  A high degree of optimisation is required.  For the methylated 
primer it is important to have a very clear band present in the IVM/ Positive control 
without any amplification in the negative or water controls.  Similarly in the unmethylated 
primer it is important to see a clear band in the unmethylated control but not in the 
methylated control or the water.    
 
 
 
Figure 6.  Serial dilutions of controls used for quantification purposes in MSP.  100 BP 
LADDER 100 base pair ladder, IVM in vitro methylated DNA (100% methylated), N, normal whole 
male genomic DNA, 1/5 20% methylated, 1/10 10% methylated. 
 
2.7.2 Materials 
70% v/v Ethanol (to wash down workstation) Sigma 
Sterile water (H2O) for injection   B Braun 
Fast start Taq DNA polymerase kit   Roche  
dNTPs 0.2mM     Applied Biosystems 
Oligonucleotides (detailed below in Table 4)  Invitrogen  
Human genomic male DNA (N)   Promega 
In Vitro Methylated DNA (IVM)   Chemicon 
Semi-skirted 96 well PCR plate (0.2ml)  Abgene 
Microseal A film      MJ Research 
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2.7.3 Method 
All MSP reactions were carried out on a Biorad Tetrad 2 peltier thermocycler.  Because of 
the repeated cycles of PCR used to amplify a PCR product from a small amount of DNA it 
is important to avoid contamination pre-PCR (Kwok and Higuchi 1989).  All PCR 
reactions were prepared in a PCR work station using a vertical laminar airflow and UV 
decontamination.  For each experiment a water blank and positive and negative controls‟ 
were run.  Undiluted IVM (representing completely methylated DNA) was serially diluted 
(1:5 and 1:10) with human genomic male DNA (N), (representing completely 
unmethylated DNA).  Primers were designed that would only amplify the methylated or 
unmethylated sequence using the methprimer website using a criteria of >100 base pairs, 
GC content 50% and observed/ expected ratio >60% 
(http://www.urogene.org.methprimer).   
70% ethanol spray was used to wash down the PCR work station before and after each 
experiment.  Pipette, tubes, tips and dH20 were exposed to UV light prior to commencing 
the experiment. A master mix with the appropriate primer sets was then prepared before 
addition of DNA. MSP master mixes were made using reagents from the Fast Start Taq 
DNA Polymerase kit which were thawed and vortexed prior to use except the Taq 
polymerase which was kept at -20
o
C until required and not vortexed. MSP reactions were 
performed in 96 well PCR plates using 1µl of modified DNA, 150ng of each forward and 
reverse primer, 0.2mM dNTPs and 1U Faststart Taq in a total volume of 25µl. The H2O 
blank control consisted of 24µl master mix and 1µl of sterile H2O in place of DNA. This is 
summarised in table 5 below: 
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Table 5 
MSP: Mastermix for one standard reaction 
Fast Start 10x Buffer 2.5µl 
DNTPs 0.5µl      
Forward sequence primer 0.5µl      
Reverse sequence primer 0.5µl      
MgCl2 25Mm 1-3µl, depending on primer conditions 
Fast Start Taq DNA Polymerase 0.2µl (add immediately prior to use) 
Sterile  H2O To 24 µl 
 
Wells were sealed with microseal flm and reactions were run on the Tetrad 2 peltier 
thermal cycler.  Each MSP reaction underwent an initial denaturation and enzyme 
activation step at 95
o
C for 5 minutes, followed by 35 amplification cycles of 95
o
C for 30 
seconds (unless otherwise indicated), appropriate annealing temperature for 30 seconds 
and elongation at 72
o
C for 30 seconds. This was followed by a final extension step at 72
o
C 
for 6 minutes.  MSP conditions are illustrated in table 5 below: 
 
Table 6 
MSP: cycling conditions. 
Initial Denaturation Step of 5mins at 95
o
C then 35 cycles of: 
Denaturation 30s 95
o
C 
Anneal 30s Temp. dependent on primer 
Elongation 30s 72
o
C 
Following these 35 cycles, final elongation step of 5 mins at 72
o
C then 4ºC for 10 
minutes. 
 
 
 
2.7.4 MSP oligonucleotides and cycling conditions 
Primer sequences and conditions for methylated and unmethylated MSP are shown below 
in table 7.  
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Table 7 
MSP primer conditions and product size. 
12k  
Microarray 
ID/ 
Gene 
 Primer Sequence 
Forward (F) /  Reverse (R)  5’→3’ 
Product 
Size (bp) 
Annealing 
Temp (
o
C) 
[Mg
2+
] 
mM 
121D9 
CRABP1 
MF 
MR 
UF 
UR 
TAT GAT TAG TGT TTC GAT CGG TTT C 
GAC CAC TTT CCT CAA CAT AAC GT 
ATG ATT AGT GTT TGA TTG GTT TTG A 
TAC AAC CAC TTT CTT CAA CAT AAC A 
104 
 
106 
60 2 
24D3 
SP5 
MF 
MR 
UF 
UR 
GGT TTT ATT TTG GGA GGT AGG TAA C 
ACA CCT CTA CGA AAA ATC CGA 
GGT TTT ATT TTG GGA GGT AGG TAA T 
ACA CCT CTA CAA AAA ATC CAA A 
96 
 
96 
65 2 
38D7 
AGBL2 
MF 
MR 
UF 
UR 
GTA TGA TAT TTA TTA ATG CGG TTT C 
CTT CCG AAA AAC TAA ACC TCG 
GTA TTG TAT TTA TTA ATG TGG TTT 
TGA 
CTT CCA AAA AAC TAA ACC TCA CC 
144 
 
144 
52 3 
17H9 
HRASLS3 
MF 
MR 
UF 
UR 
TCG GAA GTA GTA ATT TAG GTT TCG A 
AAT ACG TAC GCC CAT TAT AAA TAC G 
TTG GAA GTA GTA ATT TAG GTT TTG A 
TAC ATA CAC CCA TTA TAA ATA CAA A 
106 
 
104 
60 2 
41D12 
GLS2 
MF 
MR 
UF 
UR 
AAG GTT TTG TAG AAG GTT TTG AGT 
ACC TCA CTA AAA TAA TAC CGA ACG 
TTT GTA GAA GGT TTT GAG TTG G 
CCT CAC TAA AAT AAT ACC AAA CAC 
C 
116 
 
110 
62 2 
20F11 
NTN4 
MF 
MR 
UF 
UR 
TTT CGT AAA AGG TAG TAG AGA AGC 
CTC TCG AAA AATACCC ACG AC 
TTT ATT TTT GTA AAA GGT AGT AGA 
GAA GTG 
CCT CTC AAA AAA TCC CAC AAC 
119 
 
125 
 
60 2 
21A11 
NTN4 
MF 
MR 
UF 
UR 
CGT TTA TTT TTT ATA TTT TTT AGC GA 
CGA AAC TAA ATT AAA ATA TTC CGT C 
TGT TTA TTT TTT ATA TTT TTT AGT GA 
CAA AAC TCC CTT CCC CTC TTTC CAT 
C 
107 
 
107 
56 3 
21F11 
NTN4 
MF 
MR 
UF 
UR 
TTT CGT AAA AGG TAG TAG AGA AGC 
G 
CTC TCG AAA AAT CCC ACG AC 
TTT ATT TTT GTA AAA GGT AGT AGA 
GAA GTG 
CCT CTC AAA AAA TCC CAC AAC 
119 
 
125 
57 2 
101G6 
GLS2 
MF 
MR 
UF 
UR 
TTA TAT TTA AAG GAA AAG GTA TCG 
A 
AAC TCC TAA AAC AAA ACA AAA AAC 
G 
TTT ATA TTT AAA GGA AAA GGT ATT 
GA 
CTC CTA AAA CAA AAC AAA AAA CAA 
A 
143 
 
142 
57 2 
3 A 11 
MLLT6 
MF 
MR 
UF 
UR 
 TTC GGT GGA TAT AGG GAA TTT C 
GTT TTG GTG GAT ATA GGG AAT TTT 
AAC ACG AAA ATC GAA AAA ACG 
CAA ACA CAA AAA TCA AAA AAA CAA 
A 
98 
 
102 
59 2 
66G6 
BARX1 
MF 
MR 
UF 
UR 
GTT CGG GAG AGT TTT TGA TAG TC 
AAA CAA ATT ACC TAA TAA AAA CGA 
A 
TTG GGA GAG TTT TTG ATA GTT GT 
AAA ACA AAT TAC CTA ATA AAA ACA 
AA 
115 
 
114 
58 
 
57 
2 
 
2 
119A6 MF TCG TAG CGA TAG GTA TAA AGT TAC 100 55 2 
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NR2E1 MR 
UF 
UR 
G 
AAA AAA ACG ACC AAA TCC GA 
TGT AGT GAT AGG TAT AAA GTT ATG G 
AAA AAA AAC AAC CAA ATC CAA A 
 
100 
 
55 
 
2 
81B1 
PTTG 
MF 
MR 
UF 
UR 
GTT CGG GGT TTA GAT GGT TTC 
TAA CAC TCA TCA TCA AAC AAT TAC 
CGT T 
TGT TTG GGG TTT AGA TGG TTT T 
ACA CTC ATC AAA CAA TTA CCA TT 
85 
 
84 
56 
 
57 
2 
 
2 
114E4 
CNTNAP5 
MF 
MR 
UF 
UR 
TAG GTT GTG TAG AGG AGA GAG ATA 
GC 
ATT TCC CCC GAA TAA ACG AT 
TAG GTT GTG TAG AGG AGA GAG ATA 
GTG 
CAT TTC CCC CAA ATA AAC AAT 
96 
 
97 
65 
 
60 
3 
 
2 
127F12 
DLC1 
MF 
MR 
UF 
UR 
TGA TTA TTT TTT GTT TGG GGA TC 
ACC AAA ACT TCC CTT CAC GA 
TTG ATT ATT TTT TGT TTG GGG ATT 
AAA CCA AAA CTT CCC TTC ACA A 
83 
 
86 
62 
 
62 
2 
 
2 
5D4 
LMXIA 
MF 
MR 
UF 
UR 
ATATAGAGTAAAAAGCGACGTTCGT 
ACTTTTAAACTTACCCAACCTCGA 
GATATAGAGTAAAAAGTGATGTTTGT 
ACTTTTAAACTTACCCAACCTCAAA 
112 
 
113 
59 
 
52 
2 
 
2 
64E3 
CR2 
MF 
MR 
UF 
UR 
GAT GTA AAG TAG GGG GTT AAA AGC 
ACA ATA ATC CCT CAA AAC TAA CGA 
A 
ATG TAA AGT AGG GGG TTA AAA GTG 
A 
ACA ATA ATC CCT CAA AAC TAA CAA 
A 
85 
 
84 
65 
 
65 
2  
 
2 
Primers amplify methylated (M) or unmethylated DNA sequence (U). Forward (F), Reverse (R).  
Primers were all designed using MethPrimer (Li and Dahiya 2002) 
(http://www.urogene.org/methprimer/).  
 
2.8 Agarose gel electrophoresis 
2.8.1 Materials 
Agarose      Melford 
dH2O    
Ethidium bromide solution   NBS Biologicals 
100bp DNA Ladder     Invitrogen 
EDTA      Fisher 
Electrophoresis unit and power pack   Pharmacia 
GeneGenius bioimaging system   Syngene 
Glycerol      Fisher 
Orange G      Sigma 
Tris Base       Melford 
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2.8.2 Recipes 
TBE (5x)     
Tris base   108g 
Boric acid    55g 
0.5M EDTA   40ml 
Make up to 2L with dH2O and then dilute to 0.5x with dH2O for use in agarose gel 
electrophoresis. 
 
 
2% Agarose Gel 
0.5x TBE Buffer   100ml 
Agarose     2g 
Both ingredients were heated in the microwave for 90 seconds until the agarose was 
completely dissolved. It was then allowed to cool to “hand warm” before adding 2 droplets 
of ethidium bromide solution per 100 ml of TBE. 
 
Loading Buffer 
Glycerol    10ml 
dH2O                         30ml 
Orange G   0.25g  
2.8.3 Method 
After the PCR step, the products were separated by size using agarose gel electrophoresis. 
5µl of loading buffer was added to each PCR product and 20µl of this mixture was pipetted 
into wells of a 2% w/v agarose gel immersed in 600ml 0.5x TBE Buffer. A DNA ladder 
was run at the same time to confirm that products were of the expected size. Gels were run 
for 35-45 minutes at 150 volts. 
 
DNA was visualised with UV light using a Syngene GeneGenius Bioimaging System with 
GeneSnap version 6.03 software. For each primer sequence, samples which were positive 
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displayed visible bands in their corresponding lanes. The MSP assay including samples of 
unknown methylation status was only regarded as being successful if there was a visible 
band in the positive control lanes and no visible bands in both the negative control and 
H2O blank lane.  
2.9 Pyrosequencing of bisulphite modified 
DNA 
2.9.1 Brief outline of the technique 
Pyrosequencing of bisulphite modified DNA is another method used for assessing 
methylation status (Tost and Gut 2007).  It is a higher throughput technique and involves 
“sequencing by synthesis” and detection of hydrolysis of pyrophosphate (PPi) by 
pyrophosphatase. Design of the primers and optimisation can be more difficult than for 
MSP, however results are quantitative.  The reason optimisation can be more difficult is 
that numerous things can interfere with the final read out.  These include whether the 
binding buffer and beads are in good condition and more specific to an individual set of 
primers whether amplification is only seen as a result of a reaction of the sequencing 
primer with the product – and not the product itself forming hairpin loops – or the 
sequencing primer annealing to an incorrect sequence.  Once optimised though it is a very 
quick and highly reproducible method which provides quantitative results which can 
readily be compared across experiments and between different institutions.  Using this 
technique it is possible to assess the methylation status of several neighbouring CpGs 
individually.  Like MSP this technique utilises sodium bisulphite modified DNA.  The 
methylation sites are treated as “cytosine/thymine” or “C/T SNPs” (methylSNP) with an 
allele frequency spectrum spanning the entire range (0-100%).  An internal control can be 
included which is able to confirm the efficiency of bisulphite conversion within the 
sample.   
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In this thesis all pyrosequencing was performed on bisulphite modified DNA and therefore 
for simplicity the term „pyrosequencing‟ is used when referring to „pyrosequencing of 
bisulphite modified DNA‟.  All experiments were performed in duplicate and any 
percentages quoted represent the mean of all relevant samples in both experiments. 
2.9.2 Materials 
1x Annealing buffer      Biotage 
Binding buffer      Biotage 
Denaturation solution (0.2M NaOH)    Biotage 
70% ethanol  
Oligonucleotides @ 10µM (detailed below in Table 5) INVITROGEN 
PSQ 96 plate low      Biotage 
PSQ 96MA pyrosequencer     Biotage 
PSQ 96 reagent cartridge     Biotage 
PSQ 96 SNP reagent kit     Biotage 
Pyrosequencing thermoplate     Biotage 
Pyrosequencing vacuum prep workstation   Biotage  
Streptavidin sepharose HP      Amersham Biosciences  
Thermofast 96 well semi-skirted PCR plates   Abgene 
10x Washing Buffer      Biotage 
 
2.9.3 Method  
DNA was first bisulphite modified and PCR performed, as described previously in Chapter 
2.5, in a total volume of 25µl including 1µl of modified DNA template using 35 cycles of 
PCR (unless otherwise stated).  Also as previously described in Chapter 2.5.3, adequate 
bisulphite modification was confirmed by PCR amplification with Calponin primers.    
Pyrosequencing primers were designed using the biotage Pyro-Q-CpG software 
(www.pyrosequencing.com), by inserting the bisulphite modified sequence and selecting 
the region of CpGs of interest.  Either the forward or reverse pyrosequencing PCR primer 
was biotinylated to allow immobilisation to streptavidin coated sepharose beads after PCR 
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amplification.  10µl of PCR product was immobilised to sepharose beads and single 
stranded templates prepared using the Vacuum prep workstation in a series of wash steps 
with 70% ethanol, 0.2M denaturation solution, wash buffer and dH2O. 10µM sequencing 
primer was annealed to the template (80
o
C for 3 minutes) before analysis in the PSQ 
96MA pyrosequencer.  Analysis using the pyrosequencer involves the DNA template and 
primer complex being incubated with the enzymes DNA polymerase, ATP sulfurylase, 
luciferase, apyrase and the substrates, adenosine 5‟ phosphosulphate (APS) and luciferin 
per sample.  dNTPs are added to the reaction and incorporated into the sequencing strand if 
complementary to the template strand. This is accompanied by release of PPi which is then 
hydrolysed into ATP in the presence of APS. ATP drives the conversion of luciferin to 
oxyluciferin which generates visible light which can be detected and translated into a peak 
by the pyrosequencing software. As the process continues, the complementary DNA strand 
is built up and the nucleotide sequence determined from the signal peaks within the 
pyrosequencing programme. Incorporation of a thymine (T) at a CpG site indicates 
unmethylated DNA and incorporation of a C indicates methylation of that given site. The 
degree of methylation at individual CpG sites is then analysed using the AQ software.   An 
example of the data generated is illustrated in figure 7 below. 
 
 
 
 
 
 
 
 
 
Figure 7 Example of data generated by the pyrosequencing software.  C is % methylated, T is 
% unmethylated at a given CpG site. A adenine, C cytosine, G guanine T thymine M methylated U 
uracil (http://www.biotage.com/DynPage.aspx?id=22003&search=pyrosequencing) 
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2.9.4 Pyrosequencing oligonucleotides, cycling conditions and 
sequence analysed 
Pyrosequencing primers were designed using the Biotage PSQ Pyrosequencing software 
package.  Primer details and optimised conditions are shown in table 8 below: 
 
Table 8 
 Pyrosequencing: primer sequences and optimised conditions. 
Sequence name 
used/ Gene (if 
known) 
Primer Sequence 
Forward (F) / Reverse (R) / Sequencing (S)  5’ – 3’ 
Product 
Size (bp) 
Annealing 
Temp (oC) 
[Mg2+] 
mM 
5 D 4 
LMX1A 
FB: ATG AAT GTG GAG GAT GAG ATA GTT  
R: CCC AAT TTT ACA ATT CTA TTT TCT 
S: CAA TTT TAC AAT TCT ATT TT  
323 53 2 
119 A 6 
NR2E1 
 
F: TTT GGA GAT ATT ATA GGG GAT TTA 
RB: TCC CTC TAC ATA AAC ATA CAA AA 
S: GGG GTA ATG AAT TT 
288 50 2 
121 D 9 
CRABP1 
F: GAG AAG GTT TTG AGG AGG AGA T 
RB: ACT CTA AAA CCT CAC CCT ACA CTT 
S: GGT TTT GAG GAG GAG AT 
59 52 1 
24 D 3 
SP5 
FB: GGT GGA TTT TTT TTT TAG TAT TTT  
R: CCC AAT TAC AAT CCA AAT ACC C 
S: ACC CCA ACC CTA CCT 
207 57 2 
101 G6 
GLS2 
FB: GAG GAG AGG GGA GAT GAG  
R: CTT ACC CCC ACT CCC ACT A 
S: ACC CCC ACT CCC ACT ATA ATT CT 
79 67 3 
1 E 7 F: GGG ATT GGA AGA GTT GTT TGA 
RB:CAA CCC CAA CAA ACT CAA CTA AA 
S: TGG AAG AGT TGT TTG AGT A 
87 64 2 
21 G 5 
KIAA1383 
F: TTT AGG GGG TAG TTG TAG TAG TAA 
RB: TCC ACC TAC AAC CTA CTA CCC TA 
S: TAC AAC CTA CTA CCC TAC AC 
80 60 2 
17 G 11 
SIX1 
F: TTT AGG ATT TTT GTA GTT GTG GA 
R: CAA AAC TCC AAA CCA ACT CTT AA 
S: TGT GAG TAG TTA TTT TGA GTT AGT 
110 57 2 
F forward primer, R reverse primer, S sequencing primer, B biotinylated primer. 
 
The sequence to be analysed and the number of CpG sites to be examined for each primer 
is shown in table 9 below: 
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Table 9 
 Pyrosequencing: Analysed sequence and No. of CpG site examined. 
Microarray 
ID 
Gene 
Sequence analysed No. 
CpG 
sites 
5 D 4 
LMX1A 
CTTTYGATAAAATCTYGAYGTCCTAAACCAYGTTAAAAAYGAAYGTA 6 
119 A 6 
NR2E1 
YGGGGATTTTTYGTYGTTGYGTGYGYGGTTTTTTTYGGAAATT 7 
121 D 9 
CRABP1 
YGTGGAYGGAYGTAAGTGTAGGGTGAGGTTTTAGAGT 3 
24 D 3 
SP5 
CCCCRCTCCTAAAAACTAAATCCCTATATCCRAAAACAACRAAAATTA
AAAACCTAACTCCATTTTAAAAAACAAACAACRAAAAAAATCCRTCT
ACTAAATCTCCCCTCCRCCAACTACCCACAAATCCCCRAATCTCTCRC
AAAAATACTAAAAAAAAAATCCAC 
8 
101 G6 
GLS2 
CRCTAATTCCCRAATACCCTTCCAAAACAACRCCRCTCATCTCCCCTCT
CCTC 
4 
1 E 7 
 
GTYGGTTGGTTYGGYGGTTAGGTTAGGGYGGGGGYGAGYGTTTAGTT
GAGTTTGTTGGGGTTGGA 
6 
21 G 5 
KIAA1383 
TACCRACTCCTACRAACCCCRCTTACCACCTTACTACTACAACTAC 3 
17 G 11 
SIX1 
TYGYGGGGTTYGATYGGAAGGGAYGTTTTTTTTAAGAGTTGGTTTGGA
GT 
5 
111 D1 
OPCML 
GTAYGTATATATATATTTATTYGTTTATAYGYGYGTAGATGTTTTTAGT
AYGGGATTTGTTTTTTGTTTYGGGGGATTTAGTGAGTTGGGTTYGAGA
TTTGTATTATGTTGTGAGGTA 
8 
YG is a potential site of methylation on the forward strand otherwise known as “C/T SNP”. CR is a potential CT SNP on the reverse strand. 
 
  86 
2.10 Differential methylation hybridisation 
2.10.1 Brief outline of the technique 
Differential methylation hybridisation (DMH) is a high throughput method of examining 
the methylation status of several samples in multiple CpG residues.  Genomic DNA is 
digested with MseI (TTAA) and DNA fragments are then ligated to endlinker 
oligonucleotides and divided into two equal aliquots.  One is mock-treated, the other is 
digested with the methylation-sensitive restriction enzyme McrBC which cuts methylated 
DNA at the degenerate recognition site (G/A)
m
CN40-3000(G/A)
m
C (Stewart and Raleigh 
1998).  PCR amplification is performed with primers binding to the endlinkers. 
Unmethylated fragments are amplified in both the McrBC digest and the mock-treated 
aliquot. In contrast, methylated fragments are digested with McrBC but remain intact in the 
mock-treated aliquot. The amplicons are then labelled with cyanine 3 (Cy3) or cyanine 5 
(Cy5) and can be hybridised to one of several arrays.  This is illustrated in figure 8 below. 
 
 
 
 
  
 
 
 
 
 
Figure 8 DMH: sample preparation. Genomic DNA is digested with MseI, ligated to endlinkers 
and divided into equal aliquots. One is mock-treated, the other digested with McrBC. PCR is 
performed with primers binding to endlinkers. Unmethylated fragments are labelled in both aliquots. 
Methylated fragments remain intact only in the mock treated aliquot. Amplicons are labelled with 
Cy3 or Cy5 and hybridised to microarray. If the McrBC sample is labelled green with Cy3 and the 
mock sample red with Cy5 then if the sample contains methylated CpGs then more red signal will 
come from the mock sample than green from the digested sample and a red dot will be seen on the 
array.  If sample is unmethylated the mock and McrBC treated samples will amplify equally well 
and an equal green and red signal will be seen as a yellow spot on the array. 
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Once samples are spotted to the array they are visualised in the spectrum of red to orange 
to yellow to green.  This is shown below in Figure 9.  As described later in the Chapter a 
computer software package is utilised to quantify the degree of methylation (the intensity 
of the colour).  
 
 
 
 
 
 
 
 
Figure 9.  Example of a DMH microarray experiment for the cell line A2780. Left: McrBC 
digested DNA was labelled green (Cy3), mock-digested DNA was labelled red (Cy5); right: dye 
swap experiment. 
 
DMH was performed as previously described (Paz, Wei et al. 2003), with some 
modifications.  In the first experiment (performed by Dr Teodoridis) samples were 
hybridised to the Human CpG 12K Array (Heisler, Torti et al. 2005) (University Health 
Network, Toronto, Canada) overnight. This array is based on a CpG island library 
containing approximately 12,000 CpG-rich sequences (Cross, Charlton et al. 1994).  In the 
second experiment samples were hybridised to the larger Agilent microarray.  Arrays were 
washed with 1xSSC, 0.1% SDS and 0.2xSSC, rinsed with H2O and scanned with an Axon 
GenePix 4000A scanner (Molecular devices). GenePix Pro 6.0 was used for image 
analysis. Dye swap experiments were performed for all cell lines to ensure quality control 
and reproducibility.  
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2.10.2 Materials 
Axon GenePix 4000A scanner   Molecular devices 
MseI       New England Biolabs 
T4 DNA Ligase, 2000U/l    New England Biolabs 
Deep Vent exo(-) Thermopolymerase New England Biolabs 
McrBC      New England Biolabs 
BioPrime DNA labeling System   Invitrogen 
Aminoallyl-dUTP     SIGMA 
dATP, dCTP, dGTP, dTTP, 100mM each  Fisher 
Cot-1 DNA      Invitrogen 
3DNA 2xSDS-based hybridization buffer  Genisphere 
Nuclear extraction buffer 2 (NEB2)  New England Biolabs 
Bovine serum albumin   New England Biolabs 
Annealed H14/H24    New England Biolabs 
Thermopolymerase buffer   New England Biolabs 
Guanosine 5'-Triphosphate (GTP)  New England Biolabs 
H12 and H14 primers    New England Biolabs  
 
2.10.3 Method   
5 µl of 10x nuclear extraction buffer 2 (NEB2), 5 µl of 10x bovine serum albumin (BSA) 
(1 mg/ml) were combined in 2.5 ml tubes.  0.8 to 1 µg of DNA was added to this with 
water (MQ unless otherwise stated) to a final volume of 35 µl for the DNA and water.  The 
mix was vortexed and centrifuged briefly.  Finally 5 Ul MseI (10U/ml) was added (MseI 
kept at -20 °C until needed).  3 drops of mineral oil was layered over the reaction and it 
was incubated overnight at 37°C.  The mastermix is shown in table 10 below: 
 
Table 10 
DMH: Mse1 digest 
 Amount in µl per sample 
10X nuclear extraction buffer 2 (NEB2) 5 
10X bovine serum albumin (BSA) (1 mg/ml) 5 
DNA (0.8-1 µg) According to DNA conc. 
H20  to total 35 µl with DNA 
MseI (10U/ml) 5 
TOTAL 50 
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The reaction was then purified using the Qiagen DNA purification kit (see chapter 2.10).  
Following elution the sample was processed in a speed vac for 2 hours resulting in a dry 
pellet.  3.5 µl of each of H12 and H24 primers were combined and annealed from 55°C to 
room temperature.  7 µl of the combined primers was added to the dry pellet which had 
been reconstituted with 14.5 µl of water.  2.5 µl of 10X T4 Ligase buffer was added.  1 µl 
of T4 ligase was then added; this had been kept at -20 until needed.  The reaction was kept 
on ice at all times.  The reaction was layered over with mineral oil and incubated overnight 
at 14°C for 14 hours and then kept at 4°C.   
Table 11 
DMH: Annealing of H12/H24 primers (end linkers).   
 Amount in µl per sample 
Annealed H12/H24 primers 7 
DNA/H20 14.5 
10XT4 Ligase Buffer 2.5 
T4 Ligase (2000U/µl) 1 
TOTAL 25 
 
Next the unpurified sample was amplified and ran on a gel.  A master mix with 13.7 µl of 
water, 2 µl of DMSO, 2 µL of 10x thermoPol Buffer, 0.5 µl of H24 primer and 0.4 µl of 
10Mm dNTP was prepared on ice.  Finally 0.4 µl of deep vent which had been kept at -
20°C until needed was added and mixed gently.   
Table 12 
DMH: Annealing of H24 primer. 
 Amount in µl per sample 
H20 13.7 
DMSO 2 
10xtthermopol Buffer  2 
H24 primer 0.5 
10 mM DNTP 0.4 
Deep Vent (2U/µL) 0.4 
TOTAL 19.0 
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The reaction was placed on the thermal cycler using the cycling conditions as shown below 
in table 13: 
Table 13 
DMH: Cycling conditions for H24 primer annealing. 
 Temperature Time in minutes 
1 72°C 5 
2 97°C 1 
3 72°C 3 
4 Go to (2) 24 times  
5 72° 5 
 
A 0.8% agarose gel was prepared (see chapter 2.7).  5 µl of loading buffer was added to the 
reaction and then 10 µl was loaded onto the gel and run for 30 minutes with a 100 bp 
ladder.  DNA was visualised with UV light using a Syngene GeneGenius Bioimaging 
System with GeneSnap version 6.03 software.  A smear was expected at <500 bp fragment 
size.   
The sample was then purified using the QIA quick columns (see chapter 2.10) and treated 
in the speed vac for 2 hours, until a dry pellet formed.  Next the McrBC digestion was 
performed.  The DNA pellet was reconstituted in 24 µl of water and 12 µl was used for the 
digest, and 12 µl for a mock treated sample.  Two master mixes were made as outlined in 
the table 14 below. 
Table 14 
DMH: McrBC and mock digested samples. 
 Digest  
(µl) 
Mock (µl) 
DNA or H20 12 14 
10Xnuclear extraction buffer 2 (NEB2) 2 2 
10X Guanosine 5'-Triphosphate (GTP) 2 2 
10X bovine serum albumin (BSA) 2 2 
McrBC (20 U/µl) 2 NIL 
TOTAL 20 20 
 
  91 
The reaction was layered over in mineral oil and incubated overnight at 37°C.  Next the 
samples were amplified.  A master mix was made as shown in the table below; 
Table 15 
DMH: Mastermix for PCR amplification of McrBC and mock digested samples. 
 Amount in µl per sample 
McrBC digest 20 
H20 230.5 
10XThermopolymerase Buffer 30 
H24 primer (10 µM) 7.5 
DNTP (10 µM) 6 
Deep Vent 6 
TOTAL 300 
 
The 300 µl reaction was divided equally into 3 PCR tubes (100 µl each) and a PCR 
reaction was performed as shown in table 16 below. 
Table 16 
DMH: Cycling conditions for PCR amplification of McrBC/ mock digested samples 
Step Temperature Time in minutes 
1 72°C 5 
2 97°C 1 
3 72°C 3 
4 Go to step 2, 20 times  
5 72°C 5 
 
The sample was then purified using the QIAquick column (see chapter 2.10) and the DNA 
concentration determined using the nanodrop.  The DNA concentration was expected to be 
2-3 µg in total.  Aminoallyl labelling of the amplicon was next performed.  0.3 µg DNA 
was added to water making a final volume of 33.2 µl.  This was then combined with 30 µl 
of 2.5x random primers solution.  The sample was denatured at 95°C for 5 minutes and 
placed on ice for 2-3 minutes.  It was then centrifuged briefly.  Next it was combined with 
the following master mix; 
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Table 17 
DMH: Mastermix for Aminoallyl labelling  
 Amount in µl per sample 
10xdNTP (2 Mm A C G, 0.35 Mm T) 7.5 
10 mM aa-dUTP 1.8 
Klenow (40U/µl) 2.5 
  
This reaction was incubated at 37°C for 5 hours.  Next it was purified using the QIAquick 
columns (see chapter 2.10) and eluted in 2x40 µl of water.  The DNA concentration was 
determined using the nanodrop and the fold increase in concentration was expected to be 
13-17 times.  The samples were dried using the speed vac for 2 hours.  The final part of the 
reaction, coupling of the dyes to the DNA and hybridisation of the slides, was performed 
by Dr Teodoridis as previously described (Huang, Perry et al. 1999).   
2.11 DNA purification 
2.11.1 Materials 
100% ethanol     Sigma 
QIAquick kit and spin columns   Qiagen 
 
2.11.2 Method 
As per the manufacturer‟s instructions, briefly, 5 volumes of buffer PB were added to 1 
volume of the PCR reaction and mix.  The reaction was then placed in a QIAquick spin 
column and 2 ml collecting tube and centrifuged for 60 seconds.  The flow through was 
discarded and the column was placed back in the same tube.  To wash, 730 µl buffer PE 
was added to the column and centrifuged for 60 seconds.  The flow through was discarded, 
the column placed back in the tube and then the sample was centrifuged again for a further 
minute.  The column was then placed in a clean 1.5 ml microcentrifuge tube.  Unless 
otherwise stated, to elute DNA 40 µl of water (MQ) was added to the centre of the 
membrane and centrifuged for 1 minute with this process being repeated once (80 µl total).  
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2.12 Homogenisation of cell lysates 
2.12.1 Materials 
QIAshredder columns  Qiagen 
Lysate buffer   Qiagen  
 
2.12.2 Method 
Following siRNA experiments, ovarian cancer cell lines were spun down to a cell pellet 
using the Beckman centrifuge at 600 x g for 4 minutes.  As per the manufacturer‟s 
instructions, any liquid was aspirated and the cell pellet was then resuspended in 350 ml of 
lysate buffer.  This was then passed through a QIAshredder column and the lysate was 
collected in the 2 ml collecting tube, by centrifuging at top speed for 1 minute.  The 
collecting tubes were then fitted with lids and stored at -20°C. 
 
2.13 RNA extraction from cell lines and 
DNase digest 
2.13.1 Materials 
DNase free/RNase free water  Invitrogen  
Ethanol    Hayman 
QIAshredder spin columns  Qiagen  
RNeasy mini kit   Qiagen 
RNase-free DNase set   Qiagen 
 
2.13.2 Method 
RNA was extracted using the RNeasy Mini Kit spin protocol according to the 
manufacturer‟s instructions, with the homogenisation step being carried out using 
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QIAshredder spin columns. All centrifugation steps were carried out at room temperature 
and at ≥8000xg. DNase-free RNase-free water was used in all steps to minimise the risk of 
degradation of RNA and complementary DNA (cDNA).  Cell lysates were produced as 
outlined in chapter 2.11. An RNase-free DNase set was used to provide efficient digestion 
of genomic DNA. The DNase was removed in subsequent wash steps. This was also 
performed according to the manufacturer‟s instructions.  RNA was eluted once in 30µl of 
RNase-free H2O and then stored at -70°C until required. 
2.14 cDNA synthesis (Reverse Transcription, 
RT) 
2.14.1 Materials 
SuperScript II Reverse transcriptase Kit  Invitrogen 
2.14.2 Method 
cDNA was prepared according to the manufacturer‟s instructions by reverse transcribing 
the messenger RNA (mRNA) within 1000 ng of total RNA using the Superscript II first 
strand synthesis system and random primers.  A no RTase control was included for each 
sample. cDNA was then stored at -20
o
C until required for quantitative reverse transcription 
PCR (qRTPCR). 
2.15 qRTPCR 
2.15.1 Brief overview 
qRTPCR was carried out using two different methods in this thesis.  For the experiments 
outlined in Chapter 3 investigating the expression of LMX1A and NR2E1 the SYBR green 
system was used and for the experiments outlined in all other chapters the taqman system 
was used.  qRTPCR can be used to quantitatively evaluate the change in RNA expression 
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levels of a target gene either by comparing to the expression of a chosen sample within the 
experiment (relative expression) or by using a standard curve of known concentrations 
(absolute quantitation).  Both methods were used in this thesis.  For the absolute 
quantitation experiments investigating SP5 expression, a known concentration was 
produced using a stable vector as described in Chapter 2.16.   
In all qRTPCR experiments the expression of the house keeping gene GAPDH was 
analysed in order to allow compensation for variability in the initial concentration and 
quantity of the tRNA and in the conversion efficiency of the reverse transcription reaction.  
GAPDH was chosen because it had shown consistent expression across several ovarian cell 
lines by microarray experiment (data not shown).   
2.15.2 SYBR Green Quantitative RTPCR (qRTPCR) 
2.15.2.1 Materials  
DyNAmo HS SYBR green qRTPCR kit  Finnzymes 
Flat cap strips      Biorad 
Low 96 well white multiplate PCR plate  Biorad 
Opticon 2 DNA Engine     MJ research 
RTPCR oligonucleotides    Invitrogen 
All other reagents as described in Chapter 2.6 
 
2.15.2.2 Method 
qRTPCR was used to quantitatively evaluate the change in RNA expression levels of 
NR2E1 and LMX1A in cell lines before and after treatment with decitabine as described in 
Chapter 3.5.  qRTPCR master mixes were made up using the DyNAmo HS SYBR green 
qRTPCR kit.  The 2x master mix provided contained a hot start version of modified 
Thermus brockiamus DNA polymerase, SYBR green I binding dye, optimised PCR buffer, 
MgCl2 and dNTPs in a premixed form.  Reactions included 1x SYBR green master mix, 
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150 NG of each forward and reverse primer and 2 µl cDNA made up to 25 µl with dH20.  
The optimised conditions are shown in Table 18 below.   
 
Table 18.  qRTPCR: oligonucleotide and conditions 
Gene Primer sequence Genomic 
position 
Product 
size (BP) 
Annealing 
temp (C) 
Mg2+/ 
mM 
GAPDH F:GTCAAGCTCATTTCCTGGTATG 
R:GTCTACATGGCAACTGTGAG 
Exon 8-9 214 61 2 
LMX1A F:TCATGAACCCTACACGG   
R:GGGCTCGGCACCATAA 
Exon 9-10 143 61 2 
N2RE1 F:ATCAACAAGCCGCATTTTAG 
R:GCCTCCCTGGTTTCCAG 
Exon 1-3 160 65 2 
 
 
Reaction mixes and plates were prepared in the PCR workstation.  A negative control 
containing water instead of template cDNA was included and a standard curve derived 
from a range of known concentrations of cDNA was set up in triplicate for each sample.  
The constitutively expressed gene GAPDH was used as an internal control to normalise the 
data and the average value of 3 independent RTPCR reactions, once standardised to 
GAPDH, taken as the concentration of PCR product.  Reactions were run on an Opticon 2 
DNA Engine according to the cycling conditions in table 19 below: 
 
Table 19.  qRTPCR: cycling conditions 
Gene             Cycling conditions 
GAPDH 1. 94°C 15 mins, 2. 94°C 30 secs, 3. 63°C 30 secs, 4. 72°C 30 secs, 5. 
82°C 10 secs, 6. Plate read, 7. Go to step 2x39 times,  
8. Melting curve 70-93°C 
 
LMX1A 1. 94°C 15 mins, 2. 94°C 30 secs, 3. 63°C 30 secs, 4. 72°C 30 secs, 5. 
80° C 10 secs, 6. Plate read, 7. Go to step 2x42 times,  
8. Melting curve 70-93°C 
 
NR2E1 1. 94°C 15 mins, 2. 94°C 30 secs, 3. 63°C 30 secs, 4. 72°C 30 secs, 5. 
80°C 10 secs, 6. Plate read, 7. Go to step 2x42 times,  
8. Melting curve 70-93 °C 
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2.15.3  Taqman Quantitative qRTPCR 
2.15.3.1 Materials 
Trigene advance (1:100 dilution), (TM301)   Trigene 
Taqman Gene expression mastermix. 5 ml (4369016) Applied Biosystems 
DNase/RNase free water (10977-035)   Invitrogen  
FirstChoice® Human Ovary Total RNA (AM6974)  Ambion 
MicroAmp fast optical 96 well reaction plates (4346906) Applied Biosystems 
Microamp optical adhesive films (4311971)   Applied Biosystems 
Taqman RTPCR oligonucleotides    Applied Biosystems 
GAPDH: 4326317E 
SP5: HS01370227-AH 
MAPK: HS01046830 
PX2 thermal cycler      Thermo Electron Corporation 
StepOnePlus real time PCR machine    Applied Biosystems 
Thermospecific PICO 17 centrifuge    Heraeus 
 
2.15.3.2 Method 
Taqman primers were used in the experiments outlined in chapters 4-6.  If the CT values of 
the target gene and GAPDH were similar when tested together and individually they were 
tested in the same reaction; a technique known as multiplexing (The CT value is a relative 
measure of the concentration of target in the PCR reaction, see table below).  Instead of 
testing GAPDH and the test gene separately in the samples of interest this can be done in 
one reaction, saving on precious samples and reagents.   
In addition to reverse transcribed samples, non reverse transcribed and water samples were 
included and it was important that no amplification was seen in these.  All experiments 
were performed in triplicate.  qRTPCR was performed using the Taqman Gene expression 
mastermix, probes and StepOne software version 2 (stepone-
software.software.informer.com/).  The master mix provided contained AmpliTaq Gold® 
(hotstart taq), buffers and dNTPs.  The TaqMan® MGB probe consists of a target specific 
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oligonucleotide with a reporter dye linked to the 5‟ end of the probe, a Minor Groove 
Binder (MGB), and a non fluorescent quencher at the 3‟ end of the probe (lower 
background signal allowing more precise quantitation).  
For siRNA experiments, 3 master mixes were prepared for each 96 well plate; one for the 
GAPDH standard curve, one for the test gene standard curve and one containing both 
primers for multiplexing of the water controls and test samples.  Each reaction included 10 
µl Taqman mastermix, 1 µl of primer (singleplexing) or 1 µl of each primer (multiplexing), 
7 µl of water (singleplexing) or 6 µl of water (multiplexing), and 2µl of cDNA, which was 
prediluted 1/10, with a final volume of 20 µl.   
Reaction mixes and plates were prepared in a PCR workstation on ice following washdown 
with 70% ethanol and trigene solution. For each 96 well plate, three negative controls 
containing H2O instead of template cDNA were included along with a standard curve 
derived from a range of known concentrations of cDNA set up in triplate for each gene. 
GAPDH primers used the VIC reporter and all other primers used the FAM reporter.  
Reactions were run on an applied biosystems StepOne Real Time PCR system according to 
the cycling conditions below in Table 20. 
   
Table 20 
qRTPCR: PCR cycling conditions using Taqman primers 
Step Temperature Time 
1 50°C 2 mins 
2 95°C 10 mins 
3 95°C 15 seconds 
4 60°C 1 minute 
5 Repeat steps 3 and 4, 39 more times 
 
Taqman primers are customised and validated and although the specific sequence is not 
available information relating to their alignment can be found on their website for each 
gene examined (SP5).  
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(https://products.appliedbiosystems.com/ab/en/US/adirect/ab?cmd=ABAssayDetailDisplay
&assayID=Hs01370227_mH  
 
Several factors are important when analysing the data generated by qRTPCR and some key 
definitions which were considered in the results section are listed in table 21 below. 
 
Table 21 
qRTPCR: Definitions of terms used when analysing data 
Name Definition 
CT Intersection between an amplification curve and a threshold line.  A relative 
measure of the concentration of target in the PCR reaction.  The threshold is 
set above the background and within the exponential growth phase of the 
amplification curve. 
Efficiency If efficiency is maximal (=1) the quantity of PCR product generated at each 
cycle is optimal, reflected in the amplification plot.  If the efficiency decreases 
the quantity of PCR product generated at each cycle will decrease and the 
amplification plot will be delayed.  The optimal efficiency is between 90 and 
110%. 
Dynamic 
range 
The number of replicates and logs of template concentration required for 
accurate results.  For these experiments 3 replicates and 5 logs were used. 
R
2
 A statistical term that defines how good one value is at predicting another.  If 
R
2
=1 then you can perfectly predict the value of  X (quantity) with the value 
of Y (CT) 
Precision  The standard deviation (square root of the variance).  The greater the SD the 
lower the ability to distinguish between 2-fold dilutions 
 
Three main steps were taken when analysing the data generated using the Taqman system.   
Firstly the amplification plots for the entire plate are reviewed.  The amplification plot is 
the plot of fluorescent signal versus cycle number.  The higher the starting copy number of 
the nucleic acid target the sooner a significant increase in fluorescence is observed.  
Secondly the standard curve was reviewed.  For an experiment to have been successful it is 
important for replicates to have similar values and for all values to fit well onto one line; 
defined by the R
2
 value.  Finally, the baseline and threshold values, used to determine the 
threshold cycles (CT) for the amplification curves were set automatically using the 
Sequence detection system (SDS).  For the results of an experiment to be deemed valid it 
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was important to have a high R2 value, an efficiency value between 80-110% and 
amplification of both the reference and test gene ideally within 25 cycles of PCR.  Finally 
amplification should be seen in the reverse transcribed samples only with no amplification 
in the non reverse transcribed samples or water blanks. 
2.16 DNA cloning using miniprep (SP5, 
GAPDH, ß-ACTIN for qRTPCR) 
2.16.1 Recipes  
Lysogeny (LB) broth 
800ml H2O  
10g Bacto-tryptone.  
5g yeast extract.  
10g NaCl.  
pH to 7.5 with NaOH.  
Adjust volume to 1L with dH2O  
Sterilize by autoclaving  
 
2.16.2 Materials  
TOPO TA cloning® kit for sequencing  Invitrogen 
(reagents, pCR®4-TOPO® vector, and One shot® TOP10 chemically competent E. coli) 
LB Broth     Imperial College london 
S.O.C. medium    Qiagen 
Ampicillin      Qiagen 
LB agar plates with ampicillin  Imperial College London 
QIAquick® gel extraction kit   Qiagen 
QIAprep® miniprep kit   Qiagen 
Cooling Centrifuge    Fisher 
Shaking incubator    New Brunswick Scientific 
GeneGenius Bioimaging System   Syngene 
Nanodrop ND-1000 spectrophotometer Nanodrop 
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Taq polymerase results in a single „A‟ overhang on the 3 prime end of all PCR products.  
The vector supplied with this kit also has a 3 prime „T‟ overhang which allows the PCR to 
be ligated efficiently into the vector.   
 
2.16.3 Method 
DNA cloning was performed using the Invitrogen TOPO TA Cloning Kit for sequencing.  
qRTPCR was performed as described in Chapter 2.14.  20 μl of the PCR product and 5 μl 
of loading buffer were loaded and then electrophorised on a 1% agarose gel for 30 minutes 
as described in Chapter 2.7.  The gel was then placed in the gel imaging machine and using 
the UV function the product was visualised and cut out using a sterile scalpel.  This was 
then dissolved using the qiagen qiaquick gel extraction kit as per the manufacturer‟s 
instructions.  4 μl of the digested gel were combined with 1 μl of salt and these were mixed 
by pipetting up and down.  Following this 1 μl of the TOPO vector was added and 
combined by swirling gently (it is important not to pipette it up and down).  The reaction 
was left for 5 minutes and then placed on ice for 30 minutes.   
During this time the chemically competent cells were removed from the minus 80 °C 
storage and thawed on ice.  Superoptimal broth (SOC) media was also removed from the 
fridge and warmed to room temperature.  A heating block was prewarmed to 42 °C.  After 
the 30 minute incubation on ice 2 μl of the reaction was gently placed into the vial of 
chemically competent cells (which were kept on ice at all times).  This reaction was left for 
a further 30 minutes and then placed at 42 °C for 30 seconds.  Following this the vials were 
immediately placed back on ice and left for 2 minutes.  Next 250 μl of SOC media was 
added to each and they were placed at 37 °C with shaking for 1 hour.  After this they were 
spread onto a pre-made ampicillin/ agar plate and left in the incubator overnight.   
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Only those colonies which had taken up the TOPO vector should grow in the ampicillin 
environment.  Colonies were then picked using a pipette tip and placed in a falcon tube 
which contained 3.5 ml LB broth and 3.5 μl of ampicillin.  They were then left in a shaking 
incubator at 37 °C overnight.  The following morning a miniprep was performed as per the 
manufacturer‟s instructions using the qiagen QIAprep kit. 
Next 2.5 μl of this was used to perform an EcoR1 digest.  2 μl of 10x EcoR1 buffer, 14 μl 
of water and 2.5 μl of miniprep were mixed by pipetting up and down.  1.5 μl of EcoR1 
enzyme was then added and mixed gently.  The reaction was then placed on a heating 
block at 37 °C for 90 minutes.  Afterwards 5 μl was combined with 1 μl of orange G 
loading buffer and ran on a 1%  agarose gel for 35 minutes.  If the reaction was not to be 
run on a gel immediately then it was placed on ice for 10 minutes to stop the ecoR1 
reaction (and then stored at minus 20 °C).  If the cloning reaction had been successful then 
for SP5 a PCR product was seen at 190 bp. 
 
2.17 DNA Cloning using maxiprep (cloning 
of SP5, KIAA1383 and empty vector for 
over expression experiments) 
2.17.1 Materials 
Plasmid DNA cloned in vector as outlined in chapters 2.22 (KIAA1383) and 2.23 (SP5) 
37 °C shaking incubator   New Brunswick Scientific 
Centrifuge     Fisher 
250 ml conical flask    Corning  
Hispeed Plasmid Purifation Maxi Kit  Qiagen 
All other reagents as listed in chapter 2.16.1 
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2.17.2 Method 
SP5 and KIAA1383 were provided already cloned into their respective vector systems.  The 
empty vector for both systems was also cloned.  The work bench was cleaned down using 
trigene and all work was carried out close to a flame (from Bunsen burner).  Similarly to as 
described above, both genes were separately transformed into chemosensitive bacteria and 
colonies grown on agar plates containing ampicillin.  Plates were left overnight in a 37 °C 
incubator.  16 hours later a single colony was selected and placed into 5 ml of Lysogeny 
(LB) broth containing 5 µl of ampicillin.  This starter amplification was placed on the 
shaking incubator at 37 °C for 6 hours.  Next 400 µl of the reaction was taken and placed 
into a 500 ml conical flask containing 200 ml of LB media containing 200 µl of ampicillin.  
The conical flask was sealed using tinfoil and then placed on the shaking incubator at 37 
°C for 16 hours.  It is important that the flask holds at least twice the volume of the 
reaction.  After 16 hours the contents was transferred to a 250 ml bottle with lid and spun 
at 3200 xg for 15 minutes at 4°C.  Following centrifugion the supernatant was removed, 
sterilised in trigene and discarded.   
The cell pellet was then used as the basis for the hispeed maxi prep which was carried out 
according to manufacturer‟s instructions (with the exception of the DNA precipitation step 
which was carried out for 30 minutes rather than 5 minutes and the first three buffers 
which were used at double the volume).  DNA was eluted in 1000 µl TE buffer and passed 
through the qiaprecipitator.  This same elute was then passed through the qiaprecipitaor a 
second time in order to increased the concentration of DNA obtained.   
The DNA was then analysed on the nanodropper and the conc. and 260/280 and 230/280 
ratios noted.  DNA of adequate quality was expected to have values of 1.8 and 1.9 
respectively.  If the ratio was lower then protein or solvent contamination respectively 
were assumed and the maxiprep was repeated.  DNA was stored at minus 20°C.  Any 
cloned DNA was sent for sequencing.   
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Glycerol stocks were made by taking 100 µl of the second incubation liquid and combining 
with 100 µl of glycerol/LB mix (20 µl glycerol and 80 µl LB media).  Stocks were stored 
at minus 80°C.  The vector map for KIAA1383 is shown below in Figure 10 (below) and 
the vector map for SP5 is shown later in chapter 6.8: 
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Figure 10.  Vector map for pFN21A vector which over expressed KIAA1383 
(www.kasuza.com). 
 
2.18 Cell culture 
All tissue culture media was stored at 4
o
C 
2.18.1 Materials  
Cryotubes      Nunc 
Dimethyl sulfoxide (DMSO)    Fisher 
Fetal Bovine Serum (FBS)    Autogen Bioclear 
L-Glutamine 200mM     Gibco 
Petri dishes (5cm and 10cm)    Sterilin 
Penicillin-Streptomycin (15140-122)   Invitrogen 
Pipet-aid pipettor     Drummond Scientific 
RPMI growth medium    Gibco 
25, 75 and 175cm
2 
sterile tissue culture flasks Iwaki 
Stericup vacuum-driven filtration System  Millipore 
6, 24 and 96 well tissue culture plates  Iwaki  
TrypLE express  (12604).    Gibco 
70 umI sieve (734-0003).     VWR     
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2.18.2 Recipes 
PBS (Phosphate Buffered Saline) 
NaCl   137mM 
Na2HPO4  8.5mM 
KCl   44mM 
KH2PO4  1.4mM 
 
RPMI plus +/- 2x penicillin/ streptomycin 
RPMI 1640    500ml 
L-glutamine (2mM, final)  5ml 
Penicillin/streptomycin  2ml  
(10 000 u penicillin+10 000 μg streptomycin/ ml) 
FBS (10% final)   50ml 
 
2.18.3 Method 
Aseptic manipulations were performed using sterile glassware and plasticware in a class II 
microbiological safety cabinet with vertical airflow. All cell lines were regularly analysed 
for mycoplasma infection.  Ovarian epithelial cancer cells lines were grown and 
maintained at 37
o
C in RPMI 1640 medium supplemented with 10% FBS and 2mM L-
glutamine as monolayers in 25, 75 or 175cm
2
 flasks in the presence of 5% CO2.  
 
2.18.4 Ovarian cancer cell lines 
The cisplatin-sensitive cell lines used in these experiments were the parental cell line 
A2780 and 5 clonal derivatives (A2780p3, A2780p5, A2780p6, A2780p13 and 
A2780p14). Ten isogenically matched cisplatin-resistant cell lines were used; A2780cp70 
(Behrens, Hamilton et al. 1987) and MCP1-9 (referred to as the multi-step clones), 
(Brown, Hirst et al. 1997).  These were derived by multiple exposures to cytotoxic levels 
of cisplatin and showed a 2-5 fold resistance to cisplatin in clonogenic assays.  Six 
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additional cisplatin-resistant cell lines, derived from exposing A2780 cells to a single dose 
of cisplatin (McLaughlin, Stephens et al. 1991), were used which included C1cis6, C2cis6, 
C2E3, C3Cis6, C5E4 and C5E4(15).  These are referred to as the single step clones.  The 
final pairs were OVIP and OVIP DDP and CH1 and CH1CISR (McLaughlin, Stephens et 
al. 1991).  
In addition sensitive and resistant ovarian cancer cell line pairs derived from patients were 
used.  PEO1 (a patient with poorly differentiated serous adenocarcinoma after cisplatin, 
5FU and chlorambucil chemotherapy) and PEO1CDDP (laboratory generated resistant cell 
line following further cisplatin treatment), PEO4 (collected after clinical relapse) and 
PEO6 (collected prior to death); PEO14 (a patient with well differentiated serous 
adenocarcinoma, collected prior to treatment) and PEO23 (following relapse after cisplatin 
and chlorambucil); PEA 1 (a patient with poorly differentiated adenocarcinoma collected 
prior to treatment) and PEA2 (at relapse following cisplatin and prednimustine) (Langdon, 
Lawrie et al. 1988).  All of these cell lines are shown in Figure 11 below. 
 
 
 
 
 
 
 
 
 
 
Figure 11.  34 epithelial ovarian cancer cell lines panel.  Blue sensitive cell lines, peach 
resistant cell lines.  Solid line in vitro generated resistant clones, Broken line in vivo generated 
resistant clones.   
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Cell stocks were formed by freezing 10
6
 cells in 1ml FCS with 10% DMSO at  
-70°C in cryotubes. After 24h, samples were transferred to liquid nitrogen. Cell lines were 
replaced regularly from frozen stocks to reduce the chances of genetic drift.  
2.19 siRNA 
2.19.1 Materials 
Hiperfect transfection reagent    Qiagen 
SP5 siRNA (127988 F08, 127988 F09)   Invitrogen 
MAPK siRNA (1022564)     Qiagen 
siGENOME non-targeting siRNA pool (d-0012-6-13-05) Dharmacon  
All stars® siRNA (1027280)     Qiagen 
Cyclophilin B       Dharmacon 
All other reagents as outlined in Chapter 2.16 
 
2.19.2  Recipes  
Serum free media 
RPMI 1640 100 ml 
L Glutamine 1 ml 
 
2.19.3 Method 
Small interfering RNA (siRNA) are double stranded RNA molecules, usually between 20 
and 25 nucleotides long, which, among other functions, are involved in the RNA 
interference pathway.  They can therefore be used to modulate gene expression.  They have 
2-nt 3‟ overhangs on either end and each strand has a 5‟ phosphate and a 3‟ hydroxyl 
group.  If the gene sequence is known it is possible to design an siRNA exogenously that 
may interfere with the expression of that gene and it is therefore an experimental approach 
that can allow analysis of the phenotypic effects of suppression of a specific gene‟s 
expression.  The siRNA experiments described result in a transient reduction of gene 
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expression which can then be confirmed and quantified at the mRNA level by qRTPCR (or 
the protein level by western blot analysis) (Dennis-Sykes, Miller et al. 1985).   
In order to check that the siRNA has been successfully integrated into the cell, but without 
off target effects, it is important to run adequate positive controls.  siRNAs targeting 
ubiquitous and highly expressed housekeeping genes are commonly used controls; in this 
case MAPK was used which has been proven to cause high knockdown of its target gene. 
MAPK knockdown was confirmed by qRTPCR.  As it is not possible to exclude off-target 
effects as a result of knocking down a gene of interest it is important to measure general 
off-target effects by using a scrambled control that should not interfere with any gene 
expression.  All Stars® scrambled siRNA (Qiagen) was used in all experiments as the 
negative control and knockdown again assessed by qRTPCR.  All Stars® is known to have 
no homology to any mammalian gene.  In addition, another positive (cyclophilin) and 
negative (siGENOME non-targeting siRNA) control were tested and these showed the 
comparable results.  
Firstly, qRTPCR experiments were performed to confirm which cell lines that the gene of 
interest was expressed in.  These cells were then transfected with 3 different siRNA‟s for 
the same gene at two different concentrations.  This was to find the optimal siRNA and 
concentration for knockdown.  These initial experiments were performed using the 
concentrations of transfection reagent suggested by the manufacturer and all optimal 
siRNA doses are referred to in the text and tables below.   For each experiment a minimum 
of 5 conditions were analysed - an untreated sample where cells were passaged and seeded 
in media only; a mock treated sample where the sample was treated with the transfection 
reagent but no siRNA; and a positive control, negative control and the test siRNA.  The 
positive control was then examined by qRTPCR following RNA extraction and conversion 
to cDNA (see chapters 2.13-2.15) in order to confirm adequate knockdown.  For MAPK a 
decrease in gene expression of at least 80% was expected to confirm adequate transfection.  
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If transfection was found to be adequate the knockdown of the test gene was next 
examined, again as outlined in chapters 2.12 - 2.14.  
Cells were grown up as outlined in chapter 2.17 in 75 ml flasks.  It is important for cells to 
be approximately 60% confluent for efficient transfection in siRNA experiments. Once this 
was the case the experiment was started.  On day 1, media was aspirated off and the cells 
were washed in 10 ml of PBS.  This was then aspirated off and 6 ml of TrypLE
TM
  was 
added.  Flasks were placed flat back in the incubator for 10 minutes at standard conditions 
(37
o
C 5%CO2 in air).  Trypsanisation of cells was confirmed by microscopy and then the 
cells and trypsin were passed through a 70 um sieve into a 30ml Falcon tube to remove 
clumps of cells.  10 mls of RPMI media was washed around the flask and then this was 
also passed through the sieve.  The falcon tube was then centrifuged in a Beckman 
centrifuge at 600 xg for 4 minutes.  Any liquid was aspirated and the cell pellet was then 
resuspended in 10 ml of RPMI plus media containing 2x penicillin and streptomycin.  Ten 
µl of cells were mixed with 10 µL of trypan blue 0.4% and then counted twice using a 
Neubauer haemocytometer.     
These initial experiments were performed in 24 well plates and 20x10
4
 cells were seeded 
per well in a volume of 500 µl.  Colleagues had previously found this to be the optimal 
plating density for these cell lines.  The plate was then either placed in a humidified 
incubator at 37
o
C 5% CO2 in air for 4 hours for the cells to settle and attach or immediately 
transfected (within 30 minutes of plating).   
Next the siRNA‟s were defrosted on ice and a mastermix was made up for each test 
condition.  Serum free media was added firstly and then siRNA‟s where appropriate.  This 
mixture was then vortexed.  Hiperfect transfection reagent was then added, the mixture 
vortexed and then left for 10 minutes at room temperature.  Finally 100µl of the mastermix 
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was added drop wise onto each well attempting to evenly disperse it amongst the well.  
Mastermixes are outlined in table 22 below: 
 
Table 22.  siRNA: Mastermixes for initial experiments (24 well plates).  
Sample SFM* (µl) 2 μM  
siRNA (µl) 
Hiperfect 
(µl) 
Untreated 100 0 0 
Mock 100 0 3.25 
MAPK +/-other positive 100 3 3.25 
All stars +/-other negative 100 3 3.25 
SP5/ test gene 100 1.5 3.25 
SFM* serum free media, see recipes 
Cells were then placed in the incubator at standard CO2 and temp.  On days 2 and 3 cells 
were observed my light microscopy and any obvious effects noted e.g. suspected cell 
death.  On day 4 in exactly the same way as on day 1 cells were trypsanised, counted and 
spun down into a cell pellet.  The cell pellet was then resuspended in 350 µl of lysate 
buffer, homogenised using the Qiashredder columns and stored at -20
o
C prior to RNA 
extraction, cDNA conversion and qRTPCR as described in chapters 2.13-2.15.  
2.20 Induction of apoptosis as measured by 
Caspase-Glo® 
2.20.1 Materials  
Caspase-Glo® 3/7     Promega 
White „culturPlate 96‟ plates  PerkinElmer 
Optima luminometer   Lumistar 
Rocking table    Luckham  
  112 
2.20.2 Method 
Caspase-Glo® results in cell lysis followed by caspase cleavage of the substrate releasing 
free aminoluciferin which is consumed by luciferase generating a luminescent signal.  The 
signal is proportional to caspase activity.   At each timepoint (24, 48 and 72 hours) 100 µl 
of caspase was added directly to cells.  It was then placed on a shaking plate at room temp 
with the plate protected from light using tin foil.  This reaction was left for 2 hours.  
Following this the lid of the plate was removed and analysis performed in an Optima 
lumistar luminometer using the associated software.  The caspase solution was stored at 
minus 20 °C when not in use and protected from light using tinfoil. 
2.21 MTT  
The (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used 
in three sets of experiments in this thesis; Firstly when SP5 was knocked down in order to 
assess the effect on chemosensitvity, secondly in the caspase experiments as a means of 
normalising apoptosis for the number of surviving cells and thirdly in order to assess 
whether over expression of SP5 had an effect on chemosensitivity. 
The MTT assay is an alternative to a clonogenic assay, which measures the ability of cells 
to form colonies and proliferate following a period of drug exposure.  The MTT assay has 
the advantage of being less time consuming and allows a number of assays to be performed 
simultaneously.   
PEO14 and PEO23 cell lines were plated in 96 well plates, in triplicate for each condition.  
24 hours later they were exposed to a range of cisplatin doses when in the exponential 
phase of growth.  After 24 hours, cisplatin was removed and cells were allowed to 
proliferate for 48 hours.  The percentage of surviving cells was then determined indirectly 
by MTT reduction.  MTT is a water soluble tetrazolium dye that is reduced by live but not 
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dead cells to form a water insoluble purple formazan product.  This was dissolved in a 
suitable solvent (MTT Stop solution) and the amount of product determined 
spectrophotometrically. 
2.21.1 Materials 
Multi channel pipette    Thermo Scientific 
Troughs     Beckman Coulter 
Dimethyl sulfoxide (DMSO)   Sigma  
3-(4, 5-dimethylthiazol-2-yl)-2,   Sigma 
5-diphenyl-Tetrazolium bromide (MTT) 
Dispenser microfill    Fisher 
Plate reader     Biotek 
Microplate photometer   Labsystems 
Sorensens glycine buffer   Lab systems 
Routine tissue culture materials  See section 2.16.2 
MTT stop solution    10% SDS with 0.01% conc. HCL 
 
2.21.2 Method 
In the experiments outlined in Chapters 6.5 and 6.8 MTT experiments all included 4 wells 
treated with media only and then a range of concentrations of cytotoxic drug for each 
siRNA condition, in quadruplicate.  Flasks were incubated at standard conditions and 
inspected days 2-3 and any obvious effects e.g. increased cell death noted.  On day 4 cells 
were again washed with 10 ml of PBS, trypsinised using 6 ml of TripLE Express and 
counted having been passed through a sieve as described previously.  They were then 
seeded at a density of 1x10
4
 cells in 160 µl of „RPMI plus‟ media per well in a 96 well 
plate for the first experiments and 0.3x10
4
 for the experiments combined with the caspase 
assay.  They were incubated at standard conditions for 24 hours.       A serial 5 fold dilution 
of cytotoxic drug was prepared in PBS (for siRNA expt) and 6 fold dilution (for over 
expression Expt) and 20 µl added to the cells.  A further 20 µl of media was then added to 
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each well except for control wells that received 40 µl of media instead .All wells had a 
final volume of 200 µl.  A multichannel pipette was used to dispense the drug starting at 
the lowest drug concentration.   
On day 5, the media was replaced with 200 µl of fresh media so that the drug was 
removed.  Cells were incubated at standard conditions until day 7 when the MTT assay 
itself was performed.  For this the MTT solution was warmed for 1 hour at 37°C.  MTT 
was dissolved in PBS at a concentration of 2 mg/ml.  50 µl of MTT was then added to each 
well using the auto pipette.  The plates were incubated for 1 hour at 37
o
C.  The MTT was 
then flung off and the plates blotted upside down with paper.  200 µl of DMSO was added 
to each well and the plates were left on an agitator for 15 minutes.  The plate reader was 
switched on and a 540 nm filter inserted.  The plates were read using the ASCENT 
programme.  This provides results in a format that can be transferred to excel. 
In the experiment reported in Chapter 6.6 the MTT was used simply to normalise the 
caspase results and therefore the use of cisplatin was omitted.  Cell lysates were prepared 
as described in chapter 2.11 for each time point.   
Caspase plates were read on the Lomita optima illuminometer plate using the 
corresponding software and data exported into excel.  MTT was read on the 
spectraMaxi190 at 570 nm using Surtax Pro software and data again exported into excel.  
The average was taken for each triplicate and then the caspase results divided by the MTT 
results.  This provided a control for altered proliferation in different conditions.  RNA was 
later extracted from cell lysates and reverse transcription performed as described in 
Chapters 2.12 - 2.14.   
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2.22 Outline of siRNA knockdown experiment 
used for caspase 3/7 analysis 
normalised to MTT 
2.22.1 Materials 
All reagents as outlined in Chapter 2.18, 2.19 and 2.20 
 
2.22.2 Method 
siRNA was performed directly onto 96 well plates in a similar manner to that described in 
chapter 2.18 with some modifications.  On day one 0.3x10
7 
cells in 80 µl of RPMI plus 
media (containing 2x penicillin and streptomycin) were transfected in triplicate onto white 
96 well plates for later caspase analysis (Chapter 2.19).  Simultaneously 0.3x10
7 
cells in 80 
µl media were seeded on clear 96 wells in quadruplicate for later RNA extraction and 
qRTPCR. A third clear plate had the same cell numbers plated in triplicate for a later MTT, 
as described in Chapter 2.20.  The same five conditions were used as described in the 
previous chapter; namely untreated, mock treated, all stars scrambled control, MAPK 
control and SP5 nm siRNA.  Plates were prepared for analysis at 24, 48 and 72 hours.  The 
siRNA transfection was performed approximately 4 hours after the cells had been seeded. 
A mastermix containing serum free media, hiperfect +/- siRNA for each condition was 
prepared in 1.5 ml tubes and vortexed and left at room temp for 10 minutes.  Allstars and 
SP5 were used at 5 nm conc. and MAPK at 10 nm conc.  Untreated wells contained 20 µl 
of serum free media only, mock treated cells contained 19.8 µl of SFM and 0.2 µl of 
hiperfect.  Allstars and SP5 contained 19.5 µ, 0.2 µl hiperfect and 0.3 µl siRNA.  MAPK 
contained 19.2 µl SFM, 0.2 µl hiperfect and 0.6 µl siRNA.  They were then left in the 
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incubator at 37 degrees °C and 5% CO2.  Separate plates for caspase, MTT and cell lysates 
were then removed at each time interval (24, 48 and 72 hours) and analysed as described in 
Chapters 2.19, 2, 20 and 2.11 respectively.   
 
2.23 Flow cytometry and cell cycle analysis 
following transient over expression of 
KIAA1383 +/- cisplatin in PEA2. 
2.23.1 Materials 
pFN21A vector with halotag    Promega 
- FHC00819 
- FHC02806 
Effectene transfection kit (301425)   Qiagen 
DiACFAM halotag ligand    Promega 
Propidium iodide (P4170)    Sigma  
RNase A (R4875)     Sigma  
Triton X100 (X100 500 ml)    Sigma 
Polystyrene FACS tubes (352052)   Becton Dickinson, Oxford, UK (BD) 
FACScalibur      Becton Dickinson, Oxford, UK 
Cell quest analysis software    Becton Dickinson, Oxford, UK 
FloJo 7.6.1 cell cycle analysis software  FloJo 
Other reagents and kits as described in chapter 2.17 (maxi prep) and 2.18 (Cell culture) 
2.23.2 Methods 
2.23.2.1 Transient transfection  
The effect of over expressing KIAA1383 in PEA2 was assessed by cell cycle analysis.  
KIAA1383 were supplied within the pFN21A vector system which contains a halotag.  On 
day one, 2x10
5
 cells were seeded in 1600 μl media containing 2X penicillin and 
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streptomycin onto two 6 well plates.  Plate one was later transfected with empty vector +/- 
cisplatin in triplicate and plate two with overexpressing vector +/- cisplatin, in triplicate.   
On day 2 if cells were 40-80% confluent transfection was performed.  This was performed 
as described by the manufacturers.  Briefly, 0.4 μg DNA had previously been eluted in TE 
buffer (chapter 2.17).  This was combined with EC buffer to a final volume of 1400 μl.  3.2 
μl was added and the mixture vortexed.  It was then incubated at room temperate for 5 
minutes and centrifuged for 15 seconds.  10 μl of effectene reagent was added to the DNA 
enhancer mix and vortexed for 10 seconds.  This was incubated at room temperate for 5-10 
minutes.  While complex formation was occurring the media was aspirated off the cells 
and a PBS wash was performed.  1000 μl of fresh media was then added to each well.  600 
μl of media was then added to the complexes and mixed by pipetting up and down twice.  
This was then added immediately to wells dropwise.  The dish was swirled gently to aid 
even distribution.  The plates were placed in a 37 °C 5% CO2 incubator for 48 hours.   
On day 4 for the cisplatin treated cells 25 µM cisplatin in 2000 μl media was added and for 
the others a simple media change performed.  Plates were again incubated at 37 °C degrees 
and 5% CO2.  
2.23.2.2 Addition of fluorescent ligand.  
On day 5 the fluorescent halotag was added as per the manufacturer‟s instructions.  Firstly 
the media was changed in all wells in order to remove cisplatin.  The fluorescent tag was 
diluted 1/1000 in fresh warm media and 650 μl pipetted into each well.  This was 
incubated for 15 minutes at 37 °C and 5% CO2.  The ligand was then gently replaced with 
1000 μl warm fresh media.  This was repeated twice further with PBS finishing with 1000 
µl of warm medium.  Cells were incubated in an incubator for 30 minutes to wash out 
unbound ligand.  The cells were washed with PBS and the medium replaced for a final 
time with 2000 μl fresh warm medium. 
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2.23.2.3 Propidium Iodide fixing and staining 
Cells were next fixed, permeabilised and stained with propidium iodide containing RNase 
A.  Firstly cells were washed with PBS, trypsinised and centrifuged at 400 g.  The 
supernatant was removed and they were resuspended in 1 ml of PBS in a 1.5 ml eppendorf 
tube.  They were further centrifuged at 2500 rpm for 5 minutes.  They were next 
resuspended in 1 ml of cold 70% ethanol which was added dropwise while vortexing.  This 
reaction was then incubated at minus 20 for 30 minutes.   The reaction was then 
centrifuged for 5 minutes at 400g.  The supernatant was removed; 10 μl of each reaction 
was place in a separate eppendorf.  All tubes were then resuspended in 1 ml PBS.  500 μl 
of a mastermix containing 0.2% Triton X, 50 μg/ ml propidium iodide and 100 μg/ml 
RNase A was then added and incubated for the propidium iodide stained cells and 500 μl 
PBS added to the corresponding non stained control samples (which were made up of 10 μl 
of the initial reaction resuspended in PBS).  Eppendorfs were protected from sunlight using 
foil.  These reactions were incubated at 37 °C  for 30 minutes.  After this cells were spun at 
2500 RPM for 5 minutes and the supernatant removed.  Each vial of cells was resuspended 
in PBS and transferred to a polystyrene FACS tube just prior to analysis.  Each sample was 
then analysed using cell quest analysis software.  20 000 events were counted.  Cells were 
gated according to forward and side scatter and then FLT2 area and width.  Cell cycle 
analysis was performed on the remaining cells using FlowJo 7.6.1.   DiACFAM crosses the 
extracellular membrane and stains green and Propidium Iodide stains DNA red.  The 
controls used in the initial set up of the FACS machine are listed below: 
1. PEA2, no plasmid, fluorescent tag, no PI 
2. PEA2, no plasmid, fluorescent tag, PI 
3. PEA2, plasmid, no fluorescent tag, no PI 
4. PEA2  , plasmid, no fluorescent tag, PI   
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2.24 Stable over expression of SP5 in A2780 
cp70 with subsequent MTT experiment 
using cisplatin at varying doses 
2.24.1 Materials 
pCMV6-AC-GFP vector with SP5   Origene 
(and empty vector only control) 
Effectene transfection kit (301425)   Qiagen 
HiSpeed Plasmid maxi prep kit (12662)  Qiagen 
RPMI 1640 + L-glutamine (21875-091)   Invitrogen 
G418 sulphate (P25-011)    PAA 
Tryple Express (12604013)    Invitrogen 
PBS       In-House 
6 well plates (353046)    Falcon 
24 well plate (142475)    Nunc 
T25 vent cap (430639)    Corning 
T75s vent cap (430641)    Corning 
96 well plates (Costar 3596)    Corning 
Stericup GP filter unit 250ml (SCGPU02RE) Millipore 
MTT 2mg/ml      Sigma 
Countess cell counter      Invitrogen 
Countess chamber slides    Invitrogen 
DMSO analytical grade    Fisher 
Synergy 2 plate reader    Biotek 
Gen5 v1.05 software     Biotek 
Scout Pro balance     Ohaus 
 
Other reagents and kits as described in chapter 2.13-2.14, 2.16 (RNA extraction, cDNA 
synthesis and qRTPCR), 2.18 (Cell culture), 2.21 (MTT). 
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2.24.2 Method 
A2780 cp70 cells were plated at 3 different densities in duplicate 6-well plates; 0.5 x 10
5
, 1 
x 10
5
, 2 x 10
5
.  These were then incubated overnight (~22hrs) prior to transfection.  As 
described in Chapter 2.22.2.1, 0.4µg of DNA was used per well of plate, SP5 and vector 
only transfections in were performed in parallel at each cell density. Briefly, the volume of 
DNA containing 0.4µg was made up to 100µl using enhancer (EC) buffer and then 3.2µl of 
enhancer solution was added before vortexing for 1 sec and incubating for 5 minutes at 
room temp. 10µl of effectene reagent was then added and mixed by pipetting 5 times and 
further incubated for 10 minutes. 
 
The medium on the cells was then removed and replaced with 1600µl fresh medium. 
600µl medium (normal medium for cell culture was used for this i.e. including serum) was 
then added to the transfection mix and mixed by pipetting twice.  This solution was then 
immediately added, dropwise, to the appropriate well.  
 
Twenty four hours post transfection cells were between 40-60% confluent.  Each well of 
plate was passaged into a 100mm dish. Cells were transferred from 9.5cm
2
 growth area to 
55cm
2
 area giving an approximate split ratio of 1/6 (between 1/5 and 1/10 is 
recommended).  From this point onwards cells were maintained in medium containing 
0.5mg/ml G418 sulphate to select for cells that had taken up the plasmids containing the 
resistance gene.  The medium was replaced every 2 to 3 days to maintain a constant 
concentration of antibiotic. 
 
Four to five days post passage some colonies were visible. 6 days after passage, cells from 
the highest density were too confluent to select colonies.  Therefore cells were harvested 
for RNA to check expression on SP5 (see Chapter 2.14).  Results were encouraging 
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showing that SP5 was being expressed at a high level in the expected clones and no SP5 
was detected in the vector only control. 
Fourteen days after passage many individual colonies were visible in the remaining 
duplicate cultures. For each plate which was SP5 transfected, five individual colonies were 
removed (using 1µl of trypsin and pipette tip) and placed into a single well of 24-well 
plate. After 5 colonies were removed from each plate (to give 10 in total labelled A-J) and 
the remaining cells from each plate were pooled to give pools A and B and passaged into 
T75 flasks.  The „vector only‟ cultures had fewer visible colonies so were combined to 
create a single vector only pool (passaged into a T75 flask).  Cells were then bulked up as 
quickly as possible so that cells could be harvested for RNA and cyropreserved for future 
use (see Chapter 2.12). 
 
2.25 Statistical methods of analysis  
2.25.1 Student’s t-test 
The t-test assesses whether the means of two groups are significantly different from each 
other. This analysis is appropriate whenever you want to compare the means of two 
groups.  In this thesis a 2 tailed t-test was used assuming that the two samples could have 
unequal variance. 
 
2.25.2 The cluster quality R2 statistic 
The R
2
 statistic (R
2
 = 100VB/VT) is used to estimate the quality of an identified pattern. 
The larger the R
2
 statistic, the better the separation of the patient population and/or the 
higher the coherence between selected features. VB is a measure of variance between 
samples and VT measures the total variance of a cluster. 
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2.25.3 Logistic regression 
Logistic regression (Mayers 1963) is used to predict the probability of occurrence of an 
event by fitting data to a logistic curve. It is a generalized linear model used for binomial 
regression. It can make use of several predictor variables that may be either numerical or 
categorical.  In this thesis it was used for assessing the correlation between methylation of 
our candidate genes (used as a continous variable) with response to first line platinum-
based chemotherapy in two cohorts of ovarian cancer patients. The significance level was 
set at p<0.05. 
2.25.4 Cox proportional hazards model 
Proportional hazards models are a class of survival models in statistics. Survival models 
relate the time that passes before some event occurs to one or more covariates that may be 
associated with that quantity.  Survival models consist of two parts: the underlying hazard 
function, describing how the hazard (risk) changes over time at baseline levels of 
covariates; and the effect parameters, describing how the hazard varies in response to 
explanatory covariates.  The proportional hazards condition (Breslow 1975) states that 
covariates are multiplicatively related to the hazard. Sir David Cox observed that if the 
proportional hazards assumption holds then it is possible to estimate the effect parameter(s) 
without any consideration of the hazard function. This approach to survival data is called 
application of the Cox proportional hazards model (Cox 1972), sometimes abbreviated to 
Cox model or to proportional hazards model.  In this thesis it was used when assessing the 
effect of methylation of a candidate gene on survival, where methylation was used as a 
continuous variable (without using any arbitrary cut-off). The assumption of the 
proportional hazards was examined by fitting general linear regression model of weighted 
residuals of the Cox model, and test the non-zero slope of the model as previously 
described (Grambsch 1994  ). The significant level was set at p<0.05 (two-sided).
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2.25.5 Kaplan-Meier 
The Kaplan–Meier estimator is used for estimating the survival function from life-time 
data (Kaplan 1958).  In this thesis it was used to demonstrate if the survival of two groups 
of patients, with high/low methylation of a candidate gene determined by median of 
methylation across all the patients, is significantly different.    
A plot of the Kaplan–Meier estimate of the survival function is a series of horizontal steps 
of declining magnitude which represent the true survival function for that population. This 
method can take into account some types of censored data, for example, if a patient 
withdraws from a study, i.e. is lost from follow-up before the final outcome e.g. death is 
observed. On the plot, small vertical tick-marks indicate losses, where a patient's survival 
time has been right-censored.   
In this thesis it was used for two main reasons: firstly it provides a visual representation of 
the data and secondly it was used to analyse the combined data set, as a means of 
confirming any association or lack of association with methylation of a candidate gene.  
Compared to the Cox regression model (Cox 1972) it has the disadvantage of needing to 
use an arbitrary cut-off rather than a continuous variable, to divide the groups  - in this case 
high or low methylation, based on the median.      
 
2.25.6 PAM 
Prediction Analysis Microarrays (PAM) is a statistical technique used to identify groups of 
genes that discriminate best between classes.  In this technique the class gene centroid is 
shrunken towards the overall centroid by a threshold amount, determined by cross 
validation, following standardisation of each gene by its within class standard deviation 
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(Tibshirani and Efron 2002).  This technique was originally designed to interrogate gene 
expression microarray data and has also been used to interpret DMH data.   
2.25.6.1 Pre-processing of DMH data 
Since the Agilent custom-designed microarray was originally designed for detecting copy 
number alterations (CNA), Agilent Feature Extraction software does not provide quality 
control (QC) reports tailored for DNA methylation analysis. Therefore, 4 features shown in 
Table 23 as indicators of DMH data quality, rather than using the QC report which is 
generated for comparative genomic hybridisation (CGH) microarrays by Agilent Feature 
Extraction Software. These 4 features indicate the outliers of non-uniformity and 
population at background and foreground in green and red channels, respectively. The 
highest consistency (R
2
=0.95) between duplicates was achieved using these 4 features to 
exclude probes not fulfilling required data quality.  Probes with signal intensities over 
65000 (signal saturation) were excluded from the analysis due to the signal saturation. The 
probes with low intensities were also not taken into consideration.  
 
Table 23: PAM: Features for quality control in DMH assay 
Features (Green) Features (Red) Types Description* 
gIsFeatNonUnifOL rIsFeatNonUnifOL Boolean Boolean flag indicating if a features is a 
NonUniformity Outlier or not. A feature 
is non-uniform if the pixel noise of 
feature exceeds a threshold established 
for a „uniform‟ feature. 
gIsBGNonUniOL rIsBGNonUniOL Boolean The same concept as above but for 
background 
gIsFeatPopnOL rIsFeatPopnOL Boolean Bolean flag indicating if a feature is 
Population Outlier or not. Probes with 
replicate features on a microarray are 
examined using population statistics. 
A feature is a population outlier if its 
signal is less than a lower threshold or 
exceeds an upper threshold (1.42×IQR). 
gIsBGPopnOL rIsBGPopnOL Boolean The same concept as above but for 
background 
* Reference Guide of Agilent Feature Extraction Software (www.genomics.agilent.com/files/.../G4460-90026_FE_Reference.pdf)  
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2.25.7 SAM 
Significance analysis of microarrays (SAM) is used to identify individual sequences which 
best discriminate between classes.  SAM uses an extension of the t-statistic to assign each 
gene a score based on the change in hybridisation relative to the standard deviation of 
repeated measurements (Tusher, Tibshirani et al. 2001).  SAM then uses permutations to 
estimate the false discovery rate (FDR) for significant genes which have a score over a 
certain threshold.  Following the initial DMH experiment a cut off is arbitrarily chosen, 
between the ratios of raw signal intensities (undigested/ digested), to identify methylated 
loci.   
This technique has also been used frequently to analyse gene expression microarray 
experiments and subsequently to analyse DMH data.  The data is normalised assuming a 
normal distribution and symmetry (that only some sequences will show a change in 
methylation and that as many sequences will gain methylation as will lose it between 
groups). 
2.25.8 MLDA 
Methylation linear discrimination analysis is a statistical technique recently developed for 
analysing CpG island microarray hybridisation data (Dai, Teodoridis et al. 2008).  It uses a 
linear regression model to identify loci which are differentially methylated e.g. between 
tumour pairs or isogenically matched sensitive and resistant cell lines.  Three linear models 
are constructed.  The first one is constructed from the log-transformed signal intensities of 
unmethylated features (mitochondrial sequences).  This is used as a reference for 
unmethylation.  Next an intermediate model is constructed using the point corresponding 
to the 97.5-quantiles residual below the first linear regression line.  The third model is used 
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as a reference for methylation and is generated using features with a standardised residual 
of less than 2 from in the intermediate model.   
 
Figure 12. MLDA: An illustration of unmethylated and methylated model construction in 
MLDA in the A2780 cell line. a: Three patterns can be observed on the scatter plot of log-
transformed Cy3 (undigested) against log-transformed Cy5 (digested) intensities. b: The 
unmethylated model constructed using 94 mitochondrial sequences as a unmethylation reference. 
c: The intermediate model constructed through the 97.5 quantile residual. The point X is the 97.5 
quantile residual. The microarray probes coloured in blue (standardised residual to the intermediate 
model is less than 2) are selected to construct the methylated model. d: Methylated (in blue) and 
unmethylated (in red) models in A2780 cell line. 
 
The log likelihood ratio of a locus being methylated is proportional to the difference 
between the squared standardised residual from the methylated line and that from the 
unmethylated line.  Features consistently identified as methylated are assigned a score of 1 
and those unmethylated a score of -1; the rest are assigned a weighted score corresponding 
to their location of the plot of log likelihood ratios.  The averaged score for each locus is 
calculated, in for example the sensitive and resistant cell line, and plotted against each 
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other.  The weighted scoring system used to allocate a sensitive and resistant score is 
illustrated in Figure 13 below. 
Figure 13.  MLDA: Weighted scoring system.  
The microarray probes consistently identified as methylated candidates on 
dye-swap arrays were scored 1; unmethylated microarray probes were scored -1.  The rest of the microarray probes were assigned a weighted score 
based on their location on the plot.  LRmeth: log likelihood ratio cut-off for methylated loci; LRunmeth:log likelihood ratio cut-off for unmethylated loci.  
LR: log likelihood ratio-swapped dyes.   (Dai, Teodoridis et al. 2008). 
A robust regression model is then fitted to these data and assumed to follow a normal 
distribution so that outliers can be used to identify the differentially methylated loci 
between the sample classes.  This is shown in Figure 14a & b below:   
 
 
 
 
Figure 14.  MLDA: Outliers identifications
. a: Distribution of the observed (histogram) standardised residuals and the 
theoretical distribution based on the fitted model (dashed smooth line in red). The red and blue solid line are the positive and negative cut-offs, 
respectively. b: Scatter plot of sensitive scores against resistant scores in A2780 series cell lines. The hypermethylated loci are coloured in red and 
hypomethylated loci are in blue. The robust regression model is Y = 0.9956X + 0.0019.  Please refer to Figure 6 of Dai et al.  (Dai, Teodoridis et al. 
2008) 
 
MLDA is more comprehensively explained and illustrated in Dai et al (Dai, Teodoridis et 
al. 2008). 
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3 Characterisation of loci showing differential 
methylation in cisplatin resistant lines identified 
by PAM. 
3.1 Background and aims. 
The aim of the experiments described in this Chapter were to identify and validate novel 
DNA methylation markers for acquired drug resistance in ovarian cell lines and evaluate 
their relevance to acquired resistance in patient samples.  In a collaboration between Dr. 
Tim Huang (Ohio State University, Columbus, Ohio) and Dr. Jens Teodoridis (when at the 
University of Glasgow), DMH was performed with hybridisation onto a 12K CGI 
microarray (university Health Network, Toronto, Canada) (Heisler, Torti et al. 2005).   The 
aim was to use DMH to detect genome wide changes in CpG island (CGI) methylation in 
DNA from 34 well characterised, matched ovarian cancer cell line models (see chapter 
2.17.4) and identify DNA sequences whose methylation status discriminated between 
cisplatin-sensitive and cisplatin-resistant ovarian surface epithelial cancer cell lines.  
DMH and initial data analysis was performed by Dr Teodoridis and Ms Wei Dai and they 
performed all normalisation of the data and compiled lists used to identify potential 
candidate genes.  This is now briefly summarised.   
Once the hybridisation had been performed signal intensities were corrected for 
background intensity.  Weak (equal or less than the average plus two standard deviations 
of background signals) and frequently missing signals from each sample data set were 
removed and then PAM (Tibshirani and Efron 2002) was applied to the microarray data 
using PAM 2.0 for Excel. For further details see PAM in methods section (Chapter 2.25.4).  
In PAM results are obtained by gradually removing sequences which are creating noise by 
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increasing a threshold which is estimated by cross validation (Tibshirani and Efron 2002) 
(also see chapter 2.24.4).   
In this experiment the following filters were used in order to achieve a manageable number 
of sequences; class probabilities for resistant (0.66) and resistant (0.34).  For a more 
detailed description of these please refer to Tibshirani and Efron 2002.  By changing these 
filters smaller or much larger lists could be generated but it was considered that these 
criteria, which detected 41 sequences as differentially methylated, would provide a 
manageable number of loci from which to identify candidates for further individual 
characterisation.   
Of the 41 sequences identified, 13 had a CGI which overlapped the first exon/ promoter.  A 
CGI was defined as a stretch of DNA of at least 200bp long with at least 50% GC content 
(http://data.microarrays.ca/cpg/faq.htm).  The 13 sequences mapped to 12 genes.  This is 
shown in table 24 below.  All 41 sequences are shown and then black type is used to 
highlight those which were 5‟ and contained a CGI.  Grey highlighting function used to 
further show the loci that were selected for further individual characterisation. 
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Table 24.  CGI and corresponding genes identified from DMH and PAM  
 
 
 
 
 
 
 
 
 
 
 
 
NBA no blat alignment, > one CL more than one chromosomal location 
1http://data.microarrays.ca/cpg/searchsingleclones.htm.  Black type used to highlight sequences 
which were 5‟ and mapped to a CGI.  Bold and grey highlight used to show sequences which were 
selected for further validation.   
  
  
Microarray  
Identifier 
Chromosomal 
location 
CpG 
Island 5' Gene 
1 66_G_6 9q22.32 Yes No - 
2 46_A_12 8p11.21 No No - 
3 80_H_5 NBA        
4 119_A_6 6q21 Yes Yes NR2E1 
5 47_A_12 12q14.1 No No - 
6 81_B_1 5q33.3 Yes Yes PTTG1 
7 17_G_11 14q23.1 Yes No SIX1 
8 114_E_4 2q14.3 Yes Yes CNTNAP5 
9 127_F_12 8p22 Yes Yes DLC1 
10 42_D_9 NBA       
11 5_D_4 1q23.3 Yes Yes LMX1A 
12 20_A_1 9q32 No No ZFP37 
13 41_D_9 12q13.12 Yes Yes WNT1 
14 47_D_8 4p11 No No - 
15 109_A_6 11q12.3 Yes No AHNAK 
16 64_E_3 19q32.2 Yes Yes CR2 
17 113_E_10 18q11.2 No No - 
18 6_D_4 1q23.3 Yes Yes LMX1A 
19 17_H_9 11q13.1 Yes Yes HRASLS3 
20 35_A_11 12q24.13 Yes No - 
21 23_A_5 > one CL        
22 49_E_1 1q12 No No - 
23 109_B_5 NBA       
24 39_E_1 16p13.3 No No C1QTNF8 
25 3_A_11 17q12 Yes Yes MLLT6 
26 70_B_3 5q23.2 No No   
27 40_E_1 16p13.3 No No C1QTNF8 
28 50_D_5 3q22.1 Yes No AMOTL2 
29 14_E_8 NBA       
30 27_F_7 NBA       
31 6_G_10 21q22.3 No No RIPK4 
32 17_H_6 6q23.3 Yes Yes TNFAIP3 
33 50_F_1  NBA       
34 69_B_5 20p12.2 Yes Yes JAG1 
35 104_G_6 1q21.3 Yes Yes THEM4 
36 36_H_5 19q13.42 No No  
37 100_G_11 NBA      
38 7_D_1 20q13.12 No No  
39 121_H_10 2q21.2 No Yes  
40 47_E_5 NBA        
41 100_G_12 NBA       
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3.2 Methylation of candididate loci in 
epithelial ovarian cancer cells lines by 
MSP and pyrosequencing. 
The aim of this experiment was to confirm in the laboratory that the candidate loci arising 
from the PAM analysis did indeed show increased methylation in the resistant ovarian 
cancer cell lines.  Initially MSP was employed as a rapid method of characterising multiple 
loci.  As described in Chapter 2.9 MSP is a highly sensitive method for detecting 
methylation (Herman, Graff et al. 1996) and using serial dilutions of the positive and 
negative controls semi quantitative results can be obtained.    For MSP and pyrosequencing 
all DNA was bisulphite modified as described in chapter 2.7 and a PCR was performed 
using Calponin primers to check for complete modification of DNA (Rand, Qu et al. 
2002).   
For MSP semi-quantitative results were obtained using 1/10 and 1/20 dilutions of IVM: N 
and only including samples with a band of at least the same intensity as the 1/10 dilution.  
IVM is in vitro methylated DNA and N is normal whole male genomic DNA and 
represents the background level of methylation normal tissues.  Care was taken that no 
band was seen in the negative control or water samples and that all samples had been 
completely modified prior to starting.  No more than 35 cycles of PCR were used to 
minimise the chance of amplifying contaminant DNA.  Each experiment was performed 3 
times and the average of the experiments was used.  In all figures a 100 bp ladder is shown.  
The same 34 ovarian cancer cell lines which had been used to prepare the DMH were used 
to investigate the methylation state of candidate loci in the laboratory (see Figure in 
chapter 2.17.4).   
Any loci which showed increased methylation by MSP were next examined by 
pyrosequencing (of bisulphite modified DNA).  For pyrosequencing experiments IVM and  
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N was again used as positive and negative controls respectively.  In all pyrosequencing 
experiments the percentage of CpG methylation in human male genomic DNA (negative 
control) was used to normalise each result to the background level of methylation seen and 
eliminated any “noise”.    
Results were very reproducible between different experiments and bisulphite modifications 
and this is illustrated in Figure 15 below, where the values obtained for N in 6 independent 
experiments are shown.  Here, using SIX1 gene methylation as an example, 3 independent 
bisulphite modification of N are shown.  (Experiments 1, 2 and 3 were performed using 
one sample; experiment 4 using a second and experiments 5 and 6 using a third).   
 
 
 
 
 
 
 
Figure 15.  Variation in methylation of 5 adjacent CpGs, in SIX1 gene, in 6 experiments using 
human male genomic DNA (negative control) by pyrosequencing demonstrating 
reproducibility between experiments.   
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3.2.1 Examination of  candidate loci in cell lines by MSP 
Seven sequences mapping to six genes (LMX1A, NR2E1, CR2, CNTNAP, DLC1, PTTG) 
were chosen at random from this list to be further characterised.  Five of the genes were 
expected to show an increase in methylation in the resistant cell lines and one gene (PTTG) 
was expected to show the opposite.  Methylated and unmethylated primers were designed 
to examine the methylation status of these genes in the bisulphite modified A2780 
sensitive and resistant cell lines (see Figure Chapter 2.17.4).  PTTG had a negative score 
by PAM and was therefore expected to show less methylation in the resistant cell lines and 
was therefore added to the five loci that were chosen to be characterised as a check of the 
data.  We would expect it to show a decrease in methylation in the resistant cell lines 
although it actually showed no differential methylation.  The locus corresponding to CR2 
did not show an increase in methylation in the resistant cell lines by MSP and it was not 
possible to optimise primers to investigate CNTNAP.   
NR2E1, LMX1A and DLC1 showed increased methylation in the resistant ovarian cancer 
cell lines by MSP and were therefore also examined by pyrosequencing of the bisulphite 
modified DNA.  The results for these candidate loci are now discussed in more detail. 
3.2.2 Methylation of DLC1 by MSP and pyrosequencing 
Methylation of DLC1 was first examined by MSP.  A degree of methylation was observed 
in the A2780 sensitive cell lines with a further increase in methylation in the A2780 
multistep resistant cell lines (especially MCP1, 3, 4, 6, 7 and 9).   No methylation was seen 
in PEA1 and 2 or indeed any of the other non-A2780 based cell line pairs.   The results are 
shown for the methylated DLC1 primer in Figure 16 below: 
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Figure 16.  Methylation of DLC1 by MSP.  100 BP ladder extreme right and left of gel.  IVM 
invitromethylated DNA (positive control), 1/5 dilution of IVM :N, 1/10 dilution of IVM/N, N is whole 
male genomic DNA, H2O water control. Upper band is PCR product, lower band is primer dimer.  
Sensitive cell lines in green, resistant cell lines in red (see Chapter 2.6.4 for primer details).  
Summary of sensitive and resistant cell lines shown in chapter 2.17.4) p15 should read p14.        
 
By pyrosequencing, the background methylation was found to be 4.6% and a statistically 
significant difference was seen in the level of CpG methylation in the sensitive A2780 cell 
lines (42.7%) and in the resistant cell lines (A2780cp70 and MCP1-9) (60.2%) (student t 
test 9.14x10-
9
).  As noted by MSP minimal methylation was seen in the other ovarian 
cancer cell line pairs.  The results are shown in Figure 17 below: 
 
Figure 17.  Methylation of DLC1 in the 34 cell line panel by pyrosequencing.  Primers 
designed across 5 adjacent CpG residues and each bar represents an individual CpG.  Sensitive 
cell lines shown in light grey with resistant cell lines immediately to the right in dark grey.  Controls 
in black are IVM (invitromethylated DNA positive control), a 50:50 mix of IVM and N, and N 
(indication of background methylation in normal tissues) (see chapter 2.8.4 for primer details). 
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The pyrosequencing results therefore showed the same trends as the MSP but with the 
added quantitative information.   
3.2.3 Methylation of NR2E1 by MSP and pyrosequencing 
The CGI at NR2E1 showed a clear differentiation between the sensitive and resistant 
A2780 based cell lines by MSP with all of the sensitive cell lines showing virtually no 
methylation.  Some methylation was observed in OVIP (sensitive) and this was increased 
in OVIP DDP (resistant).  A small amount of methylation was seen in CH1 (sensitive) 
which again was marginally increased in CH1CISR (resistant).  PEO1 (sensitive) showed 
some methylation which again was more in the resistant cell lines (PEO1 CDDP, PEO4, 
PEO6).  These results are illustrated below in Figure 18. 
 
 
Figure 18.  Methylation of NR2E1 in the 34 cell line panel by MSP.  100 BP ladder extreme right 
and left of gel.  IVM invitromethylated DNA (positive control), 1/5 dilution of IVM :N, 1/10 dilution of 
IVM/N, N is whole male genomic DNA, H2O water control.  Sensitive cell lines all shown first then 
resistant cell lines starting at A2780 CP70.  Summary of sensitive and resistant cell lines chapter 
2.17.4.  For primer details see Chapter 2.6.4. 
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These results were supported by pyrosequencing, where the level of CpG methylation in 
whole male genomic DNA was 1.0% with 1.4% methylation in the sensitive A2780 cell 
lines and 50.9% methylation in the resistant A2780 based cell lines (A2780 cp70 and MCP 
1-9).  The differential methylation was shown to be statistically significant for the A2780 
based comparison (student t test p=1.82x10-
29
). Similarly to the MSP, a small increase in 
methylation was seen between OVIP (sensitive) and OVIP DDP (resistant) and this 
difference was statistically significant (student t test p=0.03).  The pyrosequencing results 
are shown in Figure 19 below: 
Figure 19.  Methylation of NR2E1 in the 34 cell line panel, by pyrosequencing.  Primers 
designed across 6 adjacent CpG residues.  Sensitive cell lines shown in light grey. Corresponding 
resistant cell lines shown to the right in dark grey.  Controls in black.  Primer details as outlined in 
Chapter 2.8.4 
MSP and pyrosequencing were shown to demonstrate the same trend of results with the 
pyrosequencing providing additional quantitative information.  Both methods 
demonstrated the clearest increase in methylation seen in the A2780 derived cell lines but a 
small increase between CH1 and CH1CISR and PEA1 and PEA2.  As previously a smaller 
degree of methylation was seen the single step A2780 resistant clones (C1CISR  to 
C5E415) compared to the multistep clones (MCPs).  This would was as predicted as the 
multistep clones were treated with repeated cisplatin treatment and changes associated with 
resistance should therefore be more pronounced.   
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3.2.4 Methylation of LMX1A by MSP and pyrosequencing 
Next the CGI within LMX1A was examined by MSP.  As shown in figure 20 some 
methylation was seen in the A2780 sensitive cell lines although this was deemed to be 
more consistently detected in the platinum resistant derivatives.  A higher level of 
methylation was seen in CH1 (sensitive) than its corresponding resistant pair CH1CISR, 
and the same level of methylation was seen for OVIP (sensitive) and OVIP DDP 
(resistant), and PEO1 (sensitive) and PEO1CDDP (resistant).  An increase in methylation 
was seen from PEO1 (sensitive) to PEO4 (resistant) but not the other in vivo derived cell 
line in this pair; PEO6.  A decrease in methylation was seen from PEA1 (sensitive) to 
PEA2 (resistant). 
   
 
 
Figure 20.  Methylation of LMX1A by MSP.  100 BP ladder extreme right and left of gel.  IVM 
invitromethylated DNA (positive control), 1/5 dilution of IVM :N, 1/10 dilution of IVM/N, N is whole 
male genomic DNA, H2O water control.  Sensitive cell lines all shown first then resistant cell lines 
starting at A2780 CP70.  Summary of sensitive and resistant cell lines chapter 2.17.4.  For primer 
details see Chapter 2.6.4 
 
By pyrosequencing the background level of methylation was much higher than had been 
seen for the previous two genes at 17.3%.  The differential methylation seen between the 
sensitive and resistant A2780 based cell lines was reproduced by pyrosequencing with a 
statistically significant increase in methylation seen in the resistant lines (21.7% vs. 
45.3%), (student t test p=1.36x10
-10
).  The increase seen between PEO1 and PEO4 which 
had been observed by MSP was not confirmed by pyrosequencing and none of the non-
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A2780 based comparisons were statistically significant.  The results are shown in Figure 
21 below. 
Figure 21.  Methylation of LMX1A in 34 cell line panel by pyrosequencing.  Primers designed 
across 6 adjacent CpG residues.  Sensitive cell lines shown in light grey. Corresponding resistant 
cell lines shown to the right in dark grey.  Controls in black.  See chapter 2.8.4 for primer details. 
 
These loci were identified by comparing 34 cell lines by PAM.  The A2780 sensitive and 
resistant cell lines dominated this comparison and it could therefore be predicted that 
differential methylation would be most pronounced there.  For DLC1 the differential 
methylation was essentially confined to the A2780 sensitive vs. MCP comparison.  NR2E1 
showed increased methylation in this comparison but also in some of the other cell line 
pairs such as CH1/ CH1CISR and PEA1/ PEA2. 
DLC1, NR2E1 and LMXIA were next examined in primary EOC tumours in order to assess 
the frequency and heterogeneity of methylation in primary tumours.  If methylation of 
these genes was important in the in vivo setting then one would predict that methylation 
would be seen in a proportion of the primary tumours.   
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3.3 Examination of candidate loci in primary 
ovarian cancer tumours 
The aim of this experiment was to take the loci identified from the first DMH experiment 
in cell lines and assess whether significant methylation was observed in patient samples.  It 
is extremely difficult to obtain samples from patients at the time of resistant disease and 
therefore tumours from patients at diagnosis were used.  A large number of these primary 
tumours were available as described in Chapter 2.4.3 and 2.4.4.  We selected patients with 
advanced stage 3 and 4 disease and excluded clear cell and mucinous pathology.  As 
survival data was available for many of these patients any correlation with survival could 
also be sought, in order to see if any of these loci could be utilised as a prognostic 
biomarker.  There is a limitation to this approach as it is possible that a gene important in 
acquired drug resistance might only show increased methylation in the resistant or post 
treatment sample – and not in the primary tumour. 
DNA from all of the tumours were bisulphite modified as previously described in Chapter 
2.5 and a calponin PCR used to check for adequate modification of all samples (Chapter 
2.5.3).  Since the patient samples are highly precious and it was hypothesised that if no 
significant methylation was seen in the first twenty samples it would be unlikely to be 
detected in the second set, and so the test set was subdivided into two.  Initially a smaller 
test panel of 22-23 tumours were examined and if any samples showed ≥50% methylation 
by pyrosequencing this was confirmed in a larger set of 54 tumours (test set (ii)).  Test set 
(I) and (ii) were then analysed to see if there was any correlation with PFS, OS and/ or 
response in a univariate analysis.  If a correlation with survival was found then the results 
were confirmed in an independent validation set of 67 tumours.  If the univariate 
association between the gene and response was confirmed then a multivariate analysis 
integrating stage and grade was performed on the combined data sets.   
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3.3.1 CpG methylation of DLC1 by pyrosequencing 
DLC1 had shown increased methylation in the resistant cell lines and it was first examined 
in the smaller test set of primary tumours (known as test set (I)).  As shown in Figure 22 
below no samples showed methylation of ≥50% (the level of methylation likely to be 
required to result in gene silencing) - and in fact none showed methylation of greater than 
20%.  
Figure 22.  Methylation of DLC1 in panel (I) of 23 primary tumours by pyrosequencing.  IVM 
invitromethylated DNA (positive control), 50:50 a 50% mix of IVM and N, N whole male genomic 
DNA (background control).  Pyrosequencing primers designed to analyse methylation status of 5 
adjacent CpG residues (each shown in a different colour). 
 
These results suggest that methylation of DLC1 in primary EOC specimens is infrequent 
and hence a rare event in primary ovarian cancer. Further examination of a larger panel of 
primary tumours was therefore not pursued as its low level of methylation in primary 
tumours might reduce its potential usefulness as a prognostic biomarker.  However, 
methylation of DLC1 could be selected for during chemotherapy and only chemonaive 
tumours were examined and therefore methylation of DLC1 was also examined in matched 
pairs of pre and post residual disease tumours (see chapter 3.4). 
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3.3.2 Methylation of LMX1A (5D4) and NR2E1 (119A6) in primary 
tumours by MSP 
Methylation of the two CGIs associated with LMX1A (5D4) and NR2E1 (119A6) had 
previously been examined in a similar panel of DNA from primary tumours, using MSP, 
by Dr Catriona Hardie, and these results are shown below.   
The methylation status of these two sequences were analysed using MSP in DNA from 199 
primary epithelial ovarian tumours which included 16 early stage (I/II) and 183 late stage 
(III/IV).   The tumours analysed comprised 125 samples from the prospective DNA 
methylation study, and 74 samples from the retrospective study, as described in Chapter 
2.4.  NR2E1 and LMX1A were methylated in 12.6% (25/199) and 61.8% (123/199) of the 
ovarian tumour samples respectively as shown below in Table 24. Methylation frequencies 
for NR2E1 and LMX1A were higher for early versus late stage disease with NR2E1 being 
methylated in 18.8% (3/16) versus 12% (22/183) and LMX1A being methylated in 75% 
(12/16) versus 60% (111/183) respectively.  No correlation with PFS, OS or response to 
chemotherapy for either gene was observed.  
Table 25 Methylation frequencies of identified sequences in epithelial ovarian tumours. 
Methylation frequency % (number methylated/total number of samples).   
 Methylation frequency of identified sequences 
Samples (N) NR2E1 (119A6) LMX1A (5D4)  
 
Retrospective stage I and II (16) 
 
18.8 (3/16) 75 (12/16) 
 
Retrospective stage III and IV (58) 
 
10.3 (6/58) 58.6 (34/58) 
 
Prospective stage III and IV (125) 
 
12.8 (16/125) 61.6 (77/125) 
 
Overall ovarian tumours (199) 
 
12.6 (25/199) 
 
61.8 (123/199) 
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3.4 Examination of candidate loci in 
matched tumour pairs from patients at 
diagnosis and time of surgery for 
residual disease 
It is possible that a locus that could be a useful biomarker for acquired drug resistance 
might not show methylation in primary tumours.  Often this „methylation mark‟ is thought 
to be selected for during the course of chemotherapy and therefore unless one investigates 
tumours from the time of residual disease or relapse a potentially useful candidate locus 
could be missed.  However matched pre- and post- chemotherapy samples are a much 
more scarce resource and this limits their use.  The expectation when using samples taken 
at the time of surgery for residual disease is that any cancer left behind following 
chemotherapy must have been resistant to the treatment that was administered.  It should 
be noted that detailed clinical data was not available for the matched pairs and it is 
therefore not possible to distinguish whether these represented platinum sensitive or 
resistant relapse.   
The aim of the next experiment was to address this question by taking the loci that had 
shown increased methylation in the in vitro generated cisplatin resistant cell lines and 
investigating whether an increase in methylation was also seen between samples from 
patients at diagnosis and when they had surgery for residual disease following a course of 
adjuvant chemotherapy; the assumption being that disease still present following 
chemotherapy is by definition more resistant.  As outlined, in Chapter 2.4.1, 10 of the 12 
pairs of ovarian surface epithelial tumours were analysed (chapter 2.4.1).  These patients 
had had a biopsy taken at the time of primary surgery and then a second one taken 
following a course of adjuvant chemotherapy.  
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3.4.1 CpG methylation of DLC1 by pyrosequencing 
The percentage of background methylation was 3.5% and the average methylation in the 
pre-treatment samples was 4.97% (range 3.5-6%) and post- treatment samples was 4.85% 
(range 3.8-9.1).  DLC1 was therefore not shown to be significantly methylated in any of 
the pre-treatment „sensitive‟ or post-treatment „resistant‟ pairs.  This is shown in Figure 24 
below:  
Figure 24.  Methylation of DLC1 in matched pairs by pyrosequencing.  Controls in black; IVM 
invitromethylated DNA, N normal male genomic DNA; Dark grey is pre treatment samples, Light 
grey is sample following chemotherapy at time of debulking surgery. 
 
3.4.2 NR2E1 and LMX1A by pyrosequencing 
NR2E1 and LMX1A methylation were also examined by pyrosequencing.  For NR2E1 
(Figure 24) and LMX1A (Figure 25), there was a background level of 3% and 10.3% 
respectively (as before, the percentage methylation in normal male genomic DNA).  
NR2E1 pyrosequencing showed a quantitative strong increase in methylation over the 7 
CpG sites in 4/12 (33.3%) paired samples following chemotherapy (pairs 1, 3, 4 and 5) as 
shown in Figure 24 below. LMX1A pyrosequencing showed a quantitative strong increase 
in methylation over the 5 CpG sites in 3/12 (25%) paired samples following chemotherapy 
(pairs 4, 5 and 10) as shown in Figure 25. These results were not affected by the 
subsequent genotyping studies which excluded pairs 7 and 12 (which had been shown not 
to be pairs from the same patients).  Histological analysis showed that the percentage of 
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tumour cells in all paired samples were almost equal which would indicate that the obvious 
increase in methylation seen in NR2E1 post-chemotherapy was not due to a quantitative 
increase in tumour cells following treatment or simply enrichment of tumour cells after 
chemotherapy.   
Figure 25.  Pyrosequencing analysis of NR2E1 in 12 paired pre-chemotherapy samples (dark 
grey) and residual disease post-chemotherapy samples (light grey). Average CpG methylation 
over 7 sites for each matched pair. Background methylation in DNA from whole male blood of 3%. 
Pairs 7 and 12 later removed after genotyping studies. 
Figure 25.  Pyrosequencing analysis of LMX1A in 12 paired pre-chemotherapy (dark grey) 
and residual disease following chemotherapy (light grey). Average CpG methylation over 5 
sites for each matched pair. Background methylation in DNA from whole male blood of 10.3%. 
Pairs 7 and 12 later removed after genotyping studies. 
 
In summary, these findings suggest that NR2E1 could be a potential biomarker of acquired 
drug resistance in ovarian cancer, given the increase in methylation in some of the matched 
tumour pairs as well as the cell lines, however this would require prospective validation.  
LMX1A is less likely to be a useful clinical marker given the higher background level of 
methylation in the sensitive cell lines; however the high level of methylation seen in the 
primary tumours is very interesting and it was felt both loci warranted further 
investigation.  The first step was to investigate whether the change in methylation at the 
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promoter of these genes correlated with a decrease in mRNA expression and this work was 
carried out in collaboration with Dr Hardie and Dr Teodoridis. 
3.5 Correlation between LMX1A and NR2E1 
promoter methylation and mRNA 
expression 
The mRNA expression levels of LMX1A and NR2E1 were quantified in A2780 and 
A2780p6, vs. MCP1, MCP6 and MCP9 using qRTPCR (see Chapter 2.14).  In order to 
assess whether the change in expression was associated with a change in methylation in 
cell lines were treated with decitabine and it was hypothesized that this would result in re 
expression of the silenced genes.  This was indeed the case although again the changes 
seen in LMX1A were less marked.  This fits with the methylation pattern that was seen 
where LMX1A was more methylated in the sensitive cell lines than NR2E1.  The results are 
shown in Figure 26 below: 
 
 
 
Figure 26.  qRTPCR values for NR2E1 and LMX1A. GAPDH qRTPCR was used for 
normalisation and values are from 3 independent experiments. Values represent the mean of three 
replicates in triplicate experiment ± 1 standard deviation. Filled bars: untreated cells, open bars: 
DAC-treated cells. (DAC = Decitabine) (please note Fold activity in Y axis should read relative 
expression but this figure was compiled by Dr Hardie and raw data is no longer available). 
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3.6 Discussion 
Two genes from this analysis, LMX1A and NR2E1, appear to be interesting candidates for 
future research in ovarian cancer.  Neither has been reported to have a role in ovarian 
cancer previously.  LMX1A is located on chromosome 1q22-q23.  It acts as a 
transcriptional activator and is required for development of the roof plate and subsequently 
for specification of dorsal cell fates in the CNS and developing vertebrae.  It is highly 
preserved amongst species, from humans to zebrafish (www.genecards.org/cgi-
bin/carddisp.pl?gene=LMX1A).   
Liu and colleagues observed a potential link between LMX1A methylation and cancer last 
year, reporting its role as a metastasis suppressor in cervical cancer (Liu, Chao et al. 2009).  
They had previously identified that it was methylated in 89.9% of squamous cell 
carcinomas of the cervix compared to 6.7% in normal cervix and they therefore planned a 
study of the functional implications of this methylation.  The authors found that over 
expressing LMX1A significantly reduced colony formation in two cell lines and that this 
also corresponded with a less invasive phenotype using a matrigel invasion assay.  They 
were able to reverse both these phenotypes using LMX1A shRNA.  In addition transcription 
factors known to be associated with EMT were assessed by RTPCR following over 
expression and knockdown.  Both LMX1A transfectants exhibited up-regulation of the 
epithelial marker CDH1 and down regulation of the mesenchymal markers CDH2 and 
vimentin.  RNA interference of LMX1A transfectants reversed the expression of CDH2 in 
HeLa cells and vimentin in CaSki cells. RNA interference of LMX1A significantly 
increased the expression of transcription factors known to be involved in EMT – SNAIL, 
SLUG and TWIST.  It was therefore concluded that LMX1A mediated cancer invasion 
through EMT related events (Liu, Chao et al. 2009).   
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In addition the authors had found that LMX1A inhibited tumour growth and metastases in a 
xenograft model and that although LMX1A was epigenetically silenced in invasive cancers 
it was expressed in precancerous cervical lesions.  These findings would fit with our 
finding that LMX1A is highly methylated in primary tumours and more methylated in post- 
chemotherapy samples and resistant cell lines and that the increase in methylation 
correlates with a decrease in expression at the mRNA level.  It is clearly important 
therefore to investigate the functional role of methylation in ovarian cancer and the 
techniques used by Liu and colleagues could be applied to an ovarian cancer model 
system. 
In the chick developing spinal cord LMX1A has been shown to induce expression of WNT1 
(Chizhikov and Millen 2004).  The WNT pathway has been implicated in numerous 
tumour types including brain (Ellison, Dalton et al.; Lindsey, Hill et al.; Clifford, Lusher et 
al. 2006), colon (You, Bryant et al. 2007; Hope, Planutis et al. 2008; Najdi, Syed et al. 
2009; Scholtka, Schneider et al. 2009), and endometrial cancers (Ellis and Ghaem-
Maghami 2011) and recently our group has uncovered methylation of multiple promoter 
CGIs of WNT pathway genes is associated with PFS of ovarian cancer patients (Dai, 
Teodoridis et al. 2010).  Another recent paper has identified LMX1A as having a role in the 
differentiation of human embryonic stem cells into midbrain dopamine neurons in culture 
and after transplantation into a Parkinson‟s disease model (Cai, Donaldson et al. 2009) and 
this highlights another potentially very interesting area of future research.   
Given that LMX1A is known to be involved in developmental processes and that this has 
been shown to be epigenetically regulated this raises the question as to whether epigenetic 
regulation of LMX1A could be important in ovarian cancer initiating cells.  Using 
differential Hoechst dye uptake, colleagues in our laboratory have recently been able to 
identify a side population within ascites that is thought to correspond with the tumour 
initiating population (Rizzo, Hersey et al. 2011).  It would therefore be possible to assess 
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the methylation and expression of LMX1A in these side populations compared to the 
normal cell population.  
NR2E1 is another transcription factor with a role in various CNS development processes.  
Again it is highly conserved amongst species; tlx is the mouse homologue 
(www.genecards.org/cgi-bin/carddisp.pl?gene=NR2E1).  Liu and colleagues have shown 
that tlx induces long term neural stem cell expansion and brain tumour initiation (Liu, 
Wang et al. 2010).  They demonstrate that tlx, which in the adult is expressed exclusively 
in the astrocyte-like B cells of the subventricular zone, acts as a key regulator of neural 
stem cell expansion and brain tumour initiation from these neural stem cells.  They found 
that over expression of tlx antagonises age-dependent depletion of NSCs and results in 
increased production of new neurone in the ageing brain.  These cells then lead to the 
development of glioma like lesions and gliomas and this process was accelerated with p53 
loss.  The tlx induced NSC expansion was associated with increased angiogenesis and 
migration and this is interesting as one of the most promising new therapy to have merged 
for gliomas in recent years is AZD2171 (cediranib) which is a pan VEGF inhibitor.  This 
agent showed a very impressive partial response rate of 56% in the recurrent/ resistant 
disease setting, in a recent Phase II study reported at ASCO (Batchelor, Duda et al. 2010).  
In addition Liu and colleagues showed that the area of over expressed tlx corresponded 
with a subpopulation overexpressing Nestin, the known neural stem cell marker. 
tlx, is an upstream regulator of PAX2 (Yu, Chiang et al. 2000) and suppresses PAX2 
expression in mice - Downregulation of PAX2 can enhance cisplatin sensitivity (Hueber, 
Waters et al. 2006), and therefore methylation and silencing of NR2E1 may increase 
chemoresistance by increasing PAX2 expression in tumours and inhibiting cisplatin-
induced apoptosis through binding to NAIP. PAX2 has also been shown to activate WNT4 
gene expression (Torban, Dziarmaga et al. 2006), although any involvement in drug 
resistance mechanisms remains to be investigated.  
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As discussed in the introduction drug resistance could be a result of enrichment of resistant 
clones selected for during the course of chemotherapy – or because of the persistence of a 
tumour initiating/ sustaining population.  The loci identified in this chapter could be 
implicated in either of these processes and the work so far does not address this question.  
NR2E1 induces cisplatin-induced apoptosis (Dziarmaga, Hueber et al. 2006; Hueber, 
Waters et al. 2006), and cisplatin-based chemotherapy may select pre-existing 
subpopulations with epigenetically silenced NR2E1, whilst on the other hand LMX1A and 
NR2E1 have both been implicated in neural stem cell and potentially cancer initiating 
processes as described. In ovarian cancer important future work would include 
characterising the phenotypic effects of over and under expressing this gene and also 
investigating whether it is associated with known stem cell markers as was seen in the 
mouse model.   
DLC1 is a gene which encodes a GTPase-activating protein (GAP) that is a member of the 
rhoGAP family of proteins which play a role in the regulation of small GTP-binding 
proteins.  GAP family proteins participate in signalling pathways that regulate cell 
processes involved in cytoskeletal changes (Ullmannova-Benson, Guan et al. 2009).  It is 
known to function as a tumour suppressor gene in multiple tumour types including 
prostate, hepatocellular, Hodgkins lymphoma, nasopharangeal, oesophageal, cervical and 
gallbladder cancers (Yuan, Durkin et al. 2003) (Garcia, Manterola et al. 2009) (Guan, Zhou 
et al. 2006) (Peng, Ren et al. 2006) (Wong, Lee et al. 2003) and a link between epigenetic 
regulation via DNA methylation and gene expression has been reported.   
However methylation of DLC1 has not been reported previously in ovarian cancer.  This 
gene has multiple transcript variants due to alternative promoters and alternative splicing 
and it is possible that this is the reason that I was not able to distinguish an increase in 
methylation in resistant cell lines, primary tumours or post chemotherapy samples (Wilson, 
McGlinn et al. 2000). Gene ontology analysis shows that this gene is involved in neural 
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tube closure, along with its role in cytoskeleton organisation.  This raises the question as to 
whether like LMX1A and NR2E1 it could have a role in neural stem cell differentiation. 
3.7 Conclusion 
The aim the experiments outlined in this chapter was to further characterise loci identified 
as differentially methylated between sensitive and resistant A2780 human ovarian cell 
lines, by DMH using a 12K CGI microarray, and attempt to identify candidate biomarkers 
of acquired drug resistance or identify key genes or pathways involved in ovarian cancer 
development.   
Methylation of NR2E1 and LMX1A was increased in resistant cell lines and matched 
tumour pairs and therefore could represent loci that are selected for during the course of 
chemotherapy.  This would however require prospective validation within a clinical trial 
setting and the number of matched tumour pairs was both limited and not annotated in 
terms of survival– it is not known whether the matched samples represent platinum 
sensitive or resistant disease and this is clearly important.  In addition as discussed the 
biological subtypes of ovarian cancer clearly have now been identified as having a key role 
in the response to chemotherapy (Lalwani, Prasad et al. 2011), However at the time of  
analysis the  subtypes of EOC used  in these samples was not determined.    
As only 3 from an expected 6 genes were identified as potential novel markers of acquired 
drug resistance in epithelial ovarian cancer, from an original list of 41 sequences, this was 
deemed to be a relatively low yield. There could have been various reasons for this.  Since 
the original DMH experiment (Heisler, Torti et al. 2005) larger and better annotated arrays 
are now available.  The human genome is thought to consist of approximately 45000 CGIs 
and this library included only 12000 of these (Cross, Charlton et al. 1994).  The annotation 
of this library frequently changed so it is possible that genes were missed that should have 
been investigated or vice versa.  Cross et al demonstrate in the initial validation of DMH 
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which uses an MSe1 digest in combination with an MBD binding column that 77% were 
likely to be CGI.  Ten percent represented rDNA and 10% were bulk DNA (Cross, 
Charlton et al. 1994).  In the table at the beginning of this chapter it is shown that 13 of 41 
sequences fulfilled our criteria of being a CGI and having a 5‟ location and this would 
argue that there are significantly more false positives in the library than proposed.    
In addition the statistical method used to extract candidate loci from the DMH data was 
originally developed for the interpretation of gene expression microarray experiments and 
it is possible that vital information is lost by not taking into account the unique biological 
differences between changes in methylation and changes in expression.  In expression 
experiments a small number of losses and gains in expression are seen whereas when 
analysing methylation a larger number of changes are seen and these tend to be 
asymmetrical – with more loci showing an increase in methylation in the resistant cell lines 
than a decrease.  The normalisation that is necessary in RNA microarray experiments could 
be detrimental when analysing methylation data and valuable information could be lost.   
The 34 cell lines panel is weighted towards the A2780 cell line series which is in vitro 
generated and it is possible that sequences and hence genes identified from this panel could 
have less biological relevance.  Of note for all genes in this chapter although a clear 
increase in methylation was seen in the A2780 sensitive and resistant cell lines it was 
minimal in the other cell line pairs raising the question as to whether this is an A2780 
effect only, and therefore of less biological relevance. 
MSP was initially used to screen the 6 genes that were selected for further characterisation.  
For PTTG a decrease in methylation was expected but instead no methylation in any cell 
line was seen.  For CNTNAP it was not possible to optimise primers and for CR2 no 
increase in methylation was seen in the resistant cell lines.  MSP is non-quantitative and 
optimisation and analysis of the gels relatively subjective.  Since the start of this thesis 
pyrosequencing of bisulphite modified DNA has effectively replaced this technique.   
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With both MSP and pyrosequencing it is possible to gain a false negative result because 
the primers were not designed to amplify exactly the same area where the maximal 
difference in methylation was identified by PAM and similarly both techniques only 
investigate a few CpG residues so it is possible to miss increased methylation by a 
relatively small change in primer location.  Using MSP false positive results can be 
obtained from incompletely methylated DNA (although a calponin PCR had been 
preformed to limit the effect of this). 
After confirming an increase in methylation in the ovarian cisplatin resistant cell lines I 
investigated for methylation in primary tumours.  The assumption was that if methylation 
was playing a role in these tumours that a heterogeneous pattern of methylation would be 
seen in the tumours – with the anticipation that this would then be increased in resistant 
tumours had these been available.  However DLC1 showed no methylation in primary 
tumours and was excluded from further analysis.  There is a risk with this as if this gene 
was a marker of acquired resistance it would not necessarily need to show this 
heterogeneous pattern of methylation at presentation that we predicted.   
In Chapter 7 the methylation status of these loci are re-examined in primary tumours on the 
OGT customised array.  This gave an additional chance to investigate the loci for which 
MSP or pyrosequencing primers were not optimised or where differential methylation had 
not been observed (CNTNAP and CR2). 
The tumour pairs that were available were obtained from patient‟s pre- and post- 
chemotherapy at the time of surgery for residual disease.  If the patients had had a 
sufficient response to be considered eligible for such an approach it is possible that the 
disease that was left behind was not drug resistant and therefore these tumour pairs would 
not be suitable for detecting changes in methylation associated with resistant disease.  No 
clinical details were available for these samples to indicate response to treatment.  At the 
time of subsequent chapters the relapsed disease pairs were available and it would be 
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interesting to go back and pyrosequence these (assuming they represent chemoresistant 
relapse). 
The correlation between methylation and expression was next examined.  This was done in 
a limited number of cell lines and not performed in tumours as RNA was not available.  
For these candidates to be of true biological relevance it needs to be demonstrated that 
increased methylation at the promoter consistently correlates with decreased mRNA gene 
expression and that this can be reversed with a demethylating agent – both in cell lines and 
in tumours.  In addition it would be important to assess the effect of methylation on protein 
expression using for example western blot analysis.  Another important series of 
experiments would assess the functional impact of increased or decreased expression of the 
genes.  As NR2E1 and LMX1A have both been associated with embryonic stem cells and 
perhaps tumour sustaining cells it would be very interesting to investigate this in the 
ovarian cancer setting. 
 
In the following chapters an attempt was made to address some of these questions.   
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4 Characterisation of loci showing differential 
methylation in cisplatin resistant lines identified 
by methylation linear discrimination analysis 
(MLDA). 
4.1 Background and aims 
The aim of the experiments in this chapter was to assess the ability of a novel statistical 
package, MLDA (Dai, Teodoridis et al. 2008), developed in our laboratory, to identify 
differentially methylated loci from the previously described 12k array.  The 16 A2780-
based sensitive and resistant cell lines (chapter 2.18.4) were used and candidates 
investigated by MSP +/- pyrosequencing.  It was hoped that these candidates could also 
represent potential markers of acquired cisplatin resistance.   
As outlined in Chapter 2.24.4 and 2.24.5, PAM and SAM were originally developed to 
interrogate microarray expression data rather than methylation data.  They rely on some 
important assumptions in order to normalise the data.  Firstly, that only a small percentage 
of genes will change expression, or in this case methylation status, and secondly that these 
changes will show symmetry, i.e. as many will show an increase in methylation as a 
decrease when comparing, for example, sensitive and resistant ovarian cancer cell lines.   
However this is not usually the case when analysing methylation data where many  loci are 
predicted to change their status and this change is likely to be asymmetrical because an 
„enrichment‟ is seen with more sequences gaining methylation in resistant cell lines than 
losing it.    
It was predicted that MLDA could therefore have advantages in detecting loci that 
optimally discriminate these isogenically matched ovarian cancer cell lines, without using 
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arbitrarily chosen cut offs or losing vital information as a result of over normalisation of 
the data. 
As this was the first time sequences generated using MLDA had been examined in the 
laboratory we wished to do this in the most unbiased manner possible.  Using the MLDA 
score, PAM and SAM an extensive list of candidate sequences was generated when 
comparing the more limited panel of 16 sensitive and resistant epithelial surface ovarian 
cancer cell lines, referred to as the A2780 cell lines in future text.  These included A2780, 
A2780 p3, A2780 p5, A2780 p6, A2780 p13 and A2780 p14 (6 sensitive) and A2780 
CP70 and MCP 1-9 (10 resistant).  Nine sequences were chosen entirely at random, which 
it was hoped reflected samples that ranked high and low by MLDA/PAM/SAM, from the 
generated list and firstly examined in the same 16 ovarian cancer cell lines, by MSP.  The 
MLDA ranking for each sequence is shown in table 26 below: 
Table 26 Candidate loci from MLDA analysis of 16 A2780 cell lines. 
 Loci Gene Chromosome Sensitive 
Score*  
 
Resistant 
Score** 
MLDA 
 Ranking*** 
3 A 11 MLLT6 17 -0.86 0.01 27 
17 H 9 HRASLS3 11 0.10 0.92 34 
20 F 11 NTN4 12 -0.81 0.03 41 
21 A 11 NTN4 12 -0.86 0.25 9 
24 D 3 SP5 12 0.25 0.71 75 
38 D 7 AGBL2 11 -0.91 0.18 11 
41 D 12 GLS2 12 -0.81 0.00 36 
101 G 6 GLS2 12 -0.91 0.025 21 
121 D 9 CRABP1 15 -0.65 0.65 2 
Sensitive score 1* is the average MLDA score  in the sensitive cell lines , Resistant score 2** is the average MLDA score in the resistant 
cell lines.  MLDA ranking*** is the rank of standardised residuals to the robust regression line constructed by the averaged sensitive 
scores against averaged resistance scores.  Further information is available in table 2, page 9, Dai et al (Dai, Teodoridis et al. 2008).  
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4.2 Examination of candidate loci in ovarian 
cancer cell lines by MSP. 
The aim of these experiments was to confirm in the laboratory that the candidate loci 
predicted by the MLDA analysis showed increased methylation in the same resistant 
ovarian cancer cell lines.  By MSP, 8 of 9 sequences showed increased methylation in 
resistant cell lines (all except 3A11/ MLLT6) (Figure 27 below).  The 8 sequences mapped 
to 6 known genes; 121D9 (CRABP1), 24D3 (SP5), 38D7 (AGBL2), 17H9 (HRASLS3), 
41D12 and 101G6 (GLS2), 21F11 and 21A11 (NTN4).  
 
 
 
 
Figure 27.  Methylation of candidate loci from A2780 analysis by MSP.  Blue line above 
controls, Green line above sensitive cell lines, Red line above resistant cell lines.  IVM in vitro 
methylated/positive control, PMN peripheral mononuclear cells/ normal whole male genomic DNA.  
1/5 and 1/10 serial dilutions of positive in negative control.100 BP ladder to the left.  Primer details 
are shown in chapter 2.6.3.  Loci names are shown on the left of each gel. 
 
The eight sequences which had confirmed increased methylation in the resistant cell lines 
were examined in a panel of 20 bisulphite modified primary tumours by MSP to identify 
loci whose methylation would be of potential clinical relevance and worthy of further 
detailed investigation.  („retrospective samples‟, Chapter 2.4.3).  Loci mapping to three 
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genes; 24D3 (SP5), 101G6 (GLS2) and 121D9 (CRABP1), all showed increased 
methylation in >20% of samples.  As the subsequent pyrosequencing results provide more 
quantitative data the MSP results are not shown.  The three loci were next pyrosequenced 
in a larger 28 cell lines panel (the 34 cell line panel, without the single step clones, C1cis6, 
C2cis6, C2E3, C3Cis6, C5E4 and C5E4(15) , (see Chapter 2.17.4) prior to pyrosequencing 
in the full panel of primary tumours.    
4.2.1 CpG Methylation of GLS2 (101G6) in ovarian cancer cell 
lines by pyrosequencing 
Although only the A2780 based sensitive and resistant cell lines were used for MSP it was 
decided to use an expanded panel of cell lines which included the in vivo pairs for 
pyrosequencing (see chapter 2.17.4).  It was anticipated that an increase in methylation 
would be seen in the A2780 resistant cell lines as these had been the cell lines used in the 
original MLDA analysis but whether an increase in methylation would be seen in other 
independent cell lines was unknown.  If an increase in methylation in these independent 
cell lines was observed it was hoped that this would reflect a more biological meaningful 
locus – in terms of the likeliness that it played a role in acquired drug resistance.   
All pyrosequencing experiments were performed in duplicate and percentages represent the 
mean of both experiments for the relevant experiments.  An increase in mean methylation 
between the A2780 sensitive and resistant cell lines was confirmed (18.5% to 46.4%) 
(student t-test p=1.48x10
-9
) however these changes were not observed in the non-A2780 
cell lines and of note in the PEA1&2 pairing a statistically significant decrease in the mean 
methlyation in the resistant cell line was observed (75.6 to 11%) (student t-test p=0.0014).  
Results are shown in Figure 28 below: 
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Figure 28.  Methylation of GLS2 in panel of 28 ovarian cancer cell lines by pyrosequencing.  
Controls in black: IVM (In Vitro Methylated DNA, positive control), serial dilutions of IVM/N, N 
(whole male genomic DNA, background control) shown.  Sensitive cell lines in light grey and 
corresponding resistant cell lines shown in dark grey.  Bars represent 4 adjacent CpG residues. 
 
4.2.2 CpG Methylation of CRABP1 (121D9) in ovarian cancer cell 
lines by pyrosequencing 
In CRABP1 a highly significant difference was seen in the mean methylation between the 
sensitive and resistant A2780 based cell lines, from 12.7 to 57.7% (student t-test 
p=1.77x10
-22
), with a background mean methylation level of 6.6%.  The differences 
between CH1 and CH1CISR, and PEO1 and its corresponding resistant cell lines were not 
statistically significant but the decrease in mean methylation between PEO14 and PEO23 
and PEA1 and PEA2 were found to be significant (student t-test p= 0.0004 and 
p=0.000127 respectively).  This is shown in Figure 29 below: 
Figure 29.  Methylation of CRABP1 in panel of 28 ovarian cancer cell lines by 
pyrosequencing.  Controls in black: IVM (In Vitro Methylated DNA, Positive control), serial 
dilutions of IVM/N, N (whole male genomic DNA, background control) shown.  Sensitive cell lines in 
light grey and corresponding resistant cell lines shown in dark grey.  Bars represent 4 adjacent 
CpG residues. 
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4.2.3 CpG Methylation of SP5 (24D3) in ovarian cancer cell lines 
by pyrosequencing 
The percentage mean methylation of IVM was 94.9% which is what would be expected but 
the background level of methylation was found to be much higher than usual at 20.7%.  
Although a statistically significant difference in methylation was seen between the A2780 
sensitive and resistant cell lines, with 42.5% and 91.6% methylation respectively (student 
t-test p=1.6x10-
14
), for most other cell lines very high levels of methylation were seen in 
sensitive and resistant cell lines (with the exception of CH1CISR which showed 
methylation of 60.4%.  The lowest value found for the rest of the cell lines was >90%) 
(student t-test p=0.003).  These very high levels of methylation were more marked than 
had been seen by MSP.  This is illustrated in Figure 30 below: 
 
Figure 30.  Methylation of SP5 in 28 ovarian cancer cell lines by pyrosequencing. Controls in 
black: IVM (In Vitro Methylated DNA, Positive control), serial dilutions of IVM/N, N (whole male 
genomic DNA, background control) shown.  Sensitive cell lines in light grey and corresponding 
resistant cell lines shown in dark grey.  Bars represent 4 adjacent CpG residues. 
 
Although this meant that methylation of this locus was less likely to be useful as a marker 
for acquired drug resistance it was still felt that it was still potentially a very interesting 
target in epithelial ovarian cancer and that it could highlight an important pathway in 
ovarian cancer pathogenesis.  Along with GLS2 (101G6) and CRABP1 (121D9), SP5 
(24D3) CpG island methylation was therefore next examined in primary tumours. 
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4.3 Examination of candidate loci in primary 
tumours  
4.3.1 CpG methylation of GLS2 (101G6) 
Methylation of the loci 101G6 within GLS2 was next assessed in the test set of 29 tumours.  
Only one sample showed methylation significantly greater than that seen in N (which as 
previously was used to represent the level of background methylation) with a „p‟ value of 
0.03.  The mean methylation across all samples was 10.9 vs. 10.5% in normal.  As only 
one sample showed significantly increased methylation this locus was not investigated in 
the larger test set.  It had been decided that if no samples in the test set showed methylation 
of ≥50% in an individual sample that methylation of this locus in ovarian cancer must be 
rare.  We were able to use a pre-defined cut-off in individual samples because 
pyrosequencing provides quantitative data, compared to the MSP data which were only 
semi quantitative.  An alternative way to choose a cut-off for this data would have been to 
chart the methylation of the gene in interest and decide on a cut-off based on the 
distribution of the curve.  The results are shown in Figure 31 below.  As stated previously 
it was possible that increased methylation may not be seen in the primary tumour but still 
play a key role at the time of  relapse when methylation could be acquired or enriched for.  
Although this locus was not further characterised at this stage, it was included in the OGT 
arrays (see chapter 7).   
Figure 31.  Methylation of GLS2 in test set (I) of 29 primary EOC by pyrosequencing.  IVM in 
vitro methylated DNA, N normal male genomic DNA, 75,50 and 25 represent serial dilutions of 
positive and negative control.  Each of four bars is an adjacent CpG residues. 
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4.3.2 CpG Methylation of CRABP1 (121D9) 
121D9 which mapped to the gene CRABP1 also did not show increased methylation in the 
panel of primary tumours when examined by pyrosequencing (see figure 32 below) and, as 
was the case for GLS2, was not investigated any further at this stage as it was felt it was 
unlikely to be a useful biomarker if so little methylation was seen in the test set of primary 
tumours.  It was however re-included when methylation in the primary tumours was 
investigated in the OGT customised arrays (see chapter 7).   
Figure 32.  Methylation of CRABP1 in test set (I) of 23 primary EOC tumours by 
pyrosequencing.  IVM in vitro methylated DNA, N normal male genomic DNA, 75,50 and 25 
represent serial dilutions of positive and negative control.   
 
4.3.3 CpG Methylation of SP5 (24D3)  
In contrast 24D3, which mapped to SP5, showed a very high level of methylation in the 
majority of tumour samples and also a higher than average level of methylation in the 
negative control (22.3%).  As previously twenty bisulphite modified patient samples were 
first examined and if methylation was seen in these a further 54 samples were investigated 
making up the test set of 74 samples.  If methylation was seen in the test set a further 66 
independent tumours were examined.  The average methylation in the tumours was 74.2% 
with only one sample showing methylation of less than 50% (sample No.15, 45.9%).  
Methylation for all the tumours in the initial test panel is illustrated in figure 33 below.  
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Figure 33.  Methylation of SP5 in test set (I) of 20 primary EOC tumours by pyrosequencing.  
IVM invitromethylated DNA, N normal male genomic DNA, 75,50 and 25 represent serial dilutions 
of positive and negative control.   
 
As SP5 showed high levels of methylation in the initial test panel it was next examined in 
an additional panel of 54 primary tumours.  The mean methylation was 74% and 6  
tumours had a mean methylation level of  ≤50% (1.1%).  Again the level of mean  
methylation in the negative control was high (22.3%).  (Figure 34a overleaf).  Here the 
mean methylation seen in 4 adjacent CpGs is shown and tumours with lower than 50% 
methylation highlighted in black.   
 
These very high levels of methylation were confirmed in an independent validation set of  
primary tumours from patients in both the retrospective and prospective data sets (see 
chapter 2.4.3 and 2.4.4).  The pyrosequencing results for a further 66 samples are shown in 
Figure 34b below.  Here the background level of methylation was 17.63%, the mean 
methylation across all tumours 68.45%, and 1.2% (8) of tumours had a methylation level 
of ≤50%.
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Figure 34a.  Methylation of SP5 in test set (ii) of 54 primary EOC tumours by pyrosequencing. Bars represent four adjacent CpGs.  Grey bars: controls and tumours 
with methylation >≥50%.  Black bars: tumours with <50% methylation.  IVM invitromethylated DNA, N normal male genomic DNA, 75,50 and 25 represent serial dilutions of 
positive and negative control.   
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Figure 34b.  Methylation of SP5 in the validation set of 66 primary EOC tumours by pyrosequencing. Bars represent four adjacent CpGs.  Grey bars: controls and 
tumours with methylation >≥50%.  Black bars: tumours with <50% methylation.  IVM in vitro methylated DNA, N normal male genomic DNA, 75,50 and 25 represent serial 
dilutions of positive and negative control.    
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4.3.4 Effect of methylation of SP5 (24D3) on patient survival and 
response to chemotherapy 
The aim of the experiments described in this next subchapter was to investigate whether 
the level of methylation of SP5 correlated with response to chemotherapy or survival for 
patients. The test and validation sets were analysed separately for progression free survival 
(PFS) and overall survival (OS), by Cox regression analysis and subsequently both data 
sets were combined in a Cox regression multivariate analysis with stage, grade, age and 
histological subtype.  Known clear cell and mucinous tumours were excluded.   Response 
to chemotherapy was assessed using logistic regression in the combined data set.  All 
statistical analysis was performed using SPSS with the help of Wei Dai. 
4.3.4.1 Response to chemotherapy (logistic regression) 
It was possible to assess 85 out of 140 patients for response to chemotherapy, taking the 
test and validation sets together.  Methylation was used as a continuous variable and no 
relationship was observed.  Various analyses were preformed comparing different 
radiological responses but in all cases the results were comparable.  This is shown in table 
27 below. 
 
Table 27 Relationship between SP5 methylation and response to chemotherapy according 
to different groupings of patients by radiological response. 
  Methylation level  (SP5) % Logistic regression model 
  Responders Non-responders       
  (Mean±SD)  (Mean±SD) OR 95% CI P 
CR+PR+SD (n=73) vs. PD (n=12) 70.1±16.5 76.6±9.4 1.03 (0.98, 1.08) 0.244 
CR+PR (n=59) vs. PD (n=12) 72.7±16.9 76.6±9.4 1.02 (0.97, 1.06) 0.444 
CR+PR (n=59) vs. SD+PD (n=26) 72.7±16.9 69.1±13.0 0.99 (0.96, 1.02) 0.331 
OR: odd ratio (OR>1 the patients with increased methylation are more likely to have poor response to first-line chemotherapy); 
 95% CI: 95% confidence interval; p value: Wald test     
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4.3.4.2 Methylation of SP5 and prognosis (Cox regression and 
Kaplan-Meier analysis) 
In addition there was no correlation between SP5 methylation and PFS or OS.  Complete 
data was available for 65 of 74 patients in the test set and 64 of 66 in the validation set in 
order to investigate the effect of SP5 methylation on PFS.  By univariate Cox model 
analysis, SP5 methylation showed a trend towards higher methylation correlating with PFS 
in the test set, however this was not statistically significant (two-sided score test p=0.064, 
HR 0.987, 95% CI 0.973-1.001) and no relationship was seen between SP5 methylation 
and OS (two-sided score test p=0.126, HR 1.015, 95% CI 0.996-1.034).  The lack of 
statistically significant correlation between SP5 and PFS or OS was confirmed in the 
validation set (two-sided score test PFS p=0.884, HR 1.001, 95% CI 0.987-1.015), (OS 
two-sided score test p=0.619, HR 0.996, 95% CI 0.981-1.012).  The results are shown in 
table 28 below: 
Table 28 Summary of statistics for SP5 methylation by univariate analysis 
 „P‟ 
value 
HR 95% confidence 
interval 
PFS test set (N=65) 0.064 0.987 0.973-1.004 
PFS validation set (N=64) 0.884 1.001 0.987-1.015 
OS test set (N=65) 0.126 1.015 0.996-1.034 
OS validation set (N=64) 0.619 0.996 0.981-1.012 
*P value is two-sided score test of the univariate Cox model. HR: hazard ratio. HR>1 indicates the increased risk of disease 
progression/death associated with the increase of methylation. HR<1 indicates the decreased risk of disease progression/death associated 
with the increase of methylation.  
The prognostic value of methylation at SP5 was then adjusted by stage, grade, age and 
histological subtype in the multivariate Cox model. Each of the variables in the 
multivariate analysis was tested individually by Wald test for its impact on PFS and OS.  
Complete data was available for 102 of the 140 patients for PFS and 104 for OS.  As 
predicted SP5 methylation did not have a significant impact within a multivariate setting 
(PFS p=0.177, 95% CI 0.979-1.004), (OS p=0.320, 95% CI 0.993-1.023).  Each of the 
variables in the multivariate analysis was tested individually for its impact on PFS and OS.  
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For PFS, patients with endometriod subtype had a better PFS (p=0.013, HR 0.364, 95% CI 
0.164-0.811).  Patients with stage 3 and 4 cancer had a significantly worse PFS (stage 2 
p=0.699, HR 0.715, 95% CI 0.131-3.909), (stage 3 p=0.002, HR 4.826, 95% CI 1.757-
13.255) and (stage 4 p=0.001, HR 5.965, 95% CI 2.046-17.393). Grade and age did not 
have a significant impact.  For overall survival stage was the only variable that had a 
statistically significant impact on survival (p=0.01, Wald test).  As a further check on the 
data and in order to produce the results in visual form Kaplan-Meier analysis was 
performed.  In case the study had been underpowered to detect a difference in methylation, 
due to sample size, the test and validation sets together (n=140), using median methylation 
as the cut off, and this confirmed no significant relationship between SP5 methylation and 
PFS (log rank test of survival curves in both groups p=0.098) (Figure 35) or OS (log rank 
test of survival in both groups p=0.963) (Figure 36). 
 
 
 
 
 
Figure 35.  Kaplan-Meier graph showing the effect of SP5 methylation on PFS in primary 
EOC (combined test and validation set).  ‘P’=0.098 (log rank test, median was used as the cut-
off).  Blue low methylation, green high methylation.  Survival in months.  Cum Survival cumulative 
survival. N=102.  
 
 
 
 
 
 
Figure 36.  Kaplan-Meier graph showing the effect of SP5 methylation on OS in primary EOC 
(combined test and validation set).  ‘P’=0.963 (log rank test, median was used as the cut-off).  
Blue low methylation, green high methylation.  survtime Overall Survival time in months.  Cum 
Survival cumulative survival. N=104. 
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4.4 Examination of SP5 (24D3) in Matched 
pairs 
In order to investigate whether the changes seen in vitro had significance for patients in 
terms of acquired drug resistance matched pairs of tumour pre- and post-chemotherapy 
were obtained.  If methylation is selected for during the course of treatment then in pairs 
where minimal methylation was seen in the pre- treatment sample an increase in 
methylation in the subsequent sample could herald a clinically useful methylation marker.  
Two sets of samples were available; from patient‟s pre- treatment and at the time of 
surgery for residual disease and from patient‟s pre- chemotherapy and at the time of 
relapse.  In principle the relapsed patients should be the most representative of acquired 
drug resistance although it was hoped that for patients with residual disease following 
chemotherapy that this is by definition also at least partly resistant to chemotherapy. 
4.4.1 Residual disease 
8 pairs of samples from patients pre-chemotherapy and at the time of surgery for residual 
disease were available.  A description of these is available in Chapter 2.4.1.  No significant 
difference was seen between pre- and post- treatment samples (p=0.61, two-sided student t-
test comparing all pre- vs. all post- samples).  This is with the caveat that these patients had 
not relapsed and did not therefore necessarily have resistant disease.  In addition ovarian 
cancer is known to be a heterogeneous disease and it is possible that the DNA extracted 
was from a part of the tumour that was less aggressive. Figure 37 below show the results 
for each individual pair. 
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Figure 37: Methylation of SP5 in residual disease pairs by pyrosequencing.  Controls in black: 
IVM in vitro methylated DNA, N normal male genomic DNA.  Each bar represents the average of 
four adjacent CpG‟s.  Dark grey pre- chemotherapy, Light post- chemotherapy. 
 
4.4.2 Relapsed disease 
These results were confirmed by examining SP5 methylation in the relapsed pairs were 
again  no significant difference was seen between pre- and post- relapse (two-sided student 
t-test p=0.93) although as stated in the methods section (2.5.2) and the discussion in the 
previous chapter it is not known whether the relpased disease samples represent sensitive 
or resistant relapse.  The results are shown in Figure 38 below.   
Figure 38: Methylation of SP5 in relapsed disease pairs by pyrosequencing.  Controls in 
black: IVM in vitro methylated DNA, N normal male genomic DNA.  Each bar represents the 
average of the 8 samples in 4 adjacent CpG‟s.  Dark grey pre-chemotherapy, Light grey post-
chemotherapy (n=2). 
 
It is perhaps not surprising that SP5 did not show differential methylation between pre- and 
post- treatment samples given the high level of methylation demonstrated in primary 
tumours and cell lines and given the highly statistical significant correlation between SP5 
methylation and response to first line chemotherapy we were keen to investigate this locus 
further.  We wished to clarify whether SP5 methylation was tissue specific and for the 
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tumours that appeared to lose methylation whether this occurred as an early or late 
phenomenon. 
4.5 Examination of SP5 (24D3) in other 
tissues 
Usually when investigating candidate loci in a panel of primary tumours low levels of 
methylation or a mixed pattern of methylation are seen.  In this case a high level of 
methylation was seen in the majority of samples, with a small proportion of samples 
showing much lower methylation.  Therefore it was hypothesised that the tumours with a 
low level of methylation could be losing methylation rather than the other samples gaining 
it.  In an attempt to address this question the methylation of eight PBMCs, 4 nOSE, 4 
normal adjacent, 4 samples which had shown low methylation, 4 samples of normal 
adjacent to the samples that had shown low methylation and the entire collection of 
primary tumours was compared and the results are shown in Figure 39 below; 
 
Figure 39. Methylation of SP5 in various ovarian tissue by pyrosequencing.  N blood whole 
male blood peripheral blood mononuclear cell, n OSE normal ovarian surface epithelium, NA 
normal adjacent, EOC epithelial ovarian cancer, LowMeth NA normal adjacent next to samples that 
had shown low methylation, LowMethEOC tumour samples that had shown less than 50% 
methylation.  Each bar represent the average across all CpGs for samples of the same type. (N=2). 
 
The highest percentage methylation was seen when the whole collection of EOC‟s were 
taken together.  A significant difference was observed in the methylation between this 
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group and both the tissue adjacent to the tumours which had shown low methylation 
(student t-test p=4.8x10
-11
) and the tumours themselves which had shown low methylation 
(student t-test p=8.8x10
-15
).   In addition the decrease in methylation between the tissue 
which was adjacent to the tumours that had shown low methylation and the low 
methylation tumours themselves was significant (student t-test p=0.03).  This could 
suggest that methylation maybe first lost in the adjacent normal with a further loss of 
methylation in a distinct group of tumours, although the numbers investigated are clearly 
small.    This pattern could indicate the role of methylation in maintaining tissue specific 
methylation patterns. 
. 
4.6 Discussion 
Eight potentially interesting candidates were identified from this experiment and the work 
of others with relation to these will now briefly be summarised. 
CRABP1 is cellular retinoic acid binding protein.  This gene encodes a specific binding 
protein for a vitamin A family member and is thought to play an important role in retinoic 
acid mediated differentiation and proliferation.    It is located on chromosome 15 and is 
highly conserved among species (www.genecards.org/cgi-
bin/carddisp.pl?gene=CRABP1).  SAGE databases demonstrate it is expressed in the brain, 
retina and spinal cord and also in skin, breast and ovarian cancers although to a lesser 
extent (www.genecards.org/cgi-bin/carddisp.pl?gene=CRABP1).  It has been shown to be 
a frequently methylated tumour suppressor gene in oesophageal cancer, colorectal cancer, 
ovarian cancer and thyroid cancer (Huang, de la Chapelle et al. 2003; Lind, Kleivi et al. 
2006; Ogino, Brahmandam et al. 2006; Tanaka, Imoto et al. 2007; Wu, Lothe et al. 2007).     
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AGBL2 is ATP/GTP binding protein-like 2.  It is located on chromosome 11 and is thought 
to play a role in the processing of tubulin (which could be of relevance given paclitaxel is 
one of the mainstays of ovarian cancer chemotherapy).  It is expressed in a wide range of 
normal and cancer tissues according to the Genenote data base and expression is seen in a 
wide range of normal tissues using the eNorthern and SAGE databases 
(www.genecards.org/cgi-bin/carddisp.pl?gene=AGBL2).  Characterisation of this gene, in 
normal tissue or cancer, or whether it is epigenetically regulated has not previously been 
reported. 
 
HRASLS3, HRAS-like suppressor 3 is a tumour suppressor gene that may be involved in 
interferon-dependent cell death.  It is located in chromosome 11 and shows conservation 
from the mouse to humans.  It is expressed in a variety of normal tissues and cancers 
according to the Genenote, eNorthern and SAGE databases (www.genecards.org/cgi-
bin/carddisp.pl?gene=HRASLS3).  Two authors have proposed its role as a tumour 
suppressor in ovarian cancer although whether gene transcription is epigenetically 
regulated has not been examined (Sers, Husmann et al. 2002; Nazarenko, Schafer et al. 
2007). 
  
GLS2 encodes a protein which is important in the regulation of glutamine metabolism.  It is 
located on chromosome 12 and highly conserved among species.  It is expressed in a wide 
variety of tissues according to the Genenote database and a wide range of cancers 
according to the eNorthern data set (www.genecards.org/cgi-bin/carddisp.pl?gene=GLS2).  
There are a small number of publications on this gene.  It is thought to be a target of p53 
(Hu, Zhang et al. 2010) and when glioma cells were transfected using cDNA, reduced 
survival, migration and proliferation was observed (Szeliga, Sidoryk et al. 2005).  It could 
therefore be hypothesised that it is a tumour suppressor gene that might be epigenetically 
regulated. 
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NTN4 belongs to a family of proteins related to laminins and is thought to play an 
important role in neural, kidney and vascular development. It is located on chromosome 12 
and conserved from mouse to humans.  Expression has been noted in a wide variety of 
tissues and also in liver, pancreatic, breast, thyroid and ovarian cancer cell lines, according 
to the eNorthern and SAGE databases (www.genecards.org/cgi-
bin/carddisp.pl?gene=NTN4).  It has not been reported, to date, to have a role in ovarian 
cancer, or to be epigenetically regulated although recently a paper was published by Nacht 
et al describing its role in inhibiting angiogenesis (Nacht, St Martin et al. 2009). 
 
SP5 is a transcriptional activator, located on chromosome 2, which has a role in the 
coordination of changes in transcription required to generate the developmental pattern in 
the developing embryo.  Using the SAGE database it is shown to be expressed in the brain 
colon, pancreas, prostate and placenta but expression has not been demonstrated in any 
cancers.  It is highly conserved among species and has two CGIs (www.genecards.org/cgi-
bin/carddisp.pl?gene=SP5).  The primers in this thesis amplified an area in the larger CGI 
which is located within the promoter.  
 
SP5 is known to be a transcription factor which antagonises SP1 (Harrison, Houzelstein et 
al. 2000) and is a downstream target of Wnt signalling (Takahashi, Nakamura et al. 2005; 
Weidinger, Thorpe et al. 2005; Chen, Guo et al. 2006; Fujimura, Vacik et al. 2007).  As 
Wnt is known to be dysregulated in EOC and has also been implicated in the pathogenesis 
of tumour initiating or sustaining cells this makes loss of methylation in tumours which 
regain expression of SP5 an important novel observation.  We have recently shown that 
methylation of key genes in the Wnt pathway has an impact on PFS on ovarian cancer 
(Dai, Teodoridis et al. 2010) and this adds further weight to the notion that methylation 
plays an important role in ovarian cancer drug resistance.   
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SP5 has been shown to be dynamically expressed during CNS development (Harrison, 
Houzelstein et al. 2000; Treichel, Becker et al. 2001; Weidinger, Thorpe et al. 2005) but it 
was only recently noted to show increased expression in colorectal, gastric and 
hepatocellular cancers with a negative impact (Chen, Guo et al. 2006).  Chen et al, using an 
inducible gene expression system combined with microarray analysis found that over 
expression of SP5 in MCF7 cells resulted in significant growth promotion supporting our 
results (Chen, Guo et al. 2006).  This fits with the high levels of methylation seen in the 
cell lines and majority of primary tumours.  The authors also identified downstream targets 
of SP5 in the microarray experiment; many of these genes have been implicated in ovarian 
cancer and drug resistance and some have been shown to have epigenetic modulation of 
their gene expression – they include p21, TGFB1, MDM2, ABCG2 and ABCC3 (see 
Chapter 1.3). 
 
4.7 Conclusion 
In these experiments the aim was to validate MLDA as a statistical technique capable of 
identifying sequences that gain methylation in resistant cell lines by DMH (Dai, Teodoridis 
et al. 2008).  The hypothesis being that such loci could represent candidate biomarkers of 
acquired platinum resistance.  It should be noted though that for this reason it was not the 
top ranking sequences that were analysed but instead random sequences, which ranked 
from 2 to 75.  Eight of nine sequences showed increased  methylation in the A2780-
derived resistant cell lines and we can therefore concluded that MLDA is at least as good at 
identifying candidate loci as PAM or SAM.  
 
Methylation of SP5 was not associated with response to chemotherapy or PFS or OS.  
Given that only a small number of tumours showed a decrease in methylation it is possible 
  175 
that both the response and survival analysis were underpowered. However analysis of the 
matched pairs also showed no significant differences.   
 
However it remains possible that a decrease in methylation at SP5 could correlate with an 
increase in expression and have functional significance – given the other publications 
relating to this gene.  If this is the case then the DMH experiment may have highlighted an 
important gene (SP5) or pathway (Wnt) in ovarian cancer. 
 
In conclusion, in this chapter we demonstrated that MLDA (Dai, Teodoridis et al. 2008), a 
novel statistical technique developed in our laboratory, was able to identify loci which 
showed differential methylation between sensitive and resistant A2780 based cell lines.  
Given that loci were chosen at random to be characterised and ranked up to 75
th 
(by MLDA 
ranking) it was encouraging that all but one locus validated in the same cell line panel.   
 
For SP5 we hypothesised we would see an increase in methylation in the resistant cell lines 
and a heterogeneous pattern of methylation in the primary tumours and although SP5 did 
not show this pattern and instead showed a very high level of methylation in nearly all cell 
lines and primary tumours, it was thought that this in itself was a interesting observation.     
 
In addition it appeared that rather than sequences gaining methylation that it may be a 
small cohort of samples that were losing methylation (which could be causing an increase 
in gene expression) - and a negative phenotypic effect from over expression of this gene 
would fit with the published work of others, as outlined above.  As a result we decided that 
further more functional experiments were warranted and these are described in Chapter 6. 
Other candidates were excluded from further analysis due to the low levels of methylation 
seen in primary tumours, but as was discussed in the last chapter this may be flawed logic.   
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There was concern though that the changes that are seen in the A2780 resistant series were 
not seen in the in vivo generated resistant cell lines and even sometimes showed the 
opposite, for example in the case of CRABP1 where a decrease in methylation was seen 
between PEO14 and PEO23.  Further refinement in the approach could be achieved by 
identifying candidate loci from methylation changes seen between in vivo generated 
sensitive and resistant cell lines (PEA1 and PEA2, PEO14 and PEO23) as opposed to in 
vitro generated cell lines (A2780 sensitive lines, A2780 cp70 and MCP 1-9), by DMH.  
This question was addressed by the experiments described in the next chapter.  
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5 Characterisation of loci showing differential 
methylation between patient derived cell line 
pairs by MLDA 
 
The experiments described in this chapter aimed to investigate whether using sensitive and 
resistant cell lines, where the resistance was generated within patients during 
chemotherapy, identified more clinically relevant methylation biomarkers of acquired drug 
resistance in ovarian cancer.  In order to address this, PEA1 (sensitive) vs. PEA2 (resistant) 
and PEO14 (sensitive) vs. PE023 (resistant) were used instead of the A2780 panel.  These 
cell lines were generated from patients with epithelial ovarian cancer who had been treated 
with platinum and subsequently developed resistance, and are referred to in the text as the 
in vivo cell lines (Langdon, Lawrie et al. 1988).   
 
Loci which showed increased methylation in the resistant in vivo ovarian cancer cell lines 
were identified using MLDA.  Figure 40a below shows how candidate loci are identified.  
Those of interest are seen as outliers on this line.  The six loci we were particularly 
interested in were those that gained maximal methylation in the resistant pair and these are 
shown in figure 40b within the red box.  
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Figure 40a.  MLDA: Sensitive and resistant scores for 6 loci which gain methylation in 
resistant cell lines.  The top two diagrams show the score in the sensitive cell line PEO14 and the 
resistant cell line PEO23.  The bottom two diagrams show the same for the PEA1 and PEA2 
pairing.  Coloured crosses highlight the position of the 6 loci within the whole data set and they can 
be seen to move from an area associated with less methylation to one of more methylation, 
between the sensitive and resistant cell lines (for a more complete explanation of how these figures 
are derived please refer to Dai et al, Figure 3 and Figure 7).  (Dai, Teodoridis et al. 2008).   
 
 
 
 
 
 
 
 
Figure 40b.  Identification of hypo- and hyper- methylated outliers by MLDA.  Loci which lose 
methylation in the resistant cell lines are shown as non filled circles within green box.  Loci which 
gain methylation in resistant cell lines are shown as non filled circles within the red box. 
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Of the 6 sequences which showed increased methylation in the two resistant cell lines by 
MLDA score, one locus did not contain a CGI and another had more than more BLAT 
(Blast like alignment tool) alignment and we therefore selected 4 sequences to characterise 
in more detail in this chapter.  These are shown in table 29 below.  We did not choose to 
characterise the sequences that showed a decrease in methylation in the resistant cell lines.  
This was a pragmatic decision given that the characterisation of each locus is time 
consuming.  We hypothesised that a gain in methylation in the resistant cell lines would be 
more functionally relevant and have more potential as a biomarker than a loss in 
methylation.     
Table 29 List of sequences gaining methylation in PEA2 and PEO23 (resistant) cell lines.   
 
MLDA    
Rank 
 
Microarray 
Identifier
1
 
 
Gene 
Symbol 
CGI
2
 PEO14 PEO23 PEA1 PEA2 
 
Residual 
score 1* 
 
Residual 
score 2* 
1 85B2 LOC113230 Y -1 -0.2 -1 0.45 0.8 1.45 
2 21G5 KIAA1383 Y -1 0 -1 0.2 1 1.2 
3 17G11 SIX1 Y -1 0.45 -1 1 1.45 2 
4 66G6 - Y -0.45 1 -1 0 1.45 1.0001 
1
http://data.microarrays.ca/cpg/searchsingleclones.htm.  
2
CGI Gardener Garden Y yes, N no. *The residual 
score is the difference of MLDA score between pair of cell lines (1: PEO14 vs. PEO23; 2: PEA1 vs. PEA2), 
and positive residual score indicates increased methylation in the resistant cell line. MLDA score (see MLDA  
paper Figure 3) (Dai, Teodoridis et al. 2008) representing how consistently the locus was methylated 
(positive score) or unmethylated (negative score) in duplicates.  
 
5.1 Examination of candidate loci in cell 
lines 
The next aim was to confirm by pyrosequencing the methylation status of candidate loci 
identified from the MLDA analysis.  The 28 cell lines, as described in chapter 3, were used 
(the full 34 cell lines panel minus the single step clones).  It was possible to optimise 
pyrosequencing primers for 3 of the 4 sequences which contained a CGI and the other, 
66G6, was examined by MSP.  The results are discussed below. 
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5.1.1 CpG methylation of LOC113230 (85B2) in 28 cell lines by 
pyrosequencing 
The results for LOC113230 (85B2) are shown in Figure 41 below (two-sided student t-test 
p=0.46 when comparing all senstive vs all resistant). 
Figure 41.  Methylation of LOC113230 in the 28 cell line panel by pyrosequencing. Controls in 
black: IVM in vitro methylated DNA, Positive control), serial dilutions of IVM/N, N (whole male 
genomic DNA, background control) shown.  Unmeth 1 and 2 whole genome amplified 
unmethylated DNA. Sensitive cell lines in light grey and corresponding resistant cell lines shown in 
dark grey.  Bars represent 6 adjacent CpG residues. 
 
From this experiment LOC113230 (85B2) would appear to be a false positive result.  
Although it appeared that there was differential methylation between the sensitive and 
resistant cell lines on the DMH experiment this was not seen by pyrosequencing.  On this 
occasion because very high levels of methylation were seen in PBMC‟s an alternative 
negative control was used and this is labelled UNMETH 1 and 2 (whole genome amplified 
unmethylated DNA).  The limitation of this approach is that pyrosequencing only 
examines a handful of CpG sites however attempts to optimise alternative primer sets were 
not successful for this locus.   
It was decided not to attempt to further characterise this locus at this time but instead to 
address the methylation status in the independent arrays, as outlined in chapter 7. 
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5.1.2 CpG Methylation of SIX1 (17G11) in 28 cell lines by 
pyrosequencing 
SIX1 showed a distinct increase in methylation in 4 out of 6 cell line pairs, most 
remarkably between the A2780 sensitive cell lines and the cisplatin resistant MCP lines 
with an increase in mean methylation from 44.56% to 72.35% (A2780 sensitive vs. A2780 
cp70 and MCP1-9, student t-test p=0.0004), the PEO1 sensitive cell line (25.5%) and the 
resistant corresponding cell lines PEO4, PEO6 and PEO1CDDP (38.63%) (student t-test 
p=0.021) and between the PEA1 and 2 pairing where an increase of 2.5% to 83.8% was 
seen (student t-test p=0.0008).  The background level of mean methylation for these 
experiments was 12.5%.  Whereas most of the loci investigated in the previous chapters 
had shown increased methylation in the A2780 based cell lines but not in the others this 
loci showed differential methylation in both the A2780 and in vivo derived pairs and this 
result was seen as highly encouraging.  The pyrosequencing results are shown in figure 42 
below: 
Figure 42.  Methylation of SIX1 in the 28 cell line panel by pyrosequencing. Controls in black: 
IVM (in vitro methylated DNA, positive control), serial dilutions of IVM/N, N (whole male genomic 
DNA, background control) shown.  Sensitive cell lines in light grey and corresponding resistant cell 
lines shown in dark grey.  Bars represent 4 adjacent CpG residues. 
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5.1.3 CpG Methylation of KIAA1383 (21G5) in 28 cell lines by 
pyrosequencing 
KIAA1383 also showed an increase in mean methylation in several of the resistant cell line 
pairings (3 of 6 pairings).  In the A2780 cell line groupings there was an increase in mean 
methylation from 50.1% to 66.8% (student t-test p=0.000461).  In the PEO14 and PEO23 
pairing there was an increase in mean methylation from 5.5% to 20.33% (student t-test 
p=0.000878) and in the PEA1 and PEA2 pair there was an increase from 4.83% to 30.33% 
(student t-test p=0.005582).  This was with a background level of methylation of 4.99%.  
The results are shown in Figure 43 below:   
Figure 43.  Methylation of KIAA1383 in the 28 cell line panel by pyrosequencing. Controls in 
black: IVM in vitro methylated DNA, positive control), serial dilutions of IVM/N, N (whole male 
genomic DNA, background control) shown.  Sensitive cell lines in light grey and corresponding 
resistant cell lines shown in dark grey.  Bars represent 3 adjacent CpG residues. 
 
5.1.4 CpG Methylation of 66G6 in 22 A2780 based cell lines by 
MSP 
One further sequence, 66G6, could not be optimised for pyrosequencing and was examined 
by MSP in the A2780 cell lines where it showed increased methylation in the resistant cell 
lines had been confirmed here also.  These results are shown in figure 44 below. 
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Figure 44.  Methylation of 66G6 in 22 A2780 derived sensitive and resistant cell lines by 
MSP. Validation using MSP of 66G6 in the cell lines analysed by DMH as well as 6 additional 
cisplatin resistant cell lines, C1Cis6-C5E4(15). (M), methylated primer set and (U), unmethylated 
primer set. H2O, reaction without template DNA; IVM, in vitro methylated DNA; PMN, DNA from 
whole male blood.  The in vivo cell lines were not available at this time.  
 
5.2 Matched pairs 
KIAA1383 and SIX were next examined in DNA from matched paired samples from 
patients with ovarian cancer (66G6 was not taken any further as I could not optimise 
pyrosequencing primers and 85B2 was not examined further because of the very high level 
of methylation seen in all cell lines).   
5.2.1 Pre chemotherapy and residual disease 
As described in Chapter 2.4.1, ten of the twelve pairs of samples from patients at diagnosis 
and at the time of surgery for residual disease, following chemotherapy, were available.  
SIX1 showed a background methylation of 6.6%.  Although 7 of 10 samples showed some 
increase in methylation in the relapse samples, for only two samples was the percentage 
methylation in the pre treatment sample ≤ the background level of methylation and when 
all pre treatment samples were compared to resistant no significant difference in 
methylation was seen  (student t-test p=0.855).  This is illustrated in Figure 45 below.   
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Figure 45.  Methylation of SIX1 in the residual disease pairs by pyrosequencing.  Controls in 
black, IVM in vitro methylated DNA, positive control), serial dilutions of IVM/N, N (whole male 
genomic DNA, background control) shown.  Dark grey is pre- chemotherapy sample, Light grey is 
corresponding post- relapse sample.  One bar represents 5 adjacent CpG‟s.   
 
KIAA1383 was also investigated in these same patient pairs.  Background methylation was 
8%.  Six of 10 samples showed a small increase in methylation in the residual tumour 
however in only two samples was the pre- residual disease sample ≤ methylated than in the 
background.  For one pair a statistically significant difference was seen between the pre- 
and post- treatment samples (student t-test p=0.0004).  Overall though when comparing all 
pre- treatment samples to all residual disease samples no significant difference was seen  in 
mean methylation (student t-test p=0.72).  This is illustrated in figure 46 below.   
Figure 46.  Methylation of KIAA1383 in the residual disease pairs by pyrosequencing.  
Controls in black, IVM in vitro methylated DNA, positive control), serial dilutions of IVM/N, N (whole 
male genomic DNA, background control) shown.  Dark grey is pre- chemotherapy sample, Light 
grey is corresponding residual disease sample.  One bar represents three adjacent CpGs.  
Mean+SD3 is mean % methylation plus three standard deviations. 
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5.2.2  Pre chemotherapy and relapsed disease 
For SIX1, 1 pair showed a significant increase in methylation in the post treatment sample 
(student t-test p=0.002) however overall no significant difference was seen between pre- 
and post- relapse samples (student t-test p=0.29).  This is illustrated in figure 47 below.  
 
Figure 47.  Methylation of SIX1 in the relapsed disease pairs by pyrosequencing.  p=0.29.  
Black columns show the controls, IVM in vitro methylated DNA, positive control), serial dilutions of 
IVM/N, N (whole male genomic DNA, background control) shown.  Dark grey bars pre-treatment, 
Light grey bars post- relapse.  One bar represents the average value for 5 adjacent CpG‟s.  One 
pair with significant student t-test is highlighted with an arrow, p=0.002. 
 
KIAA1383 was also investigated in the relapsed disease matched pairs.  Here an increase in 
mean methylation was seen in 1 of 4  relevant pairs but again when all pre- vs all relapsed 
disease pairs were analysed together no significant difference was seen (student t-test 
p=0.9).  This is illustrated in figure 48 below. 
Figure 48. Methylation of KIAA1383 in the relapsed disease pairs by pyrosequencing.  p=0.9 
Black columns show the controls, IVM in vitro methylated DNA, positive control), serial dilutions of 
IVM/N, N (whole male genomic DNA, background control) shown.  Dark grey bars pre treatment, 
light grey bars post relapse.  One bar represents the average value for 3 adjacent CpG‟s. 
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5.3 Examination of candidate loci in primary 
tumours and correlation with response 
to chemotherapy and survival 
The objective of these experiments was to examine SIX1 and KIAA1383 in primary 
epithelial ovarian cancer tumours and to investigate whether an increase in methylation, 
such as that had been seen in the resistant cell lines, was again observed.  As before these 
loci were first investigated in the smaller test panel of approximately 20 tumours.   
 
5.3.1 CpG Methylation of SIX1 (17G11) in primary tumours. 
Mean methylation in the normal control (N) in the test set was 5.7%. Similar results were 
seen in the second test set at 6.2%, and the validation set where average methylation of 
7.8% was observed.  40% of samples in the first test set had methylation of > 50% 
methylation.  The results for each of the data sets are illustrated in figure 49a-c below and 
overleaf.  As previously for the two larger data sets average methylation across the 
adjacent CpG‟s is shown and those samples with >50% methylation are highlighted. 
 
Figure 49a.  Methylation of SIX1 in test set (I) of 22 primary EOC tumours by 
pyrosequencing.  Bars represent 5 adjacent CpG residues.  IVM in vitro methylated DNA, N 
normal male genomic DNA, 75,50 and 25 represent serial dilutions of positive and negative control.   
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Figure 49b.  Methylation of SIX1 in test set (ii) of 54 primary EOC tumours by pyrosequencing. Bars represent 5 adjacent CpG residues.  Grey bars: controls and 
tumours with methylation >≥50%.  Black bars: tumours with <50% methylation.  IVM in vitro methylated DNA, N normal male genomic DNA, 75,50 and 25 represent serial 
dilutions of positive and negative control.   
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Figure 49c.  Methylation of SIX1 in the validation set of 66 primary EOC tumours by pyrosequencing. Bars represent 5 adjacent CpG residues.  Grey bars: controls 
and tumours with methylation >≥50%.  Black bars: tumours with <50% methylation.  IVM in vitro methylated DNA, N normal male genomic DNA, 75,50 and 25 represent 
serial dilutions of positive and negative control.    
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5.3.2 Effect of methylation of SIX1 (17G11) on response to first 
line chemotherapy 
No relationship was seen between methylation of SIX1 and response to chemotherapy, by 
logistic regression.  It is possible that this is because the analysis was underpowered.  Data 
was only available for 85 patients and whichever way the patient groups were split, in 
terms of RECIST response, there were only a maximum of 26 in one of the groups.  
Similarly as before it is possible for a biomarker to be of prognostic value but this not to be 
attributable to the response to first line treatment and we therefore went ahead with the 
survival analysis as outlined in the next sub-section.  The response results are shown in 
table 30 below: 
Table 30.  Relationship between SIX1 methylation and response (by RECIST). 
  Methylation level  (SIX1) % Logistic regression model 
 Responders Non-responders       
   (Mean±SD)  (Mean±SD) OR 95% CI P 
CR+PR+SD (n=73) vs. PD (n=12) 28.5±25.8 32.1±26.4 1.00 (0.98, 1.03) 0.649 
CR+PR (n=59) vs. PD (n=12) 29.2±27.2 32.1±26.4 1.00 (0.98, 1.03) 0.725 
CR+PR (n=59) vs. SD+PD (n=26) 29.2±27.2 28.9±22.7 1.00 (0.98, 1.02) 0.936 
OR: odd ratio (OR>1 the patients with increased methylation are more likely to have poor response to first-line chemotherapy); 
 95% CI: 95% confidence interval; p value: Wald test     
 
5.3.3 Effect of methylation of SIX1 (17G11) on patient survival 
By univariate Cox regression model no relationship was seen between SIX1 and PFS in 
either data set however significant results were seen for OS.  The results were conflicting 
though with an increase in methylation having a negative impact on OS in the test set and 
the converse true in the validation group.  The results are summarised in the table below 
but effectively mean that analysis of a further group of samples would be necessary to 
investigate whether there is a positive or negative impact of SIX1 on survival: 
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Table 31 Summary of statistics for univariate analysis of SIX1 methylation and survival. 
 p 
value* 
HR 95% confidence Interval 
PFS test set (n=65) 0.448 0.997 0.988-1.005 
PFS validation set (n=64) 0.083 0.987 0.973-1.002 
OS test set (n=65) 0.043 1.01 1.000-1.019 
OS validation set (n=64) 0.037 0.983 0.966-0.999 
*P value is two-sided score test of the univariate Cox model. HR: hazard ratio. HR>1 indicates the increased risk of disease 
progression/death associated with the increase of methylation. HR<1 indicates the decreased risk of disease progression/death associated 
with the increase of methylation.  Statistically significant results shown in bold. . 
 
The complete data set was again analysed by Kaplan-Meier, using median methlyation as a 
cut-off and the results substantiated those of the Cox regression model with SIX1 not 
influencing PFS or OS (log rank test of survival in both groups p=0.734 and 0.347 
respectively).  The PFS in the low methylation group was 11.5 months and in the high 
methylation group was 11 months.  The results are depicted in Figure 50. 
 
 
 
 
 
Figure 50.  Kaplan-Meier graph showing the effect of SIX1 methylation on PFS in 140 EOC 
tumours, in months, p=0.734 (log rank test, median was used as the cut-off)). Blue low 
methylation, green high methylation. 
 
OS in the low methylation group was 33.7 months and in the high methylation group was 
27 months.  This was not statistically significant and is a further confirmation of the 
conflicting univariate analysis – namely that there is unlikely to be a significant 
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relationship between SIX1 methylation and overall survival.  The Kaplan Meier plots are 
shown in figure 51 below:   
 
 
 
 
Figure 51.  Kaplan-Meier showing the effect of SIX1 methylation on OS in 140 primary EOC 
tumours, in months, p= 0.347 (log rank test, median was used as the cut-off)).  Blue low 
methylation, green high methylation. 
 
 
5.3.4 CpG Methylation of KIAA1383 (21G5) in primary ovarian 
cancer tumours 
For KIAA1383 the level of background methylation in the test set was 5.5%.  Mean 
methylation of the samples was 31.81% and 20% of samples had methylation of > 50%.  It 
was therefore investigated in the second part of the test set where similar results were seen 
with methylation in normal of 6% and average methylation in the samples of 32.8% with 
methylation of >50% in 20% samples.  The validation set was therefore analysed in terms 
of methylation of this candidate.  Here methylation in normal was 4.5% and the average 
methylation in the samples was lower at 22.12% with only 1% of samples showing 
methylation of 50%.  The results are illustrated in figure 52 a-c below.   
As before for the initial data set results for individual CpGs are shown whereas for the 
second two figures average results across 3 adjacent CpGs are shown.   
  192 
  
 
Figure 52a.  Methylation of KIAA1383 in test set (I) of primary EOC tumours by 
pyrosequencing.  Each colour represents an individual CpG.  IVM in vitro methylated DNA, 75,50 
and 25 serial dilutions of IVM with N. N normal whole male genomic DNA.
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Figure 52b. Methylation of KIAA1383 in test set (ii) of 54 primary EOC tumours by pyrosequencing.  Bars represent 3 adjacent CpG residues.  Grey bars: controls 
and tumours with methylation >≥50%.  Black bars: tumours with <50% methylation.  IVM in vitro methylated DNA, N normal male genomic DNA, 75,50 and 25 represent 
serial dilutions of positive and negative control.    
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Figure 52c. Methylation of KIAA1383 in the validation set of 66 primary EOC tumours by pyrosequencing.  Bars represent 3 adjacent CpGs.  Grey bars: controls 
and tumours with methylation >≥50%.  Black bars: tumours with <50% methylation.  IVM in vitro methylated DNA, N normal male genomic DNA, 75,50 and 25 represent 
serial dilutions of positive and negative control.   
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5.3.5 Effect of methylation of KIAA1383 (21G5) on response to 
first line chemotherapy  
The combined data set was analysed using logistic regression according to the different 
possible groupings by radiological response; again no statistically significant relationship 
was seen between methylation of this locus and response to chemotherapy and as 
explained before this maybe due to underpowering of the analysis.  Similarly as before it is 
possible for a biomarker to be of prognostic value but this not to be attributable to the 
response to first line treatment and we therefore went ahead with the survival analysis as 
outlined in the next sub-section.  The results for response to treatment are shown in table 
32 below: 
Table 32.  Relationship between KIAA1383 methylation and response (by RECIST). 
  
Methylation level  (KIAA1383) 
% Logistic regression model 
 Responders Non-responders       
   (Mean±SD)  (Mean±SD) OR 95% CI p 
CR+PR+SD (n=73) vs. PD (n=12) 26.8±23.4 24.9±17.1 1.00 (0.97, 1.03) 0.785 
CR+PR (n=59) vs. PD (n=12) 27.2±23.1 24.9±17.1 1.00 (0.97, 1.03) 0.734 
CR+PR (n=59) vs. SD+PD (n=26) 27.2±23.1 24.9±21.7 1.00 (0.98, 1.01) 0.652 
OR: odd ratio (OR>1 the patients with increased methylation are more likely to have poor response to first-line chemotherapy); 
 95% CI: 95% confidence interval; p value: Wald test     
 
5.3.6 Effect of methylation of KIAA1383 (21G5) on patient survival 
Survival data was available for the majority of the patients.  As before, the test and 
validation sets were analysed for the correlation between methylation and PFS, OS using 
univariate Cox model, and then adjusted by stage and grade in multivariate Cox model, 
respectively. The associated between methylation with response was analysed using 
univariate logistic regression model (see methods Chapter 2.25.3). 
 
In addition to the statistically significant correlation with response to chemotherapy a 
statistically significant relationship was seen between methylation of KIAA1383 and PFS 
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in the test set (two-sided score test p=0.027, HR 0.987, 95% CI 0.975-0.999).  This was 
confirmed in the validation set where a „p‟ value of 0.009 was seen (HR 0.980, 95% CI 
0.965-0.995).  In the test set no relationship was seen between KIAA1383 methylation and 
overall survival (two-sided score test p=0.833, HR 0.999, 95% CI 0.986-1.012) however a 
statistically significant relationship between methylation and OS was seen in the validation 
set (two-sided score test p=0.011, HR 0.976, 95% CI 0.961-0.995).  A summary of the 
statistics is shown in table 33 below: 
Table 33 Summary of statistics for univariate analysis of KIAA1383 methylation and survival   
*P value is two-sided score test of the univariate Cox model. HR: hazard ratio. HR>1 indicates the increased risk of disease 
progression/death associated with the increase of methylation. HR<1 indicates the decreased risk of disease progression/death associated 
with the increase of methylation.  Statistically significant results shown in bold.  Survival data available for 113 of 140 patients. 
 
As before, histological types, stage, age and grade were all integrated with KIAA1383 
methylation into a multivariate analysis.  Histological type (p=0.022) with endometriod 
tumours reflecting a better PFS (two-sided score test p=0.013, HR 0.364, 95% CI 0.164-
0.811), stage (two-sided score test p=<0.0001, with patients with stage 3 and 4 tumours 
having a worse PFS; Stage 3 two-sided score test p=0.002, HR 4.826, 95% CI 1.757-
13.255; Stage 4 two-sided score test p=0.001, HR 5.965, 95% CI 2.046-17.393) and grade 
(two-sided score test p=0.048) were all shown separately to have a statistically significant 
impact on PFS but when integrated into the model together only KIAA1383 methylation 
had a significant „p‟ value (two-sided score test p=0.039, 95% CI 0.979-0.989).  Thus, 
KIAA1383 methylation is significantly associated with PFS independent of histological 
type, stage, age and grade. 
 P value HR 95% confidence 
Interval 
PFS test set (n=65) 0.027 0.987 0.975-0.999 
PFS validation set (n=64) 0.009 0.980 0.965-0.995 
OS test set (n=65) 0.833 0.999 0.986-1.012 
OS validation set (n=64) 0.011 0.976 0.961-0.995 
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Next the same factors were examined in terms of OS.  Stage was the only factor to have a 
statistically significant influence on OS (two-sided Wald test p=0.010) with patients with 
stage 3 and 4 tumours having a poorer OS (stage 3 HR 2.219, stage 4 HR 2.409 although 
the „p‟ values were not significant). 
Kaplan-Meier analysis of all 140 tumours confirmed a statistically significant relationship 
between PFS and KIAA1383 methylation with patients with less methylation having a 
worse outcome (p=0.012 log rank test, median as cut-off), low methylation=10 months, 
high methylation 14 months).  This is shown in Figure 53 below: 
 
 
 
  
 
Figure 53.  Kaplan-Meier graph of KIAA1383 methylation and PFS (p=0.012).  (log rank test, 
median was used as the cut-off).  Green high methylation, Blue low methylation, Cum survival 
Cumulative survival. 
 
Although patients with less KIAA1383 methylation also had a worse outcome in terms of 
OS (35.9 vs. 22.3 months) this was not statistically significant (p=0.159 log rank test, 
median as cut-off).  This is shown in Figure 54 below: 
 
 
 
 
 
Figure 54.  Kaplan-Meier of Methylation of KIAA1383 and OS (p=0.159)
  
(„p‟ = log rank test, median was used as the cut-off).  Green high methylation, Blue low methylation, 
Cum survival Cumulative survival. 
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5.4 Discussion 
A smaller list of genes was generated when comparing the two in vivo derived cell lines by 
MLDA.   
1E7 maps to FAM7A2.  This gene is located on chromosome 15.  Its biological function is 
not known and it is not seen to be expressed in Genenote or eNorthern databases 
(www.genecards.org/cgi-bin/carddisp.pl?GENE=FAM7A2).  The results in this thesis 
demonstrated an increase in methylation between PEA1 and PEA2 but no methylation in 
primary tumours. 
85B2 maps to LOC113230.  Again there is no published literature on this gene and its 
function is unknown other than it is located on chromosome 19 and noted to be expressed 
in some cancer cell lines using the SAGE database (www.genecards.org/cgi-
bin/carddisp.pl?gene=LOC113230).  The CGI at LOC113230 is highly methylated in 
sensitive and resistant cell lines. 
21G5 maps to KIAA1383, a hypothetical protein located on chromosome 1.  It is a small 
gene which just spans one exon.  Expression has been noted in some tissues using 
Genenote and eNorthern databases although of note none of the databases report 
expression in normal or cancerous ovarian tissue or cell lines (www.genecards.org/cgi-
bin/carddisp.pl?gene=KIAA1383).  There are no publications relating to this hypothetical 
protein in the literature although in one publication it was noted in a list of genes shown to 
be expressed in response to the histone methyltransferase inhibitor DZnep (Miranda, 
Cortez et al. 2009).  This drug has recently been shown to suppress histone methylation 
globally having initially been thought to be selective for the H3K27 and H4K20 marks.  
This raises the question as to whether histone methylation in addition to DNA methylation 
is required. 
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5.5 Conclusion 
SIX1 and KIAA1383 were examined in primary tumours as they had shown increased 
methylation in the resistant cell lines.  Encouragingly this increased methylation was not 
unique to the in vivo cell lines they originated from but was also seen in the A2780 cell 
lines.   
In the primary tumours they showed the heterogeneous pattern that we hypothesised we 
would see if a gene was playing a role in ovarian cancer pathogenesis.  However SIX1 
methylation did not correlate with response to chemotherapy or prognosis.  Encouragingly 
though increased methylation of KIAA1383, by pyrosequencing, showed a significant 
correlation with improved PFS and in addition a correlation with improved OS was seen in 
the validation set.   
As was the case for SP5 though the direction of methylation was in the „opposite direction‟ 
to that which would be predicted by the cell line analysis  i.e.  an increase in methylation 
conferred an advantage for the patient.  As outlined previously this can be explained 
biologically by the fact methylation +/- silencing of a gene could have a different impact at 
the outset of disease compared to later in the disease course.   
Given the statistically significant correlations with both response to chemotherapy and PFS 
it seems likely that KIAA1383 is a biologically important gene, and a potential prognostic 
biomarker, however almost nothing is known about it.  It is highly conserved among 
species however other than its amino acid sequence and the low levels of expression seen 
using microarray experiments it is almost an entirely unknown candidate 
(http://www.genecards.org/index.php?path=/Search/keyword/KIAA1383).   
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Again here we have hypothesised that a decrease in methylation is resulting in an increase 
in expression but this needs to be confirmed.  Unfortunately I had difficulty examining this 
locus by qRTPCR.  It is unclear whether this is because this gene is not expressed or if it is 
a problem with the primer design (as the gene only spans one exon).  I did however 
manage to perform an overexpression experiment and the results are discussed in Chapter 
6.   
Methylation of SIX1 (17G11) did not correlate with improved response to chemotherapy 
and consistent results were not demonstrated in terms of prognosis either.  It was therefore 
not selected for further characterisation in Chapter 6, in terms of functional experiments, 
such as knockdown or over-expression, but it was investigated in the independent arrays 
described in Chapter 7. 
It was not possible to optimise primers to investigate the methylation of 66G6 by 
pyrosequencing and given the difficulty in quantifying methylation by MSP demonstrated 
thus far in the thesis a pragmatic decision was taken not to proceed further with 
investigation of this loci.  The difficulty in optimising primers was related to the extreme 
density of CpGs within the CpG island which made it difficult to position primers.  That 
said it should be noted that it did appear to be an interesting candidate within the A2780 
cell lines (the in vivo cell lines were not available at the time) by MSP and perhaps further 
investigation of its expression by qRTPCR, as a first step, is warranted. 
In conclusion, if one excludes 66G6 as it was not characterised in the primary tumours due 
to assay limitations,  this chapter has demonstrated that using the in vivo derived cell lines 
to identify genes resulted in two of three candidates examined showing a correlation with 
PFS or OS.  
 MLDA had originally identified six loci mapping to 4 genes containing CGIs and 
therefore this was felt to be very encouraging, as there was a high correlation between loci 
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identified and number correlating with survival.  Interestingly though it was higher 
methylation for both candidates that correlated with improved survival for patients and this 
at first glance is counter intuitive given that the loci were identified by MLDA because 
they showed increased methylation in the resistant cell lines.  This is possible to explain 
biologically though in that it is very possible for methylation of a gene to have a different 
phenotypic effect at diagnosis compared to at relapse.  For example methylation of BRCA1 
can silence this gene (Teodoridis, Hall et al. 2005), resulting in a higher risk of ovarian 
cancer (Thompson and Easton 2002) but that same methylation later may result in an 
improved response to platinum agents  and PARPi and hence perhaps a better PFS 
(Konstantinopoulos, Spentzos et al. 2010).  This has been presented at ASCO this year, and 
reported in abstract form, in both the platinum-sensitive (J. A. Ledermann 2011) and 
platinum-resistant relapse setting (Birrer 2011). 
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6 Functional analysis of SP5 and KIAA1383 
 
6.1 Correlation between mRNA expression 
and DNA methylation OF SP5 in cell 
lines by qRTPCR 
The aim of the experiments described in this subchapter were to investigate whether 
increased methylation at the promoter of SP5 resulted in decreased expression of the gene; 
in cell lines initially and then in tumours.  Various mechanisms exist of down regulating 
gene expression so it was expected that expression may still be seen despite a change in 
methylation and that a change in expression could be seen without a change in methylation 
- however an increase in expression would not be predicted where an increase in 
methylation was seen.   
The results in a panel of sensitive and resistant cell lines are shown in Figure 55 below.  
For A2780 sensitive cell lines (A2780, A2780 p3 and A2780 p6) vs. A2780 resistant cell 
lines (A2780 cp70, MCP1, MCP6. MCP9) a relative increase in methylation was seen to 
correlate with a decrease in SP5 expression.  For PEO1 and PEO4, one of the in vivo 
derived cell lines, no change in methylation was seen between the two cell lines but there 
was a decrease in expression.  Between the PEO14 and PEO23 pairs the level of 
methylation remained high and a smaller impact on the already low levels of expression is 
seen.  Results are shown with the y axis to the Log10. 
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Figure 55.  Effect of altered methylation of SP5 on mRNA expression.  A2780 sensitive 
(A2780, A2780 p6, A2780 p6), A2780 resistant (A2780 cp70, MCP 1, MCP6, MCP9), PEO1 
(sensitive), PEO4 (resistant), PEO14 (sensitive), PEO23 (resistant).  Methylation by 
pyrosequencing of bisulphite modified DNA (grey), expression by qRTPCR normalised to GAPDH 
and relative to A2780 (delta delta CT), (black).  Experiments performed in duplicate. 
 
As a decrease in expression was confirmed in the A2780 resistant cell lines the relationship 
between methylation and expression was next investigated in a panel of primary tumours 
for which DNA and RNA were both available. 
 
6.2 Correlation between mRNA expression 
and DNA methylation OF SP5 in primary 
ovarian cancer tumours by q RTPCR 
The aim of this experiment was to establish if the same correlation between increased 
methylation and decreased expression (and decreased methylation and increased 
expression) was seen in primary ovarian cancer tumours.  Figure 56 below demonstrates 
that for most samples this is the case.   
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Figure 56.  Scatter plot illustrating correlation between m RNA expression by qRTPCR and 
methylation by pyrosequencing for SP5.  Diamonds represent each ovarian cancer tumour 
(n=21). RTPCR with triplicates, pyrosequencing duplicates. 
 
As stated before given that DNA methylation is only one means of suppressing the 
expression of a gene these results were seen as very encouraging and lent weight to the 
hypothesis that decreased methylation of SP5 could result in increased expression of SP5 
and a downstream phenotypic effect.   
6.3 Re-expression of SP5 in cancer cell lines 
following decitabine treatment 
In order to address whether expression of SP5 was related to the methylation status, cells 
were treated with a demethylating agent, decitabine (DAC), and RNA extracted.  It was 
hypothesised that if methylation was relevant that treatment with a demethylating agent 
would result in re expression of the gene.  The results are shown in Figure 57 below.  For 
each of the cell line pairs an increase in expression is seen as a result of treatment with the 
demethylating agent although this was not statistically significant.  Results of the student t-
tests for each pair are shown to the right of the figure. 
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Figure 57.  Relative Expression of SP5 following decitabine treatment.  Error bars show 
standard deviation.  Light grey untreated cell lines, dark grey Decitabine (DAC) treated cell lines 
(DAC 0.5 μM for 4 days with daily media change). Two-sided Student t-test results shown to right. 
 
6.4 Optimisation of siRNA knockdown of 
SP5 in PEO14 and PEO23 
In the next experiment I wished to assess whether knockdown of SP5 had a phenotypic 
effect.  I first planned to knock down SP5 using siRNA and then perform an MTT 
experiment, and the first step was to optimise the conditions for this experiment; the results 
of which are now briefly presented. 
Three siRNAs targeting expression of SP5 were tried at two concentrations; 5 nM and 10 
nM.  The 2
nd
 siRNA appeared to produce the best knockdown and as the results were 
similar between the 5 and 10 nM concentrations experiments were carried out using 5 nM 
to reduce the risk of off- target effects.  The same results were seen for PEO14 (figure 58a) 
and PEO23 (Figure 58b).  The effectiveness of the SP5 knockdown was assessed by 
qRTPCR (delta delta CT) using the Taqman SP5 primers normalised to GAPDH.  The 
Allstars® scrambled control was used for relative quantitation.  All experiments were 
performed in triplicate.  
Cell line Student t-Test 
A2780 +/- DAC 0.09 
P6 +/- DAC 0.24 
MCP 1 +/- DAC 0.07 
MCP 6 +/- DAC 0.19 
MCP 9 +/- DAC 0.90 
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Figure 58a.  Knockdown of SP5 in PEO14 by siRNA measured by qRTPCR.  UnRx untreated, 
Mock transfection reagent only, AS Allstars® scrambled control, 1-3 different siRNA‟s.  Controls 
black, [5 nm] light grey, dark grey [10 nm]. 
 
 
 
 
 
 
 
Figure 58b.  Knockdown of SP5 in PEO23 by siRNA measured by qRTPCR.  UnRx untreated, 
Mock transfection reagent only, AS Allstars® scrambled control, 1-3 different siRNA‟s. Controls 
black, [5 nm] light grey, dark grey [10 nm]. 
 
The next experiment assessed the duration of SP5 knockdown at mRNA level, again by 
taqman qRTPCR.  Knockdown of SP5 was observed from 24-96 hours in PEO14 and 
PEO23.  In each experiment SP5 knockdown is expressed relative to the scrambled control 
(delta delta CT).  The results are shown in Figures 59a-d below. 
 
Sample    UnRx    Mock       AS          1             2            3            1             2            3 
 
Sample  UnRx     Mock        AS          1             2            3            1             2            3 
 
[10 nm] [5 nm] 
[5 nm] [10 nm] 
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Figure 59a.  SP5 normalised to GAPDH in PEO14: 24-96 Hours.  (For legend see 59d).   
 
 
 
 
 
 
Figure 59b.  SP5 normalised to GAPDH in PE023: 24-96 Hours.  (For legend see 59d).   
 
 
 
 
 
 
 
Figure 59c.  MAPK normalised to GAPDH in PEO14: 24-96 Hours (For legend see 59d).   
 
 
 
 
 
 
Figure 59d.  MAPK normalised to GAPDH in PEO23 24-96 Hours.  Controls black, MAPK grey.  
SP5 Red  UnRx untreated, Mock transfection reagent only, AS Allstars® scrambled control Results 
normalised to GAPDH & expressed relative to Allstars® scrambled control (delta delta CT). 
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6.5 Effect of siRNA knockdown of SP5 on 
chemosensitivity using the MTT assay 
Given that increased methylation appeared to correlate with decreased expression in the 
cancer cell lines and tumours it was hypothesised that this decreased expression could 
confer chemoresistance.  In order to address this question SP5 was knocked down by 
siRNA and then the cells were replated into a 96 well format in a variety of conditions and 
an MTT experiment performed where each condition was treated with five increasing 
concentrations of cisplatin (4X below IC50, 2X below IC50, IC50, 2X above IC50 and 4X 
above IC50).   
The actual doses of cisplatin used for each cell line in the MTT part of the experiment are 
shown in table 34 below.  These had been recently redetermined by a collegue (Dr Rizzo) 
for another study and I therefore did not repeat these experiments. 
 
Table 34.  Actual doses of cisplatin in µM which corresponded with each of the IC50 values 
 PEO14 PEO23 
IC50 X4 7.36 33.0 
IC50 X2 3.68 16.5 
IC50  1.84 8.25 
IC50/2 0.92 4.13 
IC50/4 0.46 2.06 
 
Experiment 1. 
The first part of the experiment was to perform siRNA transfections in both cell lines, 
knocking down SP5, MAPK (positive control), and including the Allstars® negative 
control.  This was performed as described in Chapter 2.18; initially 25x10
4
 cells were 
seeded in T25 flasks using the manufacturer‟s recommended quantities of transfection 
reagent and the optimised amount of siRNA.  However after 48 hours most of the cells in 
the SP5 knockdown flask were noted to have died.  Efficient transfection (>85%) of MAPK 
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and the Allstars® scrambled control was confirmed by taking lysates and making RNA 
and subsequent cDNA and performing qRTPCR.  There were not enough cells in the SP5 
flask to perform the qRTPCR.   
Experiment 2 
The reason for the especially low number of cells in the SP5 flask was unclear however it 
was presumed that the transfection mastermix was too toxic and therefore the experiment 
was repeating using 50% of the recommended quantities of the transfection reagent.  Again 
at 48 hours there were noticeably less cells in the SP5 knockdown flask compared to the 
others.  Again efficient transfection was confirmed by qRTPCR.  It was therefore 
hypothesised that it was not necessarily the knockdown itself that was toxic (as the effect 
was so much more dramatic in the SP5 knockdown flask) but that perhaps the SP5 
knockdown caused increased cell death (or less likely decreased proliferation).   
Experiment 3-6 
In order to increase the yield of cells at the end of the experiment (for the subsequent 
MTT) the next experiment was performed seeding 75x10
4
 cells into T75 flasks.  Again 
there was a very high level of cell death in the SP5 knockdown and not enough cells were 
left to continue the experiment.  The last 3 experiments were performed in T75 flasks using 
50% of the manufacturers recommended mastermix of transfection reagent and siRNA and 
using 3 flasks for the SP5 knockdown and one for each of the others.  For all experiments a 
high knockdown was consistently seen by RTPCR (≥90% for SP5 and ≥85% for MAPK).  
Photographs of the cells in each of the flasks prior to trypsanisation for the various 
conditions for one of the experiments in PEO14 are shown in Figure 60 below. 
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Figure 60.  Photographs of cells in flasks representing each of the transfection conditions.  
Photos all taken at 72 hours. 
 
In total, the experiment was performed five times in two cell lines (PEO14 and PEO23) 
using the smaller quantities of transfection reagent and on each occasion the number of 
cells alive at the end of the experiments in the SP5 treated flask was much less.  Dead cells 
in the media were washed off and after trypsanisation cells were counted, using the 
haemocytometer and the average percentage of SP5 cells, compared to scrambled control 
for the 10 experiments is shown in Figure 61 below.  Consistently there were >50% less 
cells in the SP5 knockdown flasks than in the scrambled control.  No formal test of 
viability was performed. 
 
 
 
 
 
 
 
Figure 61.  Assumed viable cell number expressed as percentage of SP5 cells compared to 
scrambled control (Allstars®).  Error bars show standard deviation over 5 experiments in each 
cell line.   
 
After 48 hours cells were trypsinised and counted (and a lysate taken for later confirmation 
of knockdown by RTPCR) then reseeded onto 96 well plates for the MTT part of the 
       Untreated              Mock               Allstars®             MAPK                 SP5 
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experiment.   The plates were left for 24 hours to allow cells to adhere and then the varying 
doses of drug were added to the appropriate wells as shown for PEO23 in Figure 62 below: 
Plate 1 of 2 
 Untreated  Mock All stars MAPK 
B  0.0 4.13 16.5 0.0 4.13 16.5 0.0 4.13 16.5 0.0 4.13 
B 0.0 4.13 16.5 0.0 4.13 16.5 0.0 4.13 16.5 0.0 4.13 
B 0.0 4.13 16.5 0.0 4.13 16.5 0.0 4.13 16.5 0.0 4.13 
B 0.0 4.13 16.5 0.0 4.13 16.5 0.0 4.13 16.5 0.0 4.13 
 2.06 8.25 33.0 2.06 8.25 33.0 2.06 8.25 33.0 2.06 8.25 
 2.06 8.25 33.0 2.06 8.25 33.0 2.06 8.25 33.0 2.06 8.25 
 2.06 8.25 33.0 2.06 8.25 33.0 2.06 8.25 33.0 2.06 8.25 
 2.06 8.25 33.0 2.06 8.25 33.0 2.06 8.25 33.0 2.06 8.25 
 
 
 
Plate 2 of 2.   
MAPK SP5          
16.5 0.0 4.13 16.5         
16.5 0.0 4.13 16.5         
16.5 0.0 4.13 16.5         
16.5 0.0 4.13 16.5         
33.0 2.06 8.25 33.0         
33.0 2.06 8.25 33.0         
33.0 2.06 8.25 33.0         
33.0 2.06 8.25 33.0         
Figure 62.  Layout for two plates for each MTT Experiment.  Each condition shown in a different 
shade of grey.  B is blank (no cells), untreated (cells in media only), Mock (includes transfection 
reagent).  Numbers in each box represent the dose of cisplatin in µM. 
 
After 24 hours the media +/- drug was removed and warm fresh media added.  48 hours 
later the MTT was added as described in chapter 2.20.  The plate was read and the value 
given for each well represented the amount of proliferation in that well.  The average of 
each of the quadruplicates was calculated.  Next the value obtained from the wells which 
contained no cells (blanks) was removed from the other values.  Then the mock cells were 
given a value of 1 and the other conditions converted to a number relative to this.   
Consistently the MTT experiments showed the lowest proliferation for the SP5 knock 
down cultures and there was only a small effect on proliferation with increasing dose of 
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cisplatin– examples of results obtained from the MTT experiments for PEO14 and PEO23 
are shown below in Figure 63a & b: 
 
 
 
 
 
 
 
 
Figure 63a.  Effect of a range of concentrations of cisplatin on proliferation of PEO14 under 
different experimental conditions, as measured by MTT (Figure represents n=1).  
 
The same results were obtained for PEO23.  The proliferation of SP5 was again much 
lower for the SP5 knockdown cells including in the samples treated with no drug and 
increasing the drug concentration appeared to have little effect, especially in the SP5 
knockdown cells.   
 
 
 
 
 
 
 
 
Figure 63b illustrating effect of a range of concentrations of cisplatin on proliferation of 
PEO23 under different experimental conditions, as measured by MTT (Figure represents 
n=1).  
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In order to assess whether the timescale of the transfection had affected chemsensitivity the 
experiment was repeated using a delayed transfection.   Again the effect of increasing 
cisplatin dose was not seen to have a consistent effect on proliferation (data not shown). 
 
Analysis of the graphs above indicates that it is likely that the cisplatin was  not at a high 
enough dose however as knockdown of SP5 expression appeared to reduce cell number it 
was not going to be possible to interpret the MTT assay.  As the phenotypic effect in the 
SP5 cells could be secondary to decreased proliferation or increased apoptosis an 
alternative approach was taken; namely to assess whether decreased expression of SP5 
resulted in induction of apoptosis.   
   
6.6 Effect of siRNA knockdown of SP5 on 
apoptosis using caspase-Glo® 3/7  
In order to address whether knockdown of SP5 resulted in increased apoptosis 
simultaneous experiments were performed where the impact of SP5 on apoptosis was 
measured by induction of caspase 3 and 7 via caspase-Glo®, whilst normalising for cell 
proliferation (using MTT).  As the biggest difference in methylation and expression had 
been in the A2780 series these experiments were initially performed in the A2780 cell line.   
 
On this occasion transfection was performed directly into the 96 well plates as described in 
chapter 2.20.  Cells were also kept for later lysis, RNA extraction, reverse transcription and 
assessment of knockdown and in addition cells were fixed and stained with crystal violet in 
an attempt to assess the effect of SP5 knockdown on cell number.  Experiments were 
repeated on three separate occasions and in each experiment triplicates were performed.  
The same controls were used as previously; namely untreated, mock, Allstars® scrambled 
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siRNA, SP5 siRNA and MAPK siRNA.  In the second two experiments an additional 
control for apoptosis, of cisplatin at a dose of 5 nm, was used.  Experiments were 
performed at 24, 48 and 72 hours.   
 
On each occasion the ability of SP5 to induce apoptosis was maximal at 24 hours.  This 
was despite a smaller degree of knockdown of SP5 by qRTPCR and a less noticeable 
phenotypic effect on cell number by microscopy, than in previous experiments.  Figure 64 
below show the induction of caspase normalised for proliferation via the MTT assay.  
Results were all expressed compared to the Allstars® scrambled control. 
 
 
 
 
 
 
 
 
Figure 64.  Induction of caspase following SP5 knockdown in A2780.  Samples normalised to 
MTT and then to Allstars® scrambled control (n=2 all conditions, n=3 for first 4 conditions ie 
cisplatin control not used in first set of experiments).  
 
These results show maximal induction of apoptosis in the SP5 knockdown at 24 hours.  
Cisplatin 5 µM was used as a positive control for the assay and as expected maximal 
apoptosis, as a result of platinum, was later at 48 hours.  Cisplatin was causing apoptosis 
when we expected and we therefore believed these results to be credible and were therefore 
encouraged to see a 20% increase in apoptosis in the SP5 knockdown.  As the experiment 
was only performed twice with the full set of conditions, i.e. including the cisplatin 
controls error bars were not added but the results were seen to be consistent in all 
experiments and encouraged us to go further forward with characterisation of this locus.     
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6.7 Effect of over expression of KIAA1383 
on cell cycle in the presence of cisplatin 
The effect of transient over expression of KIAA1383 was examined in PEA2.  KIAA1383 
was obtained already cloned into the pFN21A vector.  Vector only control and KIAA1383 
were treated with 25 µM cisplatin 48 hours after transfection and the effect on the cell 
cycle analysed 24 hours later following addition of the fluorescent ligand and propidium 
iodide (PI) staining.  Cisplatin was expected to cause S-phase stalling and a subsequent 
decrease of cells in G1 and G2.  All experimental conditions were examined in triplicate 
and results were consistent between each replicate.  A summary of the cell cycle data is 
shown graphically below in Figure 65.  It shows that overexpression of KIAA1383 causes a 
decrease in the effect of cisplatin on the cell cycle with less cells in S phase.  However this 
result was not statistically significant and requires to be repeated and as no RTPCR primers 
or antibodies are available it is not possible to demonstrate definite over expression of 
KIAA1383.   
 
 
 
 
 
 
 
Figure 65.  Effect of over expression and cisplatin treatment on the cell cycle.  Error bars 
show standard deviation of triplicate results. 
The raw data for the cell cycle analysis is also shown below in Figure 66 and confirms an 
increase in S Phase following cisplatin treatment which is reduced by KIAA1383 
overexpression. 
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Vector only 
 
 
 
 
 
Vector and cisplatin treated 
 
 
 
 
KIAA1383 over expressing only 
 
 
 
 
KIAA1383 over expressing & cisplatin treated 
 
Figure 66. FACS analysis showing initially gating and final cell cycle results for KIAA1383.  
SSC side scatter, FSC forward scatter, FLT2 green/transfected cells. W width or transit time, A 
area or total fluorescence of the particle, H height or maximal fluorescent intensity, Count is 
number of nuclei so cells in G2/M have twice the DNA of that in G0/ G1 (first peak) and are 
represented in the second peak.  S phase is the area between the two peaks. 
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6.8 Effect of over expression of SP5 on 
chemosensitivity in the presence of 
cisplatin (MTT) 
In a collaboration with Jenny Hersey at the Institute of Cancer Research the effect of 
overexpression of SP5 was examined in A2780 cp70.  This vector system allowed for 
stable over transfection and it was therefore possible to use the MTT assay to more 
directly measure chemosensitivity.  The vector map is shown in Figure 67 below: 
 
 
 
 
 
 
 
 
Figure 67.  Vector map for pCMV-AC-GFP allowing stable over expression of SP5 
 
Experiment 1.   
Cells were plated at 3 different densities in duplicate in 6 well plates:  0.5 x 10
5
, 1 x 10
5
 
and 2 x 10
5
.  These were then incubated overnight (~22hrs) prior to transfection.  
Transfection was performed and clones selected which showed persistent expression of 
SP5; as described in chapter 2.23.  qRTPCR was then performed as described in Chapter 
2.14.3 to assess expression of SP5 in transfected cell lines. This analysis was carried out 
between passage 2 and 3 and the results are shown in Figure 68 below. 
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Figure 68.  qRTPCR showing expression of SP5 in 9 separate colonies (A-H) and 2 pools of 
all colonies.  Results normalised to pool A.  Colonies circled in red were chosen for future 
experiments. RQ relative expression.  Error bars standard deviation of replicates.  Top of error bar 
accentuated as black line. 
 
Next an MTT assay was performed as described in Chapter 2.20 in order to assess whether 
cisplatin had a differential effect on chemosensitivity when SP5 was over expressed.   The 
IC50 of cisplatin in A2780 cp70 is 5.7 uM and 6 doses reflecting a range of concentrations 
from ¼ of the IC50 to 4 times the IC50 were examined (1/4 IC50, ½ IC50, IC50, 1.5 IC50, 
2XIC50, 4XIC50) in addition to wells with media only and cells and media only.  Results 
were variable between the 5 transfected groups of cells. The table below shows the 
percentage of viable cells when compared to untreated control at each drug concentration. 
 
Table 35.  Percentage of viable cells when compared to untreated control in MTT 
experiment. 
 
Cisplatin 0 uM 1.425 uM 2.85 uM 5.7 uM 8.55 uM 11.4 uM 22.8 uM 
vector only 100.0 94.1 95.7 72.6 62.2 47.9 30.3 
SP5 pool A 100.0 92.3 82.1 63.2 50.3 45.7 26.5 
SP5 pool B 100.0 114.7 105.4 76.3 75.8 56.8 39.7 
SP5 colony B 100.0 96.7 91.3 61.9 60.3 48.1 39.6 
SP5 colony G 100.0 99.4 65.2 54.0 51.8 47.3 36.7 
 
These results are plotted onto growth curves below (Figure 69 below) and are shown in 
order (a to d) of increasing SP5 expression. 
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Figure 69.  Effect of SP5 overexpression on proliferation by MTT assay.  (vector only shown 
by qRTPCR not to express SP5; A: SP5 pool B , B: SP5 colony G, C: SP5 pool A, D: SP5 colony 
B) (1 experiment, each condition in triplicate, averaged results shown).   
 
During plating of cells for MTT assay 4x10
5
 cells were taken and lysed for RNA so that 
SP5 expression could be determined. Results show that all 4 SP5 transfected lines continue 
to express SP5 at high levels and results show a similar pattern to original analysis. There 
is a small decrease in expression of SP5 in pool A. 
 
A 
D 
C 
B 
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Figure 70.  SP5 expression after second passage confirming ongoing expression.  RQ 
relative expression.  Error bars standard deviation of triplicates in one experiment.  Top of error bar 
accentuated as black line. 
 
In conclusion, no effect of over expression on proliferation of cp70 cells, in the presence of 
cisplatin, was observed.  The experiment was therefore repeated using a wider range of 
cisplatin doses.  It was done twice independently and the results are shown below: 
Experiments 2 and 3. 
In the next two experiments the dose range included higher doses of cisplatin.  All other 
experimental conditions were unchanged.  Again qRTPCR was first examined to confirm 
expression of SP5 in the various colonies.  This time it was shown relative to the empty 
vector.  qRTPCR results are shown firstly below for experiment 2 (71a) and experiment 3 
(71b). 
 
 
 
Figure 71a and b.  Expression of SP5 by qRTPCR relative to empty vector.  (Error bars not 
shown but samples were done in triplicate with standard error of mean less than 0.09). 
 
71a 71b 
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As was observed in the first experiment colony B showed very high levels of SP5 
expression.  Again pool A and B and colony G over express SP5 – although the degree of 
overexpression in colony G is lower in Expt 3.  Next the growth curves are shown for each 
separate colony.   Again with each compared to the empty vector.  Figure 72 illustrates the 
average of both experiments.     
 
 
 
 
 
 
 
 
 
 
 
 
Figure 72 a-d.  Effect of SP5 over expression on proliferation as measured by MTT (n=2). 
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Again over expression of SP5 was not shown to effect chemosensitivity when assessed 
using the MTT assay and these experiments have therefore not been taken any further. 
6.9 Discussion 
6.9.1 SP5 
SP5 is known to be a transcription factor which antagonises SP1 (Harrison, Houzelstein et 
al. 2000) and is a downstream target of Wnt signalling (Takahashi, Nakamura et al. 2005; 
Weidinger, Thorpe et al. 2005; Chen, Guo et al. 2006; Fujimura, Vacik et al. 2007).  As 
Wnt is known to be dysregulated in EOC and has also been implicated in the pathogenesis 
of tumour initiating or sustaining cells and this makes loss of methylation in tumours 
which regain expression of SP5 an important novel observation.  As discussed in the 
conclusion of chapter 4 we have recently shown that methylation of key genes in the Wnt 
pathway have an impact on PFS on ovarian cancer (Dai, Teodoridis et al. 2010) and this 
adds further weight to the notion that methylation plays an important role in ovarian cancer 
drug resistance. 
 
SP5 has been shown to be dynamically expressed during CNS development (Harrison, 
Houzelstein et al. 2000; Treichel, Becker et al. 2001; Weidinger, Thorpe et al. 2005) but it 
was only recently noted to show increased expression in colorectal, gastric and 
hepatocellular cancers with a negative impact (Chen, Guo et al. 2006).  Our data suggest 
that demethylation of SP5 results in an increase in expression of SP5 with a subsequent 
decrease in apoptosis.  Although we hypothesised that this could result in resistance to 
chemotherapy we have not been able to demonstrate this when over expressing SP5 and 
assessing chemosensitivity using the MTT assay.   
 
Chen et al, using an inducible gene expression system combined with microarray analysis 
found that over expression of SP5 in MCF7 cells resulted in significant growth promotion 
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supporting our results (Chen, Guo et al. 2006). This fits with the high levels of methylation 
seen in the cell lines and majority of primary tumours.  No association with PFS or OS was 
observed but it is possible if it is only those tumours with decreased methylation that have 
a worse outcome that the numbers in the study would therefore be underpowered to 
demonstrate this.   These experiments contribute additional information regarding the 
possible importance of decreased methylation and increased expression of the SP5 
transcription factor, and the Wnt pathway more generally in ovarian cancer.    
 
6.9.2 KIAA1383 
Given the statistically robust correlation between increased KIAA1383 methylation and 
PFS we were very keen to pursue further functional analysis of this gene.  Transient over 
expression of KIAA1383 could reduce the effect of cisplatin chemotherapy and this would 
fit with decreased methylation correlating with a poorer PFS.  My results show that over 
expression of KIAA1383 mediates the effect of cisplatin on the cell cycle and next we aim 
to assess this more directly using the GFP stable expression system (described for SP5) so 
that we can go on to do an MTT experiment with cisplatin.  This would provide a more 
direct measure of any mediation of chemosensitivity (than the inferred results from a 
change in cell cycle).  
6.10 Conclusion 
6.10.1 SP5 
In this chapter I have demonstrated that an increase in SP5 methylation correlates with a 
decrease in gene expression, in A2780 based cell lines and ovarian cancer primary 
tumours.  I have also shown that gene silencing can be reversed using a demethylating 
agent, decitabine.  siRNA-induced gene silencing appeared to cause increased cell death 
which was shown to be secondary to apoptosis, using the caspase assay.  Since I left the 
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laboratory, my colleague has since managed to optimise stable over expression of this gene 
and perform an MTT assay but this did not demonstrate an effect of over expression on 
chemosensitivity.       It is possible that knock down of this gene has a critical effect on 
cells whereas the converse is not true with over expression.  In addition over expression 
was checked at the mRNA level using qRTPCR and it is possible that this did not reflect 
an effect at the protein level.  
 
6.10.2 KIAA1383 
In the previous chapter I showed that methylation of KIAA1383 correlates with PFS.  
Using flow cytometry cell cycle analysis following transient over expression of KIAA1383 
in this chapter I have shown that over expression of KIAA1383 results in reduced S phase 
stalling, following treatment with cisplatin, in the PEA2 cell line.  This is with the caveat 
though that RTPCR primers and antibodies were not available to confirm over expression 
at either the m RNA or protein level. 
 
Further plans for both loci are discussed in the final thesis conclusion/ future plans 
(Chapters 8 and 9).   
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7 Validation of candidate loci in the OGT array  
7.1 Aims and background 
7.1.1 OGT (Phase I and II) 
Oxford Gene Technology (OGT) offer a customised arrays service, whereby samples can 
be treated by DMH (as described in Chapter 2.9) and then hybridised to CGI arrays, where 
the loci to be tested have been chosen by the investigator.  This does not limit examination 
to the promoter only and the arrays can be customised in any way required.  As this was 
the first time such an approach had been used by our group the study was divided into an 
exploratory Phase I study and confirmatory Phase II study.  The aim of the Phase I was to 
check the precision of this approach and to ask some initial exploratory questions 
regarding genes with differential methylation in the resistant cell lines.  The aim of the 
Phase II was to take genes identified in the Phase I (and previous 12k array, see earlier 
Chapters (Heisler, Torti et al. 2005)) and validate them in a large panel of primary 
tumours.  In addition in the Phase II experiment genes relating to key pathways in EOC 
were investigated. 
This focused approach offers the advantage of being high throughput but with the ability to 
ask more directed questions, for example the role of methylation in key pathways, or to 
validate  genes discovered from other approaches, for example the loci identified from the 
experiments described in the previous chapters of this thesis. 
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A diagram outlining the various validations that were performed is shown below in Figure 
73:  Briefly the candidate loci identified from Chapters 3-5 were examined in the relevant 
cell lines using the OGT I array.  These loci were then examined in primary tumours in 
OGT Phase II experiment.  
   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 73 Summary of the validation in cell lines and primary tumours (of loci identified 
from the original 12K array).  34 cell line PAM refers to candidates from chapter 3, 16 cell lines 
MLDA refers to candidates from Chapter 4 and in vivo cell lines MLDA refers to candidates from 
Chapter 5.  Canadian 12k (Heisler, Torti et al. 2005), OGT Oxford Gene Technology.  EOC 
epithelial ovarian cancer. 
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7.2 OGT Phase I 
7.2.1 Introduction 
The aim of the Phase I experiment was to assess the reproducibility of technical and 
biological replicates and to assess the effect of dye swap experiments on results.  
Biological replicates describe separate DMH preparation of the DNA (see chapter 2.10) 
and technical replicates describes separate spotting of the same DMH preparation onto 
different areas of the array.  In addition we planned to validate whether candidates 
discovered in previous experiments showed differential methylation using this alternative 
approach, and identify novel targets which could then be tested in a more comprehensive 
panel of tumours in the Phase II experiment.  The source of the genes/ loci that were used 
in this array are summarised in Figure 74 below: 
 
 
 
 
 
 
 
 
 
Figure 74.  Source of loci hybridised in the OGT Phase I study.
  
CGIs identified from DNA methylation 
profiling study by DMH assay on HCGI12K  microarray between A2780 sensitive and resistant derivatives 
generated as well as between in vivo generated cell line pairs (PEO1 vs. PEO4, PEA1 vs. PEA2, PEO14 vs. 
PEO23) performed by Dr. Jens M. Teodoridis; 2) Prognostic DNA methylation signature associated with 
progression free survival in ovarian cancer (Wei, Balch et al. 2006); 3) and 4) CGIs identified from DNA 
methylation profiling study on Orion MethylScope two-channel microarray based on McrBC restriction enzyme 
to detect differential methylation between A2780 sensitive and resistant cell lines (data not published, lists 
available from Wei Dai or Robert Brown); 5) candidate genes collected from the studies about acquired drug 
resistance in ovarian cancer through our collaborations (List available from Professor Hani Gabra or Dr. Euan 
A. Stonach from Ovarian Cancer Action); 6) other loci/genes differentially expressed before and after cisplatin 
treatment from gene expression profiling studies published from 2001 to 2008 (List available from Epigenetics 
O drive via Wei Dai or Robert Brown).  Figure from Wei Dai and further details can be found in her thesis 
published in 2011.  Also  see Dai et al, (Dai, Teodoridis et al. 2008). 
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The origins of the cell lines used in this experiment can be thought of in three parts (see 
figure 75 below).  Firstly a detailed comparison of PEO1 vs. PEO4 was made which 
investigated the effects of dye swap, independent DNA preparation and repeat 
hybridisation.  Secondly the EOC A2780 sensitive cell lines (A2780, A2780p3, A2780p5 
and A2780p6) vs. A2780 resistant cell lines (A2780cp70, MCP1 and MCP6) were 
compared and here dye swap replicates only were performed.  In the third comparison 
differences in methylation between the in vivo derived sensitive (PEO1, PEA1, PEO14) 
and resistant (PEO4, PEA2, PEO23) were sought and again dye swaps were performed.  
This is summarised in figure 75 below: (Further details of the cell lines in Chapter 2.17.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 75.  Cell lines used for OGT Phase I Expt.  Cell lines as outlined in Chapter 2.17.4.  
Peach sensitive cell lines, Blue resistant cell lines.  For the A2780-based cell lines and PEA1 vs. 2, 
and PEO14 vs. PEO23 hybridisation with a dye swap was performed.  For PEO1 vs. PEO4 the 
effect of dye swap, technical replicates and biological replicates was assessed (For a more detailed 
explanation see text above figure).     
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7.2.2 Results 
7.2.2.1 Reproducibility: dye swap, biological replicates and 
technical replicates 
Reproducibility was found to be high when investigating the effect of technical or 
biological replicates. However this was not the case when investigating the effect of dye 
swap experiments where the R
2
 results were lower.  The variability was found to be less 
when the digested samples were labelled in red and undigested samples were labelled in 
green.  A summary of this data is shown in Figure 76 below:  
 
 
 
 
 
 
Figure 76.  Bar chart showing R
2 
values for technical and biological replicates hybridised to 
the OGTI array.  Independent DNA bisulphite modification (DNA_inde_REP), separate 
hybridisations of the same bisulphite modified DNA (Hybri_REP) and dye swap.  Error bars 
represent standard error of mean (SEM).  (Figure from Wei Dai). 
 
7.2.2.2 Ability to accurately detect previously validated loci 
The ability of MLDA vs. SAM or PAM to identify candidate genes was next examined.  
Among 51 CGIs identified by MLDA on the Human CGI 12k array in the A2780 series 
cell lines previously, 32 CGI are validated by MLDA, 30 CGI by SAM and 26 by PAM on 
the OGT array.  Further details of this are supplied in the publication by Dai et al, (Dai, 
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Teodoridis et al. 2008).  We next assessed whether MLDA could identify the 14 candidates 
which had been identified using the Canadian 12k array (Heisler, Torti et al. 2005) and 
independently validated by MSP +/- pyrosequencing (Dai, Teodoridis et al. 2008).  The 
results are illustrated in Figure 77 below and demonstrate that we could detect 13 out of 14 
of the previously validated candidates (92.9% sensitivity).  This box plot was developed in 
R by Wei Dai and plots the differences/ DMH log ratios (a measure of methylation) and 
corresponding chromosome locations of the 14 loci (p=2.79x10
-4
) compared to the 
unmethylated controls on chromosome 16.   
    
 
 
 
 
 
 
 
 
 
 
Figure 77.  Box Plot showing ability of MLDA to detect candidates in the OGT Phase I 
experiment that had been detected in previous methylation hybridisation experiments as 
differentially methylated (left) compared to the unmethylated controls (right). (Figure from 
Wei Dai). 
 
7.2.2.3 Correlation between array results (DMH ratio) and 
pyrosequencing results (% methylation of bisulphite 
modified samples) 
The final test was to examine the correlation between methylation as detected by the DMH 
ratio as compared to pyrosequencing for individual loci and an example of this is shown in 
figure 78 below:  This showed a high correlation and added confidence that the probes 
were covering the area of interest. 
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Figure 78. Correlation between DMH log ratio and methylation as detected by 
pyrosequencing of bisulphite modified DNA for 17 G 11.   
 
7.2.2.4 Validation of loci identified from previous Chapters 
MLDA was used to investigate whether the genes that had been identified previously from 
the 12K array showed differential methylation in this independent array.  The results in the 
previous chapters have shown that a relatively low number of the loci that are differentially 
methylated in cell lines also show this characteristic in the primary tumours or matched 
tumour pairs (chapters 3-5).  The matched pairs especially are a very scarce and finite 
resource of tumour DNA; however if a locus is identified in the cell lines and then 
differential methylation is confirmed in a heterogeneous panel of primary tumours (OGT 
II) then it is much more likely that this candidate could be of biological relevance.   
We were able to ask two key questions following our initial tests of robustness of the data.  
Firstly to validate the loci identified in the 12K DMH experiment (Heisler, Torti et al. 
2005) in an independent platform and secondly to use the cell lines as a discovery set to 
identify new potential biomarkers in ovarian cancer.  In this study candidates were 
identified from each of the comparisons (see Figure 73, beginning of the chapter) and 
below I will focus on the validation of candidates identified in Chapters 3-5.  
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7.2.2.4.1 Examination of genes identified previously in this thesis, in the 
A2780 cell lines 
 
Using MLDA we analysed the OGT I data and detected 105 loci that gained methylation in 
the resistant cell lines and 6 that lost methylation.  All 6 of the previously identified genes 
(chapter 4) were identified and given that the two arrays are entirely independent that was 
seen as highly reassuring.  In addition 66G6 from the in vivo comparison (chapter 5) and 
DLC1, LMX1A and NR2E1 (Chapter 3) were all observed to show increased methylation in 
the resistant cell lines.  A table showing the results for the loci identified from previous 
chapters is shown below: 
Table 36 Candidates validated in the OGT array that had been identified from the 12K array 
Gene Start End chro txstart txend hit total hit/total % 
                  
34 Cell line PAM (3/3)                 
DLC1 13034461 13035285 8 12985242 13035180 7 16 43.75 
LMX1A 163590110 163590435 1 163437728 163591641 5 14 35.71 
LMX1A 163590815 163592952 1 163437728 163591641 5 34 14.71 
NR2E1 108592364 108597232 6 108593954 108616704 21 74 28.38 
         
A2780 MLDA (6/6)         
CRABP1 76420377 76421144 15 76419757 76427620 10 20 50.00 
GLS2 55167668 55168969 12 55151003 55168448 7 26 26.92 
HRASLS3 63137719 63138672 11 63098824 63138469 6 26 23.08 
AGBL2 47693315 47693682 11 47637720 47692878 3 18 16.67 
SP5 171278123 171282150 2 171280106 171282743 2 40 5.00 
NTN4 94708004 94709330 12 94575714 94708667 1 32 3.13 
                  
IN VIVO MLDA (1/5)                 
66_G_6 95747937 95748308 9 NA NA 6 14 42.86 
Start and end refer to chromosome locations of the probes, chro chromosome, txstart and txend are the start and end of the transcription 
start site.  Hit is number of probes showing increased methylation in resistant cell lines, total is total number of probes examining that 
gene, hit/total is the % of hits compared to the number of probes for the gene.  34 cell lines PAM refers to the genes identified in Chapter 
3, A2780 MLDA refers to the genes identified in Chapter 4, in vivo MLDA refers to the genes identified in Chapter 5. 
 
Our laboratory has previously worked extensively on MLH1 which is known to be 
associated with a gain in methylation in the resistant cell lines and as a check of the data 
we examined whether it appeared on this list of genes also, which it did, with 8 out of 22 
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probes showing significantly increased methylation in the resistant cell lines – adding 
further weight to the credibility of the data.   
The original 12K array had 12000 CGIs spotted, although these were not limited to CGIs at 
the 5‟ end of the gene and many of the probes also covered non-CG sites (as shown in the 
high level of false positives or „noise‟ seen in the table in chapter 3).  In contrast the OGT 
Phase I used a 15k array of 573 loci which spanned the promoter region more 
comprehensively.  In addition the genes were identified using PAM for the 34 cell 
comparison whereas MLDA was used on this occasion.  To see such a high number of 
genes being detected by these two independent methods was therefore highly reassuring.   
As stated before it would be important for a gene to show differential methylation in 
tumour samples as opposed to just cell lines if it was to be of important in ovarian cancer 
initiation or maintenance.  This question was addressed when these genes were examined 
in the OGT Phase II data set (later in Chapter 7.3).   
Next I examined whether any of the loci which had previously been identified could be 
detected as differentially methylated, by comparing the in vivo pairs, in the new data set 
(Chapter 5).   
7.2.2.4.2 Examination of thesis candidate genes in ‘in vivo’ cell lines. 
In this comparison we examined genes that showed increased methylation between the in 
vivo sensitive and resistant cell lines; PEO1, PEA1 and PEO14 vs. PEO4, PEA2 and 
PEO23.  Using MLDA, 20 loci which corresponded to 17 genes were identified as gaining 
methylation in the resistant cell lines.  Two of five of the previous identified candidates 
were validated (KIAA1383 and LOC113230) and in addition CRABP1 which had been 
identified in the A2780 comparison (Chapter 4) also showed differential methylation in 
these independent cell lines.  The results for the three genes are shown in Table 37 below: 
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Table 37.  Validation of genes identified in the 12k array in the in vivo cell lines on the OGT I 
array 
Gene Chro Start End Txstart Txend Hit total 
% 
hits/total 
CRABP1 15 76419724 76420163 76419757 76427620 5 18 27.78 
KIAA1383 1 231007677 231008330 231007260 231012715 3 22 13.64 
LOC113230 19 14046107 14046601 14044820 14046874 2 16 12.50 
Start and end refer to chromosome locations of the probes, chro chromosome, txstart and txend are the start and end of the transcription 
start site.  Hit is number of probes showing significantly increased methylation in resistant cell lines identified by MLDA in a pairwise 
comparison (3 pairs, FDR<5%), total is total number of probes examining that gene, hit/total is the % of hits compared to the number of 
probes for the gene.   
 
In this comparison more weight was lent to the PEO1 and PEO4 comparison because of 
the number of replicates of this cell line on the array.  (PEO1 and PEO4 had biological, 
technical and dye-swap comparisons whereas PEA1 and 2 and PEO14 and PEO23 had dye 
swaps only).  Given this fact it was reassuring to see 2 of 3 of the candidates validating by 
this independent method (6 loci identified, 4 mapped to 5‟ and had a CGI, then 66G6 
abandoned secondary to lack of pyrosequencing primers leaving SIX1, KIAA1383 and 
LOC113230).   
 
It is also very interesting to see differential methylation of CRABP1 given it had originally 
been identified in a comparison of the A2780 based cell lines (Chapter 4).  Again the next 
step was to examine these loci in the primary tumours in the OGT Phase II experiment. 
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7.2.3 OGT I Summary 
In this pilot study we were able to use DMH and subsequent MLDA to detect differential 
methylation in resistant cell lines with high sensitivity.  We demonstrated that dye bias 
reduces the reproducibility of dye swapped replicates and therefore excluded the use of dye 
swap in the Phase II of the study.  The variability of DNA independent replicates and 
hybridisation replicates were similar and smaller when the digested samples were labelled 
in red and undigested samples labelled with green.   
Many of the genes identified in Chapters 3-5 were shown to demonstrate increased 
methylation in resistant cell lines using this independent method.  These loci could then be 
further characterised in the larger panel of ovarian cancer primary tumours (OGT Phase II).  
In this chapter I have been able to demonstrate that loci that could have been disregarded 
(because it was difficult to design primer or optimise primers for MSP or pyrosequencing) 
were able to be validated using this high throughput technique. 
Overall it was thought that the OGT focussed array had proved to be a robust way of 
validating known candidates and also had the potential to be used to discover new targets.  
MLDA was confirmed to be a highly sensitive method for detecting differential 
methylation (Dai, Teodoridis et al. 2008).  
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7.3  OGT Phase II (Examination in primary 
tumours). 
7.3.1 Introduction 
The first aim of the OGT Phase II was to examine genes that had been identified in the 
12K array, in primary tumours.  The primary tumours are known to be very heterogeneous 
and this was therefore done with two caveats – firstly that a gene could be important in 
acquired drug resistance and be detected in the resistant cell lines but not necessarily be 
present at a detectable level at the outset of disease and therefore might not be picked up in 
the primary tumours and secondly that a negative result might not mean that a gene was 
not of relevance biologically – just that due to tumour heterogeneity the study was 
underpowered to detect the difference.   
The second aim of the OGT Phase II was as a discovery platform – i.e. to identify new 
genes that were important in ovarian cancer at the outset of disease.  This work is not 
discussed in this thesis but has recently been published, (Dai, Teodoridis et al. 2010). 
Genes from the previous 12K and OGT Phase I experiments were included along with 
other genes relating to key pathways that are known to be important in ovarian cancer (for 
example BRCA1/2, p53, MMR, mTOR and WNT).  In total 824 loci were examined in 
111 primary tumour samples, the majority of which represented advanced disease.  The 
origin of the loci/genes that were investigated is illustrated in Figure 79 and table 37 
below: 
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Figure 79. Flow diagram of origin of candidate loci for the OGT Phase II.  Data pre-processing 
data and controls are published as a supplementary table in the recent Wnt paper (see 
„Supplementary Method 1_Pre-processing of DMH data‟) (Dai, Teodoridis et al. 2010) or sources 3-
13 genes (excluding sources 1,2 and 5 which are published) see table 38 below.  Source 1 (Dai, 
Teodoridis et al. 2008), source 2 (Wei, Balch et al. 2006), source 5 (Ntougkos, Rush et al. 2005). 
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Table 38. List of genes investigated in the OGT II Experiment. 
 
Source 3 
 
Source 4 
 
Source 6 
 
Source 7 
 
Source 8 
 
Source 9 
 
Source 
10 
 
Source 11 
 
Source 
12 
 
Source 13 
 
Source 13 
in vivo DMH Paul  
Smith 
BRCA1 P53 MMR 
 Etc 
mTOR/ 
AKT 
FA OGT I Redox WNT WNT 
AK094166 AKT1S1 ATF1 APAF1 BLM AKT1 BRCA2  APEX1 APC RAC1 
AX747809 AKTIP ATM ATM BRCA1 AKT2 C17orf70 ADM CAT APC2 RAC2 
C12orf60 ASCL1 ATR ATR BRCA2 BRAF C19orf40 AGBL2 FOXO1 AXIN1 RAC3 
C15orf37 ASL BACH1 BAI1 DCLRE1C CAB39 FANCA AK124699 FOXO3 AXIN2 RBX1 
C6orf159 ASS1 BARD1 BAX DMC1 DDIT4 FANCB AREG FXN BTRC RHOA 
CYP27B1 BAPX1 BLM BBC3 EME1 EIF4B FANCC ATF3 GLRX CACYBP ROCK1 
KIAA0859 BARX1 BRCA1 BID EME2 EIF4E FANCD2 BDNF GPX1 CAMK2B ROCK2 
KIAA1383 BASP1 BRCA2 CASP3 EXO1 EIF4E1B FANCE C1orf190 GPX3 CAMK2D RUVBL1 
LOC113230 BTG2 CDKN1A CASP8 HMGB1 EIF4E2 FANCG C1orf88 GPX4 CAMK2G SENP2 
NOLA1 BTG3 CHEK1 CASP9 LIG1 EIF4EBP1 FANCI CD47 GPX7 CCND1 SFRP1 
OPCML DAB2 CHEK2 CCNB1 LIG4 FRAP1 FANCM CDH13 GSTM1 CCND2 SFRP2 
TMEM86A DUSP1 E2F1 CCNB2 MLH1 GBL PALB2 CDS1 GSTM2 CCND3 SFRP4 
TRDMT1 DUSP16 E2F2 CCND1 MLH3 HIF1A  CKLF GSTM4 CHP SFRP5 
VPS13B DUSP2 E2F3 CCND2 MRE11A KIAA1303  CNTNAP5 GSTM5 CREBBP SIAH1 
  DUSP6 E2F4 CCND3 MSH2 LYK5  COL14A1 GSTP1 CSNK1A1 SKP1 
  DUSP7 E2F5 CCNE1 MSH3 MAPK1   CRABP1 GSTT1 CSNK1E SMAD2 
  DUSP8 E2F6 CCNE2 MSH4 MAPK3   CTSL1 KEAP1 CSNK2A1 SMAD3 
  GFRP FANCA CCNG1 MSH5 PDPK1   CXCL2 MPO CSNK2A2 SMAD4 
  GLUL FANCC CCNG2 MSH6 PGF   DLC1 NFE2L2 CSNK2B SOX17 
  IGFBP1 FANCD2 CD82 MUS81 PIK3CA   DNAJC11 NOX4 CTBP1 TBL1X 
  IGFBP2 FANCE CDC2 NBN PIK3CD   DNAJC6 NOX5 CTBP2 TBL1XR1 
  IGFBP3 FANCF CDK2 NHEJ1 PIK3R1   DPH1 NRF1 CTNNB1 TBL1Y 
  IGFBP4 FANCG CDK4 PCNA PIK3R2   DUOXA2 PRDX1 CTNNBIP1 TCF7 
  IGFBP5 FANCL CDK6 PMS1 PIK3R3   DUSP1 PRDX2 CUL1 TCF7L1 
  IGFBP6 GADD45A CDKN1A PMS2 PRKAA1   DUSP3 PRDX3 CXXC4 TCF7L2 
  IGFBP7 GADD45B CDKN2A POLB PRKAA2   ENSG00000172268 PRDX4 DAAM1 TP53 
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  IGFBPL1 GADD45G CHEK1 POLD1 RHEB   EPM2AIP1 PRDX5 DAAM2 VANGL1 
  LEPRE HDAC1 CHEK2 POLD2 RICTOR   ERBB2 PRDX6 DKK1 VANGL2 
  LEPREL1 HDAC10 CYCS POLD3 RPS6   F3 SOD1 DKK2 WIF1 
  LEPREL2 HDAC11 DDB2 POLD4 RPS6KA1   FANCF SOD2 DVL1 WNT1 
  LRIG1 HDAC2 EI24 POLL RPS6KA2   FEZF2 SRXN1 DVL2 WNT10A 
  LRIG2 HDAC3 FAS POLM RPS6KA3   FOXD4 TXN2 DVL3 WNT10B 
  LRIG3 HDAC4 GADD45A PRKDC RPS6KB1   FOXE1 TXN2 EP300 WNT11 
  MSX1 HDAC5 GADD45B RAD50 RPS6KB2   GLS2 TXNRD1 FBXW11 WNT16 
  PHLPP1 HDAC6 GADD45B  STK11   GPM6B TXNRD2 FOSL1 WNT2 
  PROTOR2 HDAC7 GADD45G RAD51 TSC1   GSTM3 WWOX FRAT1 WNT2B 
  PRR5 HDAC8 GTSE1 RAD51C TSC2   HK1   FRAT2 WNT3 
  RASL12 HELLS IGFBP3 RAD51L3 ULK1   HLX1   FZD1 WNT3A 
  REDD1 MRE11A LRDD RAD52 ULK1   HOXB13   FZD10 WNT4 
  REDD2 MSH2 MDM2 RAD54B ULK2   HOXB5   FZD2 WNT5A 
  REELIN MSH6 MDM4 RAD54L ULK2   HOXD11   FZD3 WNT5B 
  RHEB NBN PERP RDM1 ULK3   HPSE   FZD4 WNT6 
  RHOB PLK1 PMAIP1 RECQL VEGFA   HPSE2   FZD5 WNT7A 
  SPINT1 RAD50 PPM1D RECQL4 VEGFB   HRASLS3   FZD6 WNT7B 
  SPINT2 RAD51 PTEN RECQL5 VEGFC   HSPB1   FZD7 WNT9A 
  TLE3 RB1 RCHY1 RFC1    IGSF4B   FZD8 WNT9B 
  ZNF655 RBBP8 RFWD2 RFC2     IL17RD   FZD9   
    SMARCA1 RPRM RFC3     IL1F8   GSK3B   
    SMARCA2 RRM2 RFC4     JAG1   JUN   
    SMARCA4 RRM2B RFC5     KIAA1383   LEF1   
    SMARCA5 SESN1 RPA1     LBH   LRP5   
    SMARCAD1 SESN2 RPA2     LBX1   LRP6   
    SMARCB1 SESN3 SHFM1     LHX2   MAP3K7   
    SMARCC1 SFN SMARCC1     LHX5   MAPK9   
    SMARCC2 SHISA5      LIPG   MYC   
    SMARCD1 SIAH1 SPO11     LMX1A   NFAT5   
    SMARCD2 STEAP3 TOP3A     LOC113230   NFATC1   
    STAT1 THBS1 WRN     MAGEA6   NFATC2   
    TP53 TNFRSF10B XRCC2     MAGEC7   NFATC3   
    UBB TP53 XRCC3     MAGEG1   NFATC4   
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    UBC TP53I3 XRCC4     MAL   NKD1   
      TP73 XRCC5     MAMDC2   NKD2   
      TSC2 XRCC6     MLH1   NLK   
      ZMAT3      MLLT6   PLCB1   
            MSX2   PLCB3   
             MT2A   PORCN   
             MYOD1   PPARD   
             NLF2   PPP2CA   
             NR2E1   PPP2CB   
             NTN4   PPP2R1A   
           NUDT4   PPP2R1B  
           P2RY8   PPP2R2A  
           PCDH15   PPP2R2B  
           PDX1   PPP2R2C  
           PEG10   PPP3CA  
           PIK3R1   PPP3CA  
           SFRP1   PPP3CB  
           SLC27A1   PPP3CC  
           SOCS1   PPP3R1  
           SP5   PPP3R2  
           TFAP2C   PRICKLE1 
           TMEM16E   PRKACA  
           TP53   PRKACB  
           TP53INP1   PRKACG  
           TRAP1   PRKCA  
           TSPAN13   PRKCB  
           TUBB2B   PRKCG  
           UBE2S   PRKX  
           UNCX4.1   PRKY  
           WNT1   PSEN1  
 
The list of loci corresponding with these genes is held on the O drive of the Epigenetics group at Imeprial College London and can be accessed via Wei Dai or Robert Brown or via NCBI (Dai, Teodoridis et al. 2010)
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7.3.2 Results 
7.3.2.1 Correlation between DMH ratio and % methylation by 
pyrosequencing 
As before, in order to assess the quality/ reliability of the data, the correlation between the 
DMH ratio and the results obtained from previous pyrosequencing of 17G11 in primary 
tumours (chapter 5.3.1) was investigated.  The results are shown in Figure 80 below (this 
was not done for all loci).    
 
 
 
 
 
 
 
 
 
Figure 80. Scatter plot of DMH ratio of individual probes vs. pyrosequencing of SIX1 in 
primary tumours (chapter 5.3.1). 
 
Using SIX1 as an example, the chromosome locations for the pyrosequencing primers, the 
DMH probes and the locus are shown in Table 39 below: 
 
Table 39 Chromosome locations for DMH probes and pyrosequencing for SIX1 
                             SIX1 (17G11) 
 Start End 
Pyrosequencing 60174234 60174273 
DMH probe 60174197 60174329 
MSE1 fragment 60173731 60174416 
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7.3.2.2 Candidates genes from Chapters 3-4 
The genes that had been identified as showing increased methylation in the resistant cell 
lines in Chapters 3-4 were first investigated to see if any of these showed increased 
methylation in the panel of 111 primary EOC tumours (tumour and patient characteristics 
are described in methods section 2.5.5).   
It was not possible to design a probe for CR2 and for SP5 the probe could not be designed 
to overlap with the exact location of the locus from the 12k array (24D3).  Of the 9 genes 
that were investigated one showed a correlation with PFS when analysed using the Cox 
regression model; CNTNAP.  This result is highlighted in bold in table 40 below: 
Table 40 Summary of effect of methylation of genes from chapters 3-4 on PFS in OGT II.   
12K ID Gene  HR HR Lower 95 HR Upper 95 p value 
 
FDR 
Chapter 3       
119_A_6 NR2E1 0.83 0.37 1.86 0.65 0.91 
5_D_4 LMX1A 0.89 0.72 1.08 0.23 0.71 
127_F_12 DLC1 0.40 0.06 2.79 0.35 0.71 
114_E_4 CNTNAP 0.49 0.27 0.86 0.01 0.14 
       
chapter 4       
17_H_9 HRASLS3 0.65 0.27 1.52 0.30 0.71 
20_F_11 NTN4 1.26 0.26 6.02 0.77 0.91 
38_D_7 AGBL2 1.81 0.05 55.85 0.73 0.91 
41_D_12 GLS2 1.22 0.13 11.25 0.86 0.93 
121_D_9 CRABP1 1.08 0.19 6.27 0.93 0.93 
12K ID 12K array identity/name, HR hazard ratio, HR Lower and higher 95 are 95% confidence intervals, *P value is two-sided score 
test of the univariate Cox model. HR: hazard ratio. HR>1 indicates the increased risk of disease progression associated with the increase 
of methylation. HR<1 indicates the decreased risk of disease progression/death associated with the increase of methylation.  FDR: False 
discovery rate estimated using the method described before (Benjamini & Hochberg, 1995). 
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It was interesting that a gene that appears to have a role in acquired drug resistance, where 
increased methylation was seen in the resistant cell lines, could also have a role at the 
outset of disease – where an increase in methylation correlates with a better PFS.  From the 
Uni Prot Swiss Prot data base http://www.uniprot.org/uniprot/Q9UHC6) it seems that 
CNTNAP may play a role in the formation of functional distinct domains critical for 
saltatory conduction of nerve impulses in myelinated nerve fibres and seems to demarcate 
the paranodal region of the axo-glial junction. In association with contactin it may have a 
role in the signalling between axons and myelinating glial cells; a role in cancer has not 
been established and nor is their documentation that this gene is epigenetically regulated. 
Next the same loci were examined in terms of the effect of methylation on overall survival 
and we did not observe any correlation between methylation and overall survival; the 
results are summarised in table 40 below. 
Table 41.  Summary of correlation between methylation and OS for each CGI and its 
corresponding gene 
12K ID Gene HR HR Lower 95 HR Upper 95 p value FDR 
Chapter 3       
119_A_6 NR2E1 0.98 0.33 2.98 0.98 0.98 
5_D_4 LMX1A 0.95 0.76 1.20 0.67 0.94 
127_F_12 DLC1 0.94 0.17 5.25 0.95 0.98 
114_E_4 CNTNAP 0.61 0.32 1.16 0.13 0.39 
Chapter 4       
17_H_9 HRASLS3 0.87 0.42 1.84 0.73 0.94 
20_F_11 NTN4 2.48 0.33 18.45 0.38 0.75 
41_D_12 GLS2 0.79 0.05 12.98 0.87 0.98 
38_D_7 AGBL2 13.99 0.38 511.70 0.15 0.39 
121_D_9 CRABP1 2.36 0.31 17.75 0.41 0.75 
12K ID 12K array identity/name, HR hazard ratio, HR Lower and higher 95 are 95% confidence intervals. *P value is two-sided score 
test of the univariate Cox model. HR: hazard ratio. HR>1 indicates the increased risk of death associated with the increase of 
methylation. HR<1 indicates the decreased risk of disease progression/death associated with the increase of methylation.
 
FDR: False 
discovery rate estimated using the method described before (Benjamini & Hochberg, 1995). 
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7.3.2.3 Candidate genes from Chapter 5 
Next the CGIs within the five genes that had been identified by comparing PEA1 and 
PEA2 and PEO14 and PEO23 (chapter 5) were examined to see whether these correlated 
with survival in the 111 primary tumour pairs.  KIAA1383 had been found to correlate with 
PFS in the primary tumours examined in Chapter 5.3.4 but the relationship between 
LOC113230 (85B2) methylation and survival had not been examined previously.  This was 
because by MSP and pyrosequencing, LOC113230  had been thought to represent a false 
positive result as it was very methylated in all controls, sensitive and resistant cell lines -  
however it is possible that the primers were simply not designed to detect the area that 
showed maximal differential methylation and this should be reinvestigated (Chapter 5).   
In this experiment LOC113230 was found to correlate with PFS and KIAA1383 and 
LOC113230 were found to correlate with OS.  A summary of the results for PFS and OS 
are shown below (Tables 42 and 43). 
 
Table 42 Effect of methylation on PFS in OGT II data set 
    Progression Free Survival (PFS) (N=111)  
12K ID Gene HR HR Lower 
95 
HR Upper 
95 
p value  
FDR 
85_B_2 LOC113230 0.04 0.003 0.68 0.02 0.14 
21_G_5 KIAA1383 0.68 0.40 1.15 0.15 0.66 
66_G_6  2.23 0.37 13.48 0.38 0.71 
17_G_11 SIX1 0.86 0.57 1.31 0.49 0.79 
HR hazard ratio, HRLower and higher 95 represent 95% confidence intervals, *P value is two-sided score test of the univariate Cox 
model. HR: hazard ratio. HR>1 indicates the increased risk of disease progression associated with the increase of methylation. HR<1 
indicates the decreased risk of disease progression/death associated with the increase of methylation. FDR: False discovery rate 
estimated using the method described before (Benjamini & Hochberg, 1995). 
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Table 43 Effect of methylation on OS in OGT II data set 
    Overall Survival (OS) (N=111)  
12K ID Gene HR HR Lower 95 HR Upper 95 p value FDR 
85_B_2 LOC113230 0.01 <0.01 0.60 0.04 0.24 
21_G_5 KIAA1383 0.45 0.23 0.89 0.02 0.24 
66_G_6  5.92 0.83 42.02 0.08 0.33 
17_G_11 SIX1 1.12 0.70 1.81 0.63 0.94 
HR hazard ratio, HRLower and higher 95 represent 95% confidence intervals, *P value is two-sided score test of the univariate Cox 
model. HR: hazard ratio. HR>1 indicates the increased risk of death associated with the increase of methylation. HR<1 indicates the 
decreased risk of disease progression/death associated with the increase of methylation. FDR: False discovery rate estimated using the 
method described before (Benjamini & Hochberg, 1995). 
 
 
LOC113230 and KIAA1383 were also examined in a multivariate analysis which included 
the usual confounding factors such as age, stage, grade and histological subtype.  PFS 
remained significant for LOC113230 at „p‟=0.04 (two-sided score test) and the result for 
overall survival approached significance (p=0.06) (two-sided score test).  For KIAA1383 
the correlation with OS was also upheld (p=0.01) (two-sided score test).  As these loci 
were shown to validate on a different platform to their discovery platform these results 
were deemed to be highly significant and lent further weight to the ongoing functional 
analysis of KIAA1383 (Chapter 6).   
 
7.3.2.4 OGT II Summary 
The purpose of the OGT Phase II was to examine whether loci identified as showing 
differential methylation in ovarian cancer sensitive and resistant cell lines had a role at the 
outset of disease.  One of 11 genes derived from chapters 3-5, CNTNAP, showed a 
statistically significant relationship with PFS.  This was a gene that I had not been able to 
optimise MSP primers for and this shows the benefit of examining loci using different 
methods.   
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Two of four loci identified from the in vivo comparison, KIAA1383 and LOC113230 
correlated with survival and this would support the notion that the in vivo derived cell lines 
may be of more use when attempting to identify biologically relevant targets.  In addition 
because the multiple probes are designed to investigate an individual gene it is possible to 
detect differential methylation that could be missed by pyrosequencing – as is likely to be 
the case for LOC113230 and so DMH combined with array analysis has been demonstrated 
to be useful for both candidate validation and the identification of novel genes.   
 
This data set consisted of tumours which were mostly late stage and excluded more 
unusual subtypes such as clear cell and mucinous tumours.  It would be very interesting to 
investigate whether any of these loci had predictive as well as prognostic ability as 
biomarkers and also whether methylation of these genes is required in some types of 
ovarian cancer but not others – as this could lead to a better understanding of the biology 
underpinning the different biological subtypes.   
 
Increasingly it will be possible to assess the efficacy of predictive biomarkers as increasing 
numbers of patients are treated with biological agents in combination with standard 
chemotherapy.  For example numerous studies reported over the last 18 months have 
shown the benefit of antiangiogenic agents (Burger, Sill et al. 2007; Cannistra, Matulonis 
et al. 2007; Nimeiri, Oza et al. 2008) and the recent abstract at ASCO by Gourley et al has 
demonstrated that patients with a subtype of high grade serous tumours, expressing 
markers associating with angiogenesis, can be identified by RNA profiling of formalin-
fixed paraffin-embedded tumour samples (C. Gourley 2011).   
 
It would also be of interest to assess whether these changes in methylation could be 
detected in serum and whether the methylation of any of these genes is tied in with 
response to debulking surgery as this is another factor that could affect PFS and OS.    The 
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prognostic benefit of methylation of these markers in early stage disease has not been 
assessed in this study but this would be especially useful.  Most clinicians would agree that 
a large area of concern is the patients with early stage disease who are treated with 
chemotherapy - where a smaller proportion benefit from it (compared to those with 
advanced disease).   
 
In conclusion, this focussed approach which analysed the methylation status of previously 
identified candidates (from cell lines) has identified 3 genes that appear to have a role at 
the outset of disease and confer prognostic information. The next important step was 
therefore to test these loci in the acquired resistance setting and for this we have used the 
Agilent 244 array of 10 matched pre- and post- relapse tumour pairs and work is ongoing.  
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8 Thesis Conclusion and outline of future work 
8.1 Summary of thesis findings 
One of the first aims of this project was to validate pyrosequencing as an improved 
method, compared to MSP, of assessing methylation of candidate genes.  MSP is a highly 
sensitive technique (Herman, Graff et al. 1996) but does not allow for quantification and 
therefore makes correlations with survival more difficult.  I have demonstrated throughout 
this thesis that pyrosequencing (Tost and Gut 2007) provides highly reproducible 
quantitative data and information on a number of adjacent CpGs.  In addition in Chapter 
7.2.2.2 I have demonstrated that for one candidate gene, SIX1, that MLDA results correlate 
well with pyrosequencing results.   
 
During the course of my studies MLDA was developed by our group as an alternative 
method of biostatistically analysing differential methylation from DMH experiments (Dai, 
Teodoridis et al. 2008).  In order to validate the ability of MLDA to identify significant 
differences in differential methylation between sensitive and resistant cell lines and 
validate this novel statistical technique (Dai, Teodoridis et al. 2008), the experiments 
outlined at the beginning of Chapter 4 were undertaken.  I demonstrated that the loci that 
were predicted by MLDA to show increased methylation in resistant cell lines did indeed 
do so (all except one, MLLT6).  MLDA is therefore a highly sensitive method for 
identifying genes which show differential methylation between cisplatin-sensitive and -
resistant cell lines.   
 
In the original PAM analysis in Chapter 3 several genes did not map to the 5‟ end or 
contain a CGI, close to a known gene.  In contrast in the MLDA analysis of Chapter 4 
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although candidates were chosen at random and ranked from 2-75 by MLDA score 
(highest ranking representing largest difference in methylation between sensitive and 
resistant cell lines) many of those that could be investigated individually, by 
pyrosequencing, did show increased methylation in the resistant cell lines and most 
mapped to the 5‟ end and contained CGIs.  In addition MLDA takes into account the 
unique biological differences that are seen when examining methylation as opposed to 
expression changes (a larger number of assymetrical changes not following a normal 
distribution and without „over-normalisation‟ of the dataset with the loss of valuable 
information).   
 
In addition it was proposed that the in vivo generated cell line pairs (Langdon, Lawrie et al. 
1988) could be more biologically relevant than the in vitro generated cell lines and could 
therefore be useful models for identifying clinically relevant biomarkers.  I have been able 
to show that although a comparison of this small number of available paired lines generates 
a smaller number of candidates than the in vitro derived pairs, that these do indeed seem to 
be biologically relevant – as at least two of four genes in Chapter 5 showed a correlation 
with PFS or OS in ovarian cancer patients.  This is important as although criticisms are 
often raised with regards to the artificial nature of cell line models compared to 
experiments using patient samples they are a less finite resource and may well be more 
appropriate at the discover stage of biomarker development.  In addition whereas 
information is not always available on whether matched tumours represent platinum 
sensitive or resistant relapse this information is available for the in vivo derived cell lines 
(Langdon, Lawrie et al. 1988).   
 
In Chapter 6 functional experiments were undertaken in an attempt to further characterise 
the role of potential candidate genes in acquired drug resistance.  We chose SP5 and 
KIAA1383 to focus on for these experiements.  SP5 was selected because of its high level 
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of methylation in most of the cell lines and also the majority of primary tumours.  We 
hypothesised that instead of a gain of methylation being relevant here it may be a loss of 
methylation in a sub-group of tumours.  We predicted that this loss of methylation could 
result in an increase in expression and if this was under epigenetic regulation that treatment 
with decitabine, a demethylating agent, would reverse this gene repression.  This was 
indeed the case; albeit in a small number of samples and with the proviso that although the 
trend was always in the correct direction (more methylation = less expression) that this was 
not always statistically significant.  Following on from this experiment we hypothesised 
that if a small number of primary tumour samples were losing methylation and that this 
was resulting in an increase in expression with a negative outcome that if we knocked 
down the gene, using siRNA that we should see a phenotypic effect.  In the experiments 
outlined in Chapter 5.10 I showed that it was not possible to perform a valid MTT 
experiment to investigate the effect of SP5 knockdown on chemosensitivity, because when 
SP5 was knocked down a high proportion of the cells died.   
 
Given this interesting observation I went onto perform an apoptosis assay where I was able 
to demonstrate that knockdown of SP5 caused an approximately 20% increase in apoptosis 
(Chapter 6.6).  As a result we were interested to know whether if SP5 knockdown caused 
increased apoptosis whether the reverse would be true – and we predicted if this was the 
case that over expressing SP5 would cause increased proliferation and possibly a reduction 
in chemosensitivity.  These experiments were then performed by my colleague, Jenny 
Hersey, who successfully demonstrated that she could stably over express SP5 in the 
A2780 CP70 cell line.  The stable clones which over expressed SP5 emerged quickly 
compared to the vector only control– within less than a week – and this encouraged us that 
SP5 might indeed promote proliferation.  However, using an MTT experiment we did not 
see any alternation in proliferation in the presence of cisplatin, a surrogate for modulation 
of chemosensitivity. The limitations of this experiment and future plans are discussed later. 
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For KIAA1383, our plans to investigate the phenotypic effect, were more hampered.  For 
nearly all experiments which involve under- or over-expressing a gene of interest, and 
assessing the phenotypic effect of this, it is necessary to show that one has indeed 
modulated the target – either at the mRNA or protein level.  The fact that I was unable to 
optimise the KIAA1383 RTPCR primers therefore caused huge limitations. 
 
With this in mind we felt the best first experiment would be to over express KIAA1383 
transiently and investigate whether there was any effect on cell cycle modulation.  At least 
with this method there was the ability to gate our cells (FLT2 High vs. FLT2 low) and 
ensure we had green fluorescing cells in the over expressing populations and this should be 
a surrogate for over expression of the gene of interest.  In addition in these experiments 
controls were included which included the vector alone so that if we did see a positive 
result it would be more likely it was coming from the over expression of KIAA1383, rather 
than the vector alone.   
 
We were encouraged to observe that KIAA1383 did seem to attenuate the effect of cisplatin 
on the PEA2 cell line, resulting in less S phase stalling.  These results require to be 
confirmed and ideally in experiments that include proof of overexpression either at the 
mRNA or better protein level.  Again this will be discussed in the later section; outline of 
future work (Chapter 8). 
 
The work that is described in Chapter 7 was carried out in parallel to the other 
experiments, and given the time taken to design the probes, perform the DMH, hybridise 
the samples and extract the results using bioinformatic approaches, was only recently 
analysed.   
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It showed that genes that had been disregarded in early chapters because of technical 
difficulties with primer design or which had not looked interesting in terms of their pattern 
of methylation (CNTNAP and LOC113230) according to our hypothesis (biomarkers of 
acquired platinum resistance would show increased methylation in resistant cell lines or 
matched tumour pairs, and a heterogeneous pattern of methylation in primary tumours) 
were in fact correlated with survival.  It also confirmed that KIAA1383 appeared to be a 
possible prognostic biomarker.  This was an independent and substantially better annotated 
array so these results were seen as very encouraging.  It should be noted though that there 
is overlap between the primary tumour samples used in Chapters 3-5 and those hybridised 
in Chapter 7 so this is not a truly independent validation. Plans for further work on these 
candidate loci are again discussed later in Chapter 8.10.   
    
8.2 Tumour heterogeneity in EOC 
In the longer term it is the aim of our group to develop further cell lines where the 
resistance is generated within patients rather than by repeated drug treatment in the 
laboratory.  Clinically the different underlying biology in ovarian cancer is important, and 
if matched sensitive and resistant cell line models could be generated in patients reflecting 
clear cell vs. mucinous vs. HGS vs. LGS for example this would be extremely useful.   
 
As an example it is suspected clinically that mucinous tumours behave more like colorectal 
cancers and hence, as discussed in the introduction, the current clinical trials are examining 
the use of colorectal regimens in such patients – if this hypothesis could be formally tested 
in the laboratory this would be very relevant and could direct which therapies are guided 
towards which patients – true tailoring of patients treatment.     
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Patient samples are clearly hugely important, especially matched pre- and post- samples 
however the examinations in matched tumour pairs in this thesis generated disappointing 
results and were limited by both the small number of samples and the lack of clinical 
annotation for the samples.  As discussed in the introduction, the platinum free interval 
(Markman 2001) is a critical surrogate for response to chemotherapy, and therefore it is 
crucial to know whether the relapse samples represented platinum sensitive or resistant 
relapse.  In addition when using the residual disease pairs the assumption is that disease 
removed at the time of „second look surgery‟ represents resistant disease, however there is 
no way of knowing this for sure, with the current samples.   
 
As discussed in the introduction it is becoming increasingly clear that ovarian cancer is 
highly heterogeneous from the outset of disease with quite different biological pathways 
involved, and genes over- and under- expressed, in different subtypes.  This has huge 
implications when using a relatively small panel of matched pairs as it is possible they all 
represented, for example, HGS, which is relatively platinum sensitive or the clear cell or 
mucinous subtypes, which are more platinum resistant (Mackay, Brady et al. 2010).   
 
In addition it has been noted that although stage per se is important that the distribution of 
stage at presentation is different for the different histological subtypes.  HGS tumours more 
commonly present with later stage disease (35.5% of stage I/II cancers vs. 87.7% of stage 
III/IV cancers) whereas endometriod (26.6% early stage vs. 2.5% late stage) and clear cell 
sub types (26.2% vs. 4.5%) are enriched within early stage disease (Gilks, Ionescu et al. 
2008; Kobel, Kalloger et al. 2010).  These results suggest that the different biological 
subtypes do not progress through the stages in an advancing manner and instead that the 
differences in stage from the outset are determined by the underlying histological subtype.   
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This clearly has implications when attempting to derive prognostic biomarkers.  One 
would predict that the earlier disease stage that the cancer is detected at the better the 
prognosis however given the enrichment of patients with HGS pathology who present in 
the later stages this represents a huge technical challenge.  Some small hope is provided by 
the fact it does appear that some of these changes may be detectable at very early stages. 
The precursor lesion in Type II tumours is less clearly understood (see Chapter 1.1 and 
table 1) and their origin unknown until recently when studies suggested that a large 
proportion originate in the fallopian tube seccretory epithelial cell (FTSEC) – This was 
uncovered following pathological analysis of tissue from BRCA patients with germline 
mutations who were having prophylactic surgery.  This putative serous carcinoma 
precursor lesion was observed in the fimbriated end adjacent to the ovary and if  >12 
FTSECs were observed this was termed „the p53 signature‟ and although it was 
concerningly morphologically benigh on H&E staining it showed intense nuclear p53 
immunostaining (Karst, Levanon et al. 2011).  These „p53 signatures‟ were frequently the 
same as the patients somatic mutations suggesting a common origin for both (Lee, Miron 
et al. 2007).            
 
In addition matters are further complicated because although patients with mucinous and                                                                                                                                                                                                                            
have a favourable prognosis when diagnosed with early stage disease the opposite is the 
case when the disease is diagnosed when Stage III or IV.   In an analysis of patients treated 
in the Gynaecologic Cancer InterGroup study of approaching 9000 women, with advanced 
ovarian cancer, median survival was noted to be the following; endometriod (50.9 months), 
HGS (40.8 months), clear cell (21.3 months), mucinous (14.6 months) (Mackay, Brady et 
al. 2010).  This is presumably because these patients are more resistant to the standard 
treatment of carboplatin and paclitaxel and highlights the need for predictive biomarkers. 
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Another challenge with ovarian cancer, compared to some of the other solid tumours, is 
that the targeted agents that have been showing promise in the clinic in other cancers are 
likely to only be effective in small sub-groups – and this may explain the disappointing 
results of trials of targeted agents until recently.  For example patients with LGS tumours 
have activating mutations in KRAS and BRAF which could be targeted with MEK or 
BRAF inhibitors but these mutations are only found in approximately 20% of patients and 
LGS only make up around 5% of EOCs (see table 1 in introduction).  Similarly it is 
suspected that clear cell tumours of the ovary may behave more like clear cell tumours of 
the kidney (Zorn, Bonome et al. 2005) and therefore may respond to drugs such like 
sunitinib.  Again clear cell tumours make up a small proportion of ovarian cancers and 
therefore if this agent is to be fairly assessed it is critical that this sub group is selected out. 
 
Some encouragement can be taken from the study presented at ASCO this year (2011) by 
Ledermann and colleagues.  In a Phase II randomized placebo-controlled study they treated 
patients who had platinum sensitive relapsed HGS cancer with the PARP inhibitor, 
olaparib (AZD2281)  (J. A. Ledermann 2011).  They were selecting out platinum sensitive 
patients in order to test the existence of the „BRCAness phenotype‟ and its predicted 
response to synthetic lethality using a PARP inhibitor (Konstantinopoulos, Spentzos et al. 
2010).  The results were very encouraging with a 4 month improvement in PFS (J. A. 
Ledermann 2011) and given that HGS is the most prevalent subtype this makes the results 
of huge utility.  The limitation to this approach being that, like the PFI, one has to treat 
patients and assess the length of time to relapse ie their “platinum sensitivity” in order to 
know whether these agents might be helpful.  What would be more clinically useful would 
be if a gene expression profile or methylation profile could identify patients prospectively 
who had the BRCAness phenotype and then these patients could be given the relevant 
agents upfront (Konstantinopoulos, Spentzos et al. 2010).  This approach may be feasible 
in the next few years.  As discussed previously, David Bowtells laboratory recently 
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presented a gene expression profile which divided patients into 6 subgroups and 4 of these 
validated in an independent data set (Tothill, Tinker et al. 2008) and more recently, again 
this year at ASCO, the Gourley laboratory have been able to prospectively identify a sub 
group of patients with HGS cancer that over expression angiogenesis markers (C. Gourley 
2011).  The most encouraging results seen this year in ovarian cancer were with the use of 
the angiogenesis inhibitor, bevacizumab, and it does therefore seem feasible that in the 
next few years predictive biomarkers really could become „real-time‟.  There is potential to 
investigate whether changes in methylation also differentiate tumours into these distinct 
sub groups and if this was the case this would be of clinical utility as DNA methylation is 
well suited to clinical studies (see chapter 8.5 and 8.6).         
 
In order to address the issue of a lack of matched samples in more homogenous sub-
groups, during the course of this project, I wrote a clinical trial protocol (under Dr 
Glasspools supervision in Glasgow) to collect matched samples from patients.  Several 
studies have shown the ability to use surrogate tissues such as plasma (Gifford, Paul et al. 
2004), serum and ascites (Ibanez de Caceres, Battagli et al. 2004), and in this protocol we 
are collecting plasma +/- ascites +/-  tumour from patients at diagnosis and relapse.  Over 
the last two years we have collected approximately 40 samples although unfortunately few 
of them are matched, highlighting the difficulties in trying to collect these very valuable 
samples.     
 
Despite the concerns outlined above it still seems likely that genes that show differential 
methylation between „sensitive‟ and „resistant‟ tumour pairs could be more biologically 
relevant than those derived from cell lines.  And although the A2780 series represent 16 
sensitive and resistant cell lines it is possible that in reality we are only testing 3 variables 
as the cell lines are isogenically matched (A2780 sensitive, A2780 CP70 single high dose 
of cisplatin, and the MCPs multiple doses of cisplatin).  Therefore in work which is 
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ongoing the loci identified in this thesis are being examined in a small number of matched 
tumour pairs which have been prepared by DMH by myself and hybridised to the Agilent 
244k array.  Clearly this could be repeated using a larger number of matched samples if it 
proves successful and in the meantime we will endeavour to obtain more clinical 
information with regard to theses samples. 
 
   
8.3 The increasing availability of publically 
available datasets for validation 
Examining the relationship between  methylation and expression for each individual locus 
can be time consuming and if parallel experiments could be preformed examining 
differential methylation and expression this could be an efficient means of better 
identifying interesting candidates.  In addition, in several recent studies (Noushmehr, 
Weisenberger et al. 2010), (Tothill, Tinker et al. 2008) investigators have begun to test 
their candidate genes in publically available large well annotated data sets such as the 
TCGA resource (cancergenome.nih.gov).   
 
The Cancer Genome Atlas (TCGA) began as a three-year pilot in 2006 with an investment 
of $50 million each from the National Cancer Institute (NCI) and National Human 
Genome Research Institute (NHGRI). The TCGA pilot project showed that a national 
network of research and technology teams working on distinct but related projects could 
pool the results of their efforts and develop an infrastructure for making the data publicly 
accessible. Importantly, it proved that making the data freely available would enable 
researchers anywhere around the world to make and validate important discoveries. The 
success of the pilot led the National Institutes of Health to commit major resources to 
TCGA to collect and characterize more than 20 additional tumour types.  Various 
  258 
platforms exist including those investigating gene, exon, miRNA, and protein expression, 
copy number variation, single nucleotide polymorphisms (SNPs), loss of heterozygosity 
(LOH) and especially relevant to this thesis, DNA methylation 
(https://wiki.nci.nih.gov/display/TCGA/Array-Based+Data).   
 
Investigators used the infinium 27k array, which utilises bisulphite modified DNA 
(www.illumina.com/.../infinium_humanmethylation27_beadchip_kits.ilmn) and allows the 
opportunity to investigate methylation changes focussed around the promoter and 
elsewhere in the genome.  In addition correlations between methylation and expression can 
be made a much larger scale basis than the approach taken in this thesis. 
 
 
8.4 Validation of the OGT CGI focussed 
array. 
An additional important task was to begin to perform experiments using customised arrays; 
both for biomarker validation and discovery.  Our group has now gained a substantial 
amount of experience using the Agilent technology in conjunction with the OGT focussed 
platforms and a further collaborative experiment is planned.  This experience spans from 
the bioinformatics utilised to design probes and the statistics used to identify loci right 
through to the validation in the wet laboratory.  Given that our group is focussed on DNA 
changes around the promoter there is a benefit of designing more probes to focus around 
this particular area of interest (as opposed to an array like the infinium 27k array which has 
broader coverage of the genome but less detail around the promoter and therefore may 
miss changes in differential methylation in this area).  In collaboration with two post 
doctoral fellows in our laboratory I have gained experience in the technical preparation of 
the samples for such arrays.  (Dr Teodoridis and Dr Zeller). 
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8.5 Using methylation or expression arrays 
to identify key pathways and driving 
(epi)mutations. 
One of the primary aims of our group is to use differential methylation to identify key 
genes, or biological processes or pathways.  In work not focussed on this thesis and driven 
by one of my colleagues, Wei Dai, we have recently identified that methlyation plays a key 
role in the Wnt pathway and that this has prognostic significance (Dai, Teodoridis et al. 
2010) and work is ongoing assessing other pathways that are associated with ovarian 
cancer and drug resistance (As per Figure 78 and table 38).  Similar approaches have been 
succesfully utilised by others to demonstrate pathways and genes with critical 
dysregulation; either by assessment of epigenetic changes (Anderton, Lindsey et al. 2008; 
C. Gourley 2011) or more commonly gene expression profiles (Tothill, Tinker et al. 2008; 
C. Gourley 2011). 
 
 
8.6 The benefits to using methylation as a 
biomarker   
Methylation is a stable change and DNA lends itself well to clinical studies.  In the 
development of a biomarker it is critical that a test can be performed with highly 
reproducible results – and if a test is to be „rolled out‟ to a large number of patients then it 
is important that the assay is not too sensitive to small differences in how it is handled.  For 
example DNA is more stable than RNA and less prone to degradation through, for example 
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, temperature changes.  This means that if DNA is to be extracted from a tumour that the 
handling of that sample from the time of surgical resection to processing by the pathologist 
is less critical than for example if RNA was required from fresh frozen tissue.  The release 
of DNA into body fluids and again its relative stability compared to other sources of 
biomarkers, means that relatively non-invasive means of monitoring epigenetic changes in 
tumour can be used. Since normal tissues tend not to have CGIs methylated, then the 
sensitivity of detecting tumour specific changes is increased and is less prone to be being 
confounded by normal cell contamination.  In addition in terms of then analysing 
individual candidate, techniques such as pyrosequencing once optimised are relatively less 
operator and institution dependent and relatively higher through put compared to RTPCR.  
As discussed earlier DNA has the benefit of being able to be extracted from various tissues 
including blood, plasma, ascites and tumour and can be stored for relatively long periods of 
time at -20°C without degradation. 
 
 
8.7 The interaction between DNA 
methylation and other epigenetic 
mechanisms and the role of tumour 
initiating cells 
In the introduction to this thesis the interplay between chromatin, methylation and micro 
RNAs is discussed and it is likely that over the next few years that this will be increasingly 
well understood and may better explain the function of differential methylation.  In 
addition this thesis has focussed on changes in methylation at the promoter but it is 
becoming increasingly clear that changes within the gene body are also important (Ball, Li 
et al. 2009). 
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During the course of this project the existence of cancer stem cells or tumour initiating 
cells has been increasingly debated.  This was not the focus of this project but it is very 
interesting to note that many of the candidates that were identified as potential biomarkers 
of acquired drug resistance had links to stem cells – such as NR2E1 and LMX1A, as 
discussed in Chapter 3.  It does seem increasingly likely that researchers working in drug 
development in ovarian cancer will attempt to target the stem cell component and if 
methylation is demonstrated to have a role in altering the expression of stem cell genes 
then methylation could have a role both as a biomarker of stem cell phenotype and in terms 
of the utilisation of epigenetic therapies.   
The table below summarises the key findings relating to genes in this thesis that showed 
differential methylation between cisplatin sensitive and resistant cell lines or correlated 
with survival in primary ovarian cancer tumours.  In addition the final column documents 
any speculative roles in developmental biology or stem cell function.  In this small number 
of candidates there does appear to be an enrichment of transcription factors involved in 
developmental biology. 
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Table 44.  Key findings from the literature for genes outlined in this thesis. 
 
Relevant reference(s) Drug resistance/ general cancer role Putative stem cell/ developmental biology role 
LMX1A. ( LIM homeobox transcription factor 1, alpha).  Transcriptional factor.  (Chapter 3) 
(Liu, Chao et al. 2009) 
(Chizhikov and Millen 2004) 
Metastasis suppressor in cervical cancer. 
Methylated 89.9% of squamous cell carcinomas of 
cervix compared to 6.7% in normal cervix. 
Over-expression reduces colony formation and a less 
invasive phenotype is observed using a matrigel 
invasion assay.   
Development of the roof plate and specification of dorsal cell fates in the 
CNS and developing vertebrae.  In the chick developing spinal cord 
LMX1A has been shown to induce expression of WNT1.   
LMX1A as having a role in the differentiation of human embryonic stem 
cells into midbrain dopamine neurons in culture and after transplantation 
into a Parkinson‟s disease model. 
N2RE1(nuclear receptor subfamily 2, group E, member 1) (tlx is mouse homologue.) Transcription factor.  (Chapter 3) 
(Yu, Chiang et al. 2000) (Dziarmaga, 
Hueber et al. 2006; Hueber, Waters 
et al. 2006) 
tlx, is an upstream regulator of PAX2  and suppresses 
its expression in mice. 
Downregulation of PAX2 can enhance cisplatin 
sensitivity. 
 
PAX2 activates WNT4 gene expression.  
In the adult is expressed exclusively in the astrocyte-like B cells of the 
subventricular zone - acts as a key regulator of neural stem cell 
expansion and brain tumour initiation.  The area of over expressed tlx 
corresponds with overexpression of Nestin (neural stem cell marker).  tlx 
induced NSC expansion is associated with increased angiogenesis and 
migration. 
CRABP1 (cellular retinoic acid binding protein 1).  Retinoic acid mediated differentiation and proliferation.    (Chapter 4) 
(Huang, de la Chapelle et al. 2003; 
Lind, Kleivi et al. 2006; Ogino, 
Brahmandam et al. 2006; Tanaka, 
Imoto et al. 2007; Wu, Lothe et al. 
2007).    
Frequently methylated tumour. suppressor gene in 
oesophageal cancer, colorectal cancer, ovarian cancer 
and thyroid cancer.  
SAGE databases demonstrate it is expressed in the brain, retina and 
spinal cord and also in skin, breast and ovarian cancers although to a 
lesser extent (www.genecards.org/cgi-bin/carddisp.pl?gene=CRABP1).   
 
CNTNAP (contactin-associated protein 1).  An innate immunity gene (Chapter 4) 
(Lee et al 2009). Not known. Role in the formation of functional distinct domains critical for saltatory 
conduction of nerve impulses in myelinated nerve fibers.  Demarcates 
the paranodal region of the axo-glial junction. In association with 
contactin may have a role in the signaling between axons and 
myelinating glial cells 
SP5.  Transcriptional activator (Chapter 4) 
(Harrison, Houzelstein et al. 2000; 
Treichel, Becker et al. 2001; 
Weidinger, Thorpe et al. 2005) . 
Increased expression in colorectal, gastric and 
hepatocellular cancers. 
Over expression in MCF7 cells resulted in growth 
Role in the coordination of changes in transcription required to generate 
the developmental pattern in the developing embryo.   
Antagonises SP1 and is a downstream target of Wnt signalling  
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(Takahashi, Nakamura et al. 2005; 
Weidinger, Thorpe et al. 2005; Chen, 
Guo et al. 2006; Fujimura, Vacik et 
al. 2007).  
promotion. 
Downstream targets of SP5 implicated in ovarian 
cancer and drug resistance include p21, TGFB1, 
MDM2, ABCG2 and ABCC3 (see Chapter 1.3). 
Dynamically expressed during CNS development  
LOC113230 hypothetical protein.  (Chapter 5)) 
None Unknown. Unknown. 
KIAA1383 hypothetical protein.  (Chapter 5) 
None Unknown. Unknown. 
SIX1 (sine oculis homeobox 1).  Transcription factor.  (Chapter 5) 
Coletta, Christensen et al 2008.  
McCoy, Iwanaga et al 2009 
DNA dependent regulation of transcription. 
Over expression induces genomic instability and is 
sufficient for malignant transformation.  Can induce 
mammary tumours to undergo epithelial –
mesenchymal transition. 
Role in limb development, ureteric bud development, kidney 
development and in expansion of the mouse mammary epithelial stem/ 
progenitor cell pool.  
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8.8 Difficulties encountered/ limitations of 
the experiments described within this 
project 
One difficulty in the present study is when a candidate is identified which is “unknown” - 
for example in the case of KIAA1383.  If the decreased methylation correlates with 
increased expression then there is the ability to investigate the functional effect of over and 
under expression but this does not get to the bottom of what the function of the gene is and 
which other genes it is associated with or which pathway it is important in.  In the case of 
KIAA1383 it was not found to be expressed in any cancers on a wide variety of publically 
available data bases and nor was it known to show homology to any other known genes.  
Due to the small size of this gene which only spans one intron it has thus far not been 
possible to optimise RTPCR primers and there are no commercially available antibodies in 
order to examine this protein by western blotting.  It then becomes very difficult to know 
where to go next with such a candidate – but given the consistent correlation between 
differential methylation and PFS it is frustrating not to be able to take characterisation of 
this locus further. 
It could be argued that if a change in methylation correlates with a significant difference in, 
for example, OS or PFS, that whether or not there are known functional consequences of 
this change is irrelevant and that this finding alone is enough to make it a valuable 
biomarker.  But in the longer term most would argue that more can be gained by trying to 
identify the functional consequences of a change in methylation.   
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Throughout this thesis MLDA has proved sensitive at detecting differential methylation 
between cisplatin-sensitive and resistant cell lines.  However candidates that show 
differential methylation in the cell lines do not necessarily show this in the matched pairs 
and there is a lack of an adequate number of well annotated samples to investigate whether 
a change seen in vitro ie in the cell lines represents a genuinely important gene in vivo – in 
the patient.  In addition two of the genes that correlated with survival in ovarian cancer, 
including in the validation experiment of Chapter 7, did so in the „opposite direction‟ to 
that which would have been predicted from the cell lines experiments; namely an increase 
in methylation correlated with improved survival. 
   
8.9 Alternative approaches that could have 
been utilised 
Various alternative approaches could have been taken in order to identify genes or 
pathways which are predictive or prognostic biomarkers in epithelial ovarian cancer.  In 
the years following the start of this project much larger and better annotated microarrays 
have become available and in 2011 one would not use the 12k array which was used in 
Chapters 3 and 4.    
In addition the DMH experiments were performed in a limited number of cell line pairs 
given that the many of the A2780 series are isogenically matched.  These experiments 
could be refined by using a larger number of cell line pairs – and preferably using a larger 
number of the in vivo derived cell lines.   
Another alternative, especially in terms of identifying prognostic markers, would be to do 
the initial experiments in a panel of well annotated primary tumours as opposed to cell 
lines; or to perform the DMH in an adequately powered set of paired samples which are 
known to represent truly platinum –resistant disease.  Validating individual candidates, by 
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methods such as MSP or pyrosequencing, is time-consuming and as described earlier in 
this chapter increasingly well annotated public data bases, such as the TCGA, are 
becoming available, which can be utilised to validate candidates in an independent dataset.   
In terms of identifying key pathways, as described throughout this thesis, it is becoming 
increasingly clear that the pathways which are dysregulated are very different depending 
on the biological subtype.  Therefore a more robust way of identifying key pathways or 
genes is to ensure that an adequate number of all kinds of epithelial ovarian cancer are 
represented on the microarray – in the experiments outlined in this thesis I tended to try 
and use primary tumour samples that represented high stage and grade – assuming that 
these are the tumours in which candidates of acquired drug resistance would be most 
enriched – and in retrospective probably selecting out the HGS sub-population (as clear 
cell and mucinous tumours were generally excluded). 
An additional refinement would be to investigate whether groups of genes rather than an 
individual candidate correlates with survival and also to test formally whether there is an 
enrichment for particular types of genes, or groups of genes within a particular key 
pathway – for example using a Gene Ontology (GO) analysis 
(http://www.geneontology.org/GO.tools.microarray.shtml).   
8.10 Outline of Future Work 
8.10.1 KIAA1383 
In the immediate term one of my colleagues is going to continue the work on over- 
expression of KIAA1383 and SP5.  Providing KIAA1383 can be stably over-expressed in 
cells, the next plan would be to perform an MTT assay.As referenced earlier in the thesis, 
KIAA1383 has been noted to be over expressed as a result of DZNep (a histone 
methyltransferase inhibitor) treatment and it would therefore be worth investigating the 
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role of histone methylation in the regulation of this gene.  It would appear that its main 
scientific merit currently is as a prognostic biomarker and if we could confirm some 
preliminary phenotypic effect we could consider investigating this prospectively in a 
clinical trial setting.  Additionally we plan to investigate whether it has been shown to be 
either over expressed or hypermethylated in the TCGA publically available data sets.     
 
8.10.2 CNTNAP, NR2E1, LMX1A 
In addition some other genes which were identified in the cell lines and then later validated 
in the experiments described in Chapter 7 should be further investigated.  CNTNAP was 
initially observed to show increased methylation in the resistant cell lines, in the DMH 
experiment outlined in Chapter 3.  In the OGT Phase II experiment it was also shown to 
correlate with PFS in a panel of primary ovarian cancer tumours.  This gene has very little 
published in relation to its function and is a novel candidate in terms of a relationship to 
cancer.  Similarly nothing has been published with regards to the potential role for 
methylation in modulating gene expression.  Like NR2E1, LMX1A and DLC1 it appears to 
be involved in neural development.  It seems to demarcate the paranodal region of the axo-
glial junction and in association with contactin may have a role in the signalling between 
axons and myelinating glial cells (www.genecards.org/cgi-
bin/carddisp.pl?gene=CNTNAP1). 
 
8.10.3 LOC113230 
LOC113230 (85B2), which was identified from the comparison of the in vivo generated 
cell lines, in the experiments described in Chapter 5 also showed a correlation with 
survival in the OGT Phase II experiments.    It correlated with PFS (HR 0.04, „p‟=0.02, 
FDR 0.14) and OS (HR 0.01, „p‟=0.04, FDR 0.24) by univariate analysis and PFS 
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(„p‟=0.04) in a multivariate analysis; with the results for OS („p‟=0.06) also approaching 
significance (for full details of results see chapter 7.3.2.3).   
When this candidate was examined by pyrosequencing a high level of methylation 
including in normal controls was observed but it is possible that the primers could be 
redesigned.  We plan to optimise RTPCR primers to investigate whether although there 
doesn‟t appear to be a large change in methylation whether there is a larger change in 
expression – and also to see whether the use of a demethylating agent reverses this.  In 
addition we are planning over expression experiments involving this candidate and if 
successful an MTT experiment; as was described for SP5 and KIAA1383 in Chapter 6.7 
and 6.8. 
In the longer term MLDA has now been validated as a sensitive method of detecting 
differential methylation.  The work done by my colleague Wei Dai has validated our 
approach of probe design and statistical interrogation in the OGT arrays.  It seems likely 
that future work will involve high throughput detection methods with ongoing use of 
pyrosequencing to validate individual loci in the laboratory.  For loci such as LOC113230 
and KIAA1383 which appear to have a real correlation with survival then prospective 
validation of these biomarkers in clinical samples may be warranted.  How far our 
laboratory goes in terms of trying to characterise and define the function of these unknown 
candidates is difficult to predict at this stage and the first step will be to see the results of 
the over expression experiments which are ongoing. 
Now that we have shown that we can correlate methylation in the primary tumours with 
survival or response to chemotherapy in selected candidates, we plan to perform further 
experiments examining changes in methylation in samples from patients at diagnosis and 
relapse; including ascites samples.  If DNA of a high enough quality can be obtained from 
surrogate tissues then this opens up several opportunities for future work. 
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